CA1339953C - 2',5'-phosphorothioate oligoadenylates and antiviral uses thereof - Google Patents
2',5'-phosphorothioate oligoadenylates and antiviral uses thereofInfo
- Publication number
- CA1339953C CA1339953C CA000580426A CA580426A CA1339953C CA 1339953 C CA1339953 C CA 1339953C CA 000580426 A CA000580426 A CA 000580426A CA 580426 A CA580426 A CA 580426A CA 1339953 C CA1339953 C CA 1339953C
- Authority
- CA
- Canada
- Prior art keywords
- thioadenylyl
- compound
- adenosine
- phosphorothioate
- monophosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Optically active compounds of the formula
Description
2',5'-PHOSPHOROTHIOATE OLIGOADENYLATES
AND ANTIVIRAL USES TH~REOF
Field of the Invention The invention relates to synthetic analogues of naturally occurring antiviral 2l,5'-oligoadenylates wherein the internucleotide phosphodiester linkages are replaced with optically active phosphorothioate groups. The compounds have increased metabolic stability where the stereoconfiguration around one or more of the chiral - 10 phosphorous atoms is the Sp configuration.
Reference to Government Grant The invention described herein was made, in part, in the course of work supported by National Institutes of Health grant POl CA-29545 and National Science Foundation grant DMB84-15002.
Background of the Invention The full nomenclature of the subject matter of the present invention involves extremely long terms. It is customary for those skilled in the art to abbreviate oligoadenylate analogues and related terms in a manner well-known to them. These general and customary abbreviations are set forth herein below and may be utilized in the text of this specification.
-2- 1 3 ;~ ) 3 Abbreviations:
2-5A, 2',5'-oligoadenylate or p3An Oligomer of adenylic acid with 2',5'-phosphodiester linkages and a 5'-terminal triphosphate group.
A2, A3 and A4: Dimer, trimer and tetramer of adenylic acid with 2',5'-phosphodiester linkages.
pA3~ ppA3 (or p2A3), pppA3 (or p3A3): 5'-terminal mono-, di- and triphosphates of A3 AMPS: Adenosine 5'-O-phosphorothioate.
SVPD: Snake venom phosphodiesterase.
2'-PDE: 2'-phosphodiesterase Rp: The R stereoconfiguration about a chiral phosphorous atom in a phosphorothioate internucleotide linkage.
Sp: The _ stereoconfiguration about a chiral phosphorous atom in a phosphorothioate internucleotide - linkage.
RNase L: 2-5A dependent endoribonuclease.
ARpARpA: (Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine.
ASpARpA: (Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-~2'-5')-adenosine.
ARpASpA (Rp)-P-thioadenylyl-(2'-5')-(_p)-P-thioadenylyl-(2'-5')-adenosine.
ASpAspA: (_p)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
PARpARpA~ PpARpARpA~ pppARpARpA~ pASpARpA~ pPASPARP
pPPASpARpA, pARpASpA ~ ppARpAspA, pppARpAspA, pAsp ppAspAspA~ and pppAspAspA: 5'-mono-, di- and triphosphates of ARpARpA~ ASpARpA~ ARpASpA and ASpAspA.
AND ANTIVIRAL USES TH~REOF
Field of the Invention The invention relates to synthetic analogues of naturally occurring antiviral 2l,5'-oligoadenylates wherein the internucleotide phosphodiester linkages are replaced with optically active phosphorothioate groups. The compounds have increased metabolic stability where the stereoconfiguration around one or more of the chiral - 10 phosphorous atoms is the Sp configuration.
Reference to Government Grant The invention described herein was made, in part, in the course of work supported by National Institutes of Health grant POl CA-29545 and National Science Foundation grant DMB84-15002.
Background of the Invention The full nomenclature of the subject matter of the present invention involves extremely long terms. It is customary for those skilled in the art to abbreviate oligoadenylate analogues and related terms in a manner well-known to them. These general and customary abbreviations are set forth herein below and may be utilized in the text of this specification.
-2- 1 3 ;~ ) 3 Abbreviations:
2-5A, 2',5'-oligoadenylate or p3An Oligomer of adenylic acid with 2',5'-phosphodiester linkages and a 5'-terminal triphosphate group.
A2, A3 and A4: Dimer, trimer and tetramer of adenylic acid with 2',5'-phosphodiester linkages.
pA3~ ppA3 (or p2A3), pppA3 (or p3A3): 5'-terminal mono-, di- and triphosphates of A3 AMPS: Adenosine 5'-O-phosphorothioate.
SVPD: Snake venom phosphodiesterase.
2'-PDE: 2'-phosphodiesterase Rp: The R stereoconfiguration about a chiral phosphorous atom in a phosphorothioate internucleotide linkage.
Sp: The _ stereoconfiguration about a chiral phosphorous atom in a phosphorothioate internucleotide - linkage.
RNase L: 2-5A dependent endoribonuclease.
ARpARpA: (Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine.
ASpARpA: (Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-~2'-5')-adenosine.
ARpASpA (Rp)-P-thioadenylyl-(2'-5')-(_p)-P-thioadenylyl-(2'-5')-adenosine.
ASpAspA: (_p)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
PARpARpA~ PpARpARpA~ pppARpARpA~ pASpARpA~ pPASPARP
pPPASpARpA, pARpASpA ~ ppARpAspA, pppARpAspA, pAsp ppAspAspA~ and pppAspAspA: 5'-mono-, di- and triphosphates of ARpARpA~ ASpARpA~ ARpASpA and ASpAspA.
-3- 133~ ~3 ARpARpARpA: ( Rp) -P-thioadenylyl-(2'-5' )-(Rp)-P-thioadenylyl-( 2 ' -5 ' )-( Rp)-P-thioadenylyl-(2' -5' )-ade nos i ne .
A Rp AS p A Rp A : ( Rp ) - P - t h i o a d e n y l y l - ( 2 ' - 5 ' ) ~ P-th ioadenyl yl - ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenos ine .
A Rp A Rp A S p A : ( P~p ) - P - t h i o a d e ny 1 y 1 - ~ 2 ' - 5 ' ) - ( Rp ) - P -th ioadeny ly 1- ( 2 ' -5 ' ) - ( _p ) -P-th ioadenylyl- ( 2 ' -5 ' ) -adenos i ne .
ARpASpAspA: (Rp)-P-thioadenylyl-(2'-5')-(_p)-P-thioadenylyl-(2' -5' )-(Sp)-P-thioadenylyl-(2'-5' )--ade nos i ne .
ASpARpARpA: ( Sp ) -P-th ioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenosine .
ASpASpARpA: (_p)-P-thioadenylyl-(2'-5~ )-(_p)-p-thioadenylyl-(2'-5' )-(_p)-P-thioadenylyl-(2~-5~ )-adenosine.
ASpARpAspA: ( Sp ) -P-th ioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl-(2'-5' )-(Sp)-P-thioadenylyl-(2'-5' )-adenosine.
ASpASpASpA: (_p)-P-thioadenylyl-(2'-5~ )-(_p) th ioadenylyl- ( 2 ' -5 ' ) - ( Sp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenosi ne .
pARpARpARpA, ppARpARpARpA, pppARpARpARpA, pARpAspARpA~ ppARpAspARpA~ pPPARpAspARpA~ pARpARpASPA' ppARpARpAspA, pppARpARpAspA ~ pARpAspAspA ~ ppARpASpASp PPPARpASpASpA~ pASpARpARpA~ ppAspARpARpA~ pppAspARpARpA~
PASpASpARpA ~ pPASpASpARpA ~ pppAspAspARpA~ pAspARpAspA~
ppAspARpAspA~ pppAspARpAspA~ pAspAspAspA~ pPASpASpASpA' pppAspAspAspA: 5 ' -mono-, di- and triphosphates of the above tetramers .
(_p) - ATP-alpha-S: Adenosine 5'0-(Sp)-(l-th i ot r iph ospha te ) .
Background of the Invent ion The 2-5A system is widely expected to be involved in the antiviral mechanism of interferon and may also be 1 ~ '3 '~ 9 ~-~ 3 involved in the regulation of cell growth and differentiation. 2-5A synthesized from ATP by 2',5'-oligoadenylate synthetase [ATP: (2'-5')oligo(A)-adenyltransferase (EC 2.7.7.19)1 exerts its biological effects by binding to and activating its only known target enzyme, the unique 2-5A-dependent endoribonuclease RNase L
(EC 3.1.27). RNase L cleaves viral and cellular m~NA or rRNA, thereby inhibiting protein synthesis. Hovanessian et al, ~ur. J. Biochem. 93:515-526 (1979); Kerr et al, Proc.
Natl. Acad. Sci. USA. 75:256-260 (1978). It has been reported that 2-5A protects plant tissue from infection by tobacco mosaic virus. Devash et al, Science 216:415 (1982). 2-5A, however, is metabolically unstable. It is degraded by a cellular 2'-phosphodiesterase and phosphatases. Knight et al, Meth. Enzymol. 79:216-227 (1981); Minks et al, Nucleic Acids Res. 6:767-780 (1979);
Williams et al, Eur. J. Biochem. 92:455-462 (1978).
The literature is replete with structurally-modified 2-5A molecules with modifications in the adenyl or ribosyl moiety designed to explore the biological role of the 2-5A
synthetase/RNase L system. The primary source of conformational flexibility in the 2-5A molecule is in the backbone, similar to 3',5'-linked RNA and DNA. Srinivasan et al, Nucleic Acids Res. 13:5707-5716 (1985). However, theoretical and experimental analyses have revealed that the conformation of 2', 5'-linked dinucleotides and polynucleotide chains are significantly different from 3',5'-linked nucleotides. Id. The ribose-phosphate backbone of 2-5A has also been demonstrated to be the major antigenic determinant in the molecule. Johnston et al, Biochemistry 22:3453-3460 (1983).
Few reports have appeared on the synthesis of 2-5A
analogues with backbone m-odifications. Core analogues containing methylphosphonate and methylphosphotriester 13~9 73~ 3 groups have been synthesized. Eppstein et al, J. Biol.
Chem. 257:13390-13397 (1982); Jager et al, Nucleic Acids Res. Sym. Ser. No. 9:l49-152 (1981). However, complete loss of activity was observed with the "uncharged"
methylphosphotriester analogues. Eppstein et al, supra.
Substitution of the 2',5'-phosphodiester linkages with 3', 5'-linkages has also lead to substantial decrease in biological activity. Lesiak et al, J. Biol. Chem.
258:13082-13088 (1983). Replacement of only one 2',5'-internucleotide linkage has resulted in at least one order of magnitude loss of activity. Nearly complete loss of biological activity was observed when both 2',5'-phosphodiester linkages in the 2-5A trimer were replaced with 3',5'-bonds.
Haugh et al, Eur. J. Biochem. 132:77-84 (1983), reported that the affinity of pA3 to RNase L in mouse L929 cell extracts is approximately 1,000 times greater than that of A3.
Nelson et al, J. Org. Chem. 49:2314-2317 (1984), describe diastereomeric pairs of the phosphorothioate analogue of A3 without resolution of individual enantiomers. Eppstein et al, J. Biol. Chem. 261:5999-6003 (1986) report metabolic stabilities and antiviral activity of purported ARpARpA/ASpARpA and ARpASpA/AspAspA racemic mixtures without resolution of individual enantiomers.
Lee and Suhadolnik, Biochemistry 24:551-555 (1985), and Suhadolnik and Lee in The 2-5A System: Holecular and Clinical Aspects of the Interferon-Regulator Pathway, Williams, B.R.G. and Silverman, R.H., Eds. (1985), Alan R.
Liss, Inc., New York, p. 115-122, disclose the enzymatic synthesis of the alpha-phosphorothioate 5'-triphosphates of ARpARpA and ARpARpARpA from (_p)-ATP-alpha-S Such compounds are metabolically unstable. Preparation of the corresponding stereoisomers with Sp internucleotide -6- 1~3~ 3 phosphorothioate linkages was not possible owing to the stereospecificity of 2-5A synthetase for the substrate (Sp)-ATP-alpha-S, which is inverted to yield trimer and tetramer products containing 2',5'-phosphorothioate internucleotide linkages of the P~p configuration exclusively. Because nucleoside tranferases provide exclusively the inverted configuration when ~p-ATP-alpha-S
is the substrate, 2',5'-phosphorothioate oligoadenylates containing internucleotide phosphorothioate groups of the Sp configuration cannot be synthesized enzymatically.
Summary of the Invention Compounds of the present invention useful in inhibiting viral infections in plants and mammals have increased metabolic stability and/or antiviral activity.
The compounds are optical isomers and water-soluble salts thereof of the formula NHz HO p-O--C~
~,:
~o NHz -O- '=S N~N
C~N NJ
HO OH
substantially free of contamination by other optical isomers of the same formula, wherein m is zero, 1,2 or 3; n is 1 or 2; and at least one of the internucleotide phosphorothioate groups r -7- 13399 '~
I
is of the Sp configuration.
The invention also comprises a method of inhibiting viral infection in mammals or plants by administering an antiviral effective amount of a compound according to the above formula, or a water-soluble salt thereof, and antiviral compositions containing such compounds with a carrier.
Compounds according to the formula wherein n is 2 may be utilized to form oligoadenylate conjugates with the macromolecular carrier poly(L-lysine) for intracellular transport. Such poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates have the formula l H2 l H2 ( ICH2)4 ( ~CH2)4 NH2CHCO~Rq~NHCHCOOH
wherein q is an integer from about 60 to about 70, and R is randomly R' or (ICH2)4 -NHCHCO-.
From about five to about ten of the R ~rou~s comprise R'.
R' has the following formula wherein m is 0,1,2 or 3:
~33~13 i3 HO--p-O--CH2 N~NJ
o L--~~.l ~ml~j HO
~- ,=5 N ~NZ
~ <~N ~NJ
HO ¦
1 0 ~~ N H2 -O-P=S N~N
HO
-~- '=S NH2 CH ~N~J
,~
t CH2 )~
--NH-CH-CO--Preferably, at least one of the phosphorothioate groups o -O- P=S
o of the poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates is of the Sp configuration.
605~-58 1~3~
g Description of the Figures Figure lA represents the results of a radiobinding assay indicating the ability of 2',5'-phosphorothioate adenylate trimer cores and 5'-monophosphates to compete with p3A4[32PlpCp for binding to the RNase L in L929 cell extracts. Approximately 60% of the probe was bound in the absence of added oligonucleotide (total dpm = 23,000). The curves are labelled as follows: A3 (o); p3A3 (x); pA3 (-);
ARpARpA (~); ASpARpA (O); ARpASpA (~); ASpAsp (O); pARpARp (~); pASpARpA (~); pARpAspA (~); pASpAspA (J).
Figure lB represents the results of a core-cellulose assay indicating the ability of the 2',5'-phosphorothioate adenylate trimer cores and 5'-monophosphates to activate partially-purified RNase L from L929 cell extracts to hydrolyze the substrate poly(U)-3'-[32P3pCp. Activation of RNase L was determined by conversion of poly(U)-3'-[32P]pCp to acid-soluble fragments. 100% represents 30,000 cpm of labelled poly(U)-3'-[32P]pCp bound to glass fiber filters. The curves are labelled in the same manner as Figure lA.
Detailed Description of the Invention The activation of the unique 2-5A-dependent endoribonuclease, RNase L, by 2',5'-oligoadenylates, and its hydrolysis of rRNA, tRNA and cellular and viral mRNA, is important in the inhibition of viral replication and regulation of cell growth. RNase L is known to be the substrate target for 2-5A. It is one of the chief functional enzymes of the interferon-induced biological cascade. While modified analogues of 2-5A have been reported, they are not metabolically stable, or fail to activate RNase L. The introduction of the phosphorothioate group in the 2',5'-internucleotide linkages of 2-5A, induces physical, chemical and biochemical modifications in the 2-5A molecule including (i) Rp/Sp chirality, (ii) -lO- 133~ 3 lowered pKa, (iii) altered metal ion chelation, (iv) charge modulation, (v) increased bond length, (vi) altered degree of hydration and (vii) increased metabolic stabilities.
The metabolic stability of the 2',5'-phosphorothioate oligoadenylates is greater than authentic 2-5A. This metabolic ~,tability is greatly enhanced where at least one of the internucleotide phosphorothioate 2',5'-linkages is of the Sp configuration. While racemic mixtures of the trimer cores have been reported, Nelson et al, J. Org. Chem. 49:2314-2317 (1984) and Eppstein et al, J. Biol. Chem 261:5999-6003 (1986), efforts to resolve the compounds have failed. The level of antiviral activity of the trimer core racemates reported by Eppstein et al is such that the dosages required ~or treatment would be prohibitively toxic. At least one of the purported racemates of Eppstein et al, the ARpASpA/AspAspA racemate, is of little value since, as we have found, the ASpAspA
stereoisomer selectively inactivates RNase L, thereby preventing ARpASpA from exerting its antiviral effect through activation of RNase L. This is most undesirable since, as we have found, ARpASpA is the most attractive of the four trimer core stereoisomers, since it both activates RNase L and is metabolicly stable.
We have succeeded in preparing the fully resolved 2',5'-phosphorothioate adenylate trimer cores, thus making possible the practical use of the important ARpASpA
stereoisomer. Our method of stereo-specific chemical synthesis also makes possible the preparation of the eight separate stereoisomers of the 2',5'-phosphorothioate tetramer. Preparation of the tetramer molecules enables conjugation with the carrier (poly)L-lysine, shown to be an effective vector for introducing 2',5'-oligoadenylates and analogues into intact cells. Poly(L-lysine) conjugation to trimer molecules is not feasible, owing to the destruction -11- 1339l~-j3 of the 2'-terminal ribosyl moiety and subsequent i nact ivat ion of the molecu le . Con jugat ion to poly ( L-lysine) permits efficient intracellular transport of the 2' ,5'-phosphorothioate oligoadenylates while preserving intact within the con jugate the trimer moiety believed necessary for good biological activity.
Correlation of biological properties with absolute configuration has only been possible with the preparation of the fully resolved 2 ',5 ' -phosphorothioate adenylate trimer cores described herein. However, the trimer core compounds have been found to bind and/or activate RNase L
only modestly. We have found that the RNase L activation by the 2 ',5 ' -phosphorothioate core molecules is significantly enhanced by 5 ' -phosphorylation.
P~ase L activation by authentic 2-SA requires the triphosphate form of the trimer . The 5 ' -monophosphate form of 2-5A is a potent inhibitor of the RNase L-activating activity of the triphosphate. Miyamoto et al., J. Biol.
Chem 258: 15232-15237 (1983) i Black et al., FEBS Let.
191: 154 - 158 (1985); Torrence et al., Proc. Natl. Acad. Sci.
USA 78: 5993-5997 (1981) . We have surprisingly found that the cores and monophosphates of the present phosphorothioate analogues of 2-5A, unlike authentic 2-5A, activate RNase L.
The phosphorothioate trimer cores ARpARpA, ASpARpA, ARpASpA, and ASpAspA, are chemically synthesized and separated by preparative thin layer chromatography on silica gel . The four t rimer cores are prepared from 6-N-benzoyl- 3 ' -O-tert -butyld imethyls i lyl-5 ' -O-monomethoxytri tyladenos ine-2-O- (p-nitrophenylethyl )-octahydroazonino-phosphoramidite by stereospec i f ic synthesis, which relies on separation of fully resolved protected intermediates followed by removal of all blocking ~ ~ 3 ~3 1~ ~ 3 groups to yield the fully-resolved 2',5'-phosphorothioate trimer adenylate cores.
The trimer cores are prepared according to the following reactiorn scheme wherein "BZ" denotes the benzoyl radical ~Si" denotes the tert-butyldimethylsilyl radical and "MMTr" re~resents the monomethoxytrityl radical. While not part of the invention, the preparation of the dimer core enantiomers ARpA (6A) and ASpA (6B) is included for completeness.
-13- ~339~3 NH - C - C~,Hs N11B2 NHB2 CH30 ~C~O ~N 02N ~ CH2CH2 0 P - N~ s~ N
MMTrO~J HO~
CH3 - C - Si-O OH (~)O 1O ~) o O(~) CH3 C~3 02N 1~ CH2CH20 - P -N ~
N8Z NHeZ
~N NHBZ
MMTrO ~ N> Mt1TrO
02N~CH2CH20-Pj ~~ 02N~o pO ;5 N
~00~ - y, ~A I ~B I (~)~ ~ (~) NHBZ NHBZ
~N NtlE~Z ~N
6 A -- HO ~ N~S~ \> ~ ~N>
02N ~ H2017 ~S ~ 02N~ CH2CH20 _ ~ S ~I
(~30 ~(~) ~0 0 -14- 13 3 ~ ~ ) 3 NHBZ ¦ ~1BZ
~[ N N11BZ ~N N-IBZ
MMTrl) ~ N~N~ ~ MMTrO ~ N
o N , NHBZ @)o S I Nt~Z
02N~ 0~,0 - ~ --~~ ~N
~ O .--~~J 02N ~ Ot2CH20 - P~ yy S (~)0 0~) - 5 @)0 0(~) ~A ~B
NHBZ I NHE~2 ~N NHBZ ~N MlBZ
NMMTrO ~ N~5~N~>
o2N~3 0~0 P~ ~ ~J N NHE~ZN O N ~ 0~ ~ ~ ~ ~ N NllBZN
(~)~ ~ )0 1 ~ ~
02N~ ~~20 ~~~5 N ~O N~ 0120'l2o ~!~5 ~N~'N
(~)0 0(~ ~)0 0(~) -15- 1339~-~3 The blocking groups are removed from the fully-protected intermediates 7A, 7B, 8A, and 8B to yield the corresponding fully resolved trimer cores ARpARpA (9A), ASpA~pA ( 9B), ARpASpA ( lOA) and ASpASpA ( lOB):
1 3 3 9 9 j rf3 ~N~N HO-C~Ng <N~N ~NX~N
O ~x~H~ H ~ Ng ~N~
HO ~' ~~ NH2 HO O~ ,O NH HO o 'OcH ~N~N'J ~ <N~N'; ~N~HO o~p--s HO OH HO OH HO OH, HO ON
RpRp -SpRp RpSp SpSp 1339~ ~3 The compounds of the invention are advantageously prepared as soluble salts of sodium, ammonium or potassium.
- The preparative scheme begins with 6-N-benzoyl-3 ' -0-tert-butyldimethylsilyl-5 '-0-monomethoxy-trityladenosine (compound lE), which is advantageously prepared from adenosine according to the procedure of Flockerzi et al, Liebigs Ann. Chem., 1568-1585 (1981) .
Preparation of the compounds of the present invention is illustrated in more detail by reference to the following non-limiting examples. 3-Nitro-1,2,4-triazole; chloro-octahydroazonino-p-nitrophenylethoxyphosphate; 2,5-dichlorophenylphosphoro-dichloridate; and p-nitrophenylethanol used in the examples may be prepared advantageously from published procedures: Chattopadhyaya et. al. Nucleic Acids Res. 8:2039-2053 (1980); Schwarz et al., Tetrahedron Lett. 5513-5516 (1984); Uhlmann et al., ~elv. Chim. Acta 64:1688-1703 (1981). These compounds are also available commercially in the United States. 2,5-Dichlorophenyl-phosphorodichloridate may be obtained from Fluka Chemical Corp., 980 S. Second St., Ronkonkoma, New York 11779, ( "Catalog 15: Chemika-Biochemika" 1986/1987, no. 36212). 3-Nitro-1,2,4-triazole is available from Aldrich Chemical Co., P.O. Box 355, Milwaukee , WI 53201 (1986-1987 cat. no. 24,179.2). P-Nitrophenylethanol is available from Fluka Chemical Corp. (cat. no. 73,610).
Chloro-octahydroazonino-p-ni trophenylethoxyphosphate may be prepared according to Example lA, below.
Pyridine and triet:hylamine used in the examples were purified by distillation over ~OH, tosyl chloride and calcium hydride. Dichloromethane was distilled over calcium chloride and then passed through bas ic a lumina .
Pure acetonitrile was obtained by distillation over calcium hyd r i de .
Purification of the protected nucleotides was achieved by preparative column chromatography on silica gel 60 (0.063-0.2 mesh, Merck) and by preparative thick layer chromatography on silica gel 60 P~2s4 (Merck). Thin layer chromatography ("TLC") was carried out on precoated thin layer sheets F 1500 LS 254 and cellulose thin layer sheets F 1440 from Schleicher ~ Scheull.
The starting material, 6-N-Benzoyl-3-0-tert-butyldimethylsilyl-5'-0-(4-monomethoxytrityl~adenosine (Compound lE) and the reagent 6-N-benzoyl-2',3'-bis-O-(tert-butyldimethylsilyl)-adenosine (Compound lG), are prepared according to Example 1.
a. N6,N6,2',3',5'-O-Pentabenzoyladenosine: (lA) To a suspension of 5.34 g (20 mmole) adenosine (Sigma, dried at 80~C/10-3 Torr for 24 h) in 100 ml dry pyridine, 33.74 g (240 mmole) benzoyl chloride was added dropwise. After 20 h stirring at room temperature (nr.t.") the mixture was treated with 16 ml dry MeOH and then extracted with CHC13 (3 x 250 ml). The organic phase was washed with water (3 x 250 ml), dried over Na2SO4, and evaporated to dryness.
Final coevaporation was performed with toluene. The residue was dissolved in CHC13/MeOH 2/1 by heating, and after cooling to r.t., petrolether (diethylether) was added until the sol~tion became turbid. After standing for 12 h at 0~C 12.18 g was obtained, and from the mother liquor, 2.66 g of the product were isolated as colorless needles of m.p. 183-184~C., yield 14.84 9 (94%).
b. 6-N-Benzoyl adenosine (lB): A solution of 7.88 g (10 mmole) of the pentabenzoyl adenosine (lA) in 150 ml dry pyridine and 50 ml dry MeOH was treated with 50 ml 1 M
sodium methylate solution. After 15 min the solution was poured onto an ice cold solution of a 110 ml DOWEX ion exchanger 50 x 4 (pyridinium form) in ca 20 ml water.
* Trademarks .. .
, .
-19- ~ 3 ~ 3 After 5 h stirring the pH was 5.5-6Ø After filtering from the ion exchanger, the residue was washed with boiling - MeOH/water (3/1). The filtrate was evaporated to dryness and crystallized,from IMeOH/water 2/1 to give 3.25 g (83%) of the product as colorless needles, m.p. 151-153~C.
c. 6-N-Benzoyl-5'-O-(4-methoxytrityl) adenosine (lC): 17.9 9 (46 mmole) 6-N-benzoyl adenosine H2O (lB) was evaporated with dry pyridine (3 x 100 ml) and finally dissolved in 150 ml dry pyridine and 21.31 9 (69 mmole) p-monomethoxytrityl chloride. The reaction solution was stirred at 50~C for 14 h and dry MeOH (50 ml) was added and allowed to come to r.t. The product was extracted with CHC13 (3 x 400 ml) and washed with water (3 x 400 ml). The organic phase was dried over Na2SO4 and evaporated to dryness. Final coevaporation was performed with toluene.
Purification was performed using a silica gel column (16 x 2.5 cm, Merck) and eluted with 3 liter EtOAc/MeOH 7/3 to give 25.6 9 (87%) of an amorphous powder. Crystallization was accomplished with acetone/water to yield the product, m.p. 120-125~C.
d. 6-N-Benzoyl,-2'-O-(tert-butyldimethylsi,lyl)-5'-O-(4-methoxytrityl) adenosine (lD);
6-N-Benzoyl-3'-O-(tert-butyldimethylsilyl)-5'-0-(4-methoxytrityl) adenosine (lE);
6-N-benzoyl-2',3'-O-bis(tert-butyldimethylsilyl)-5'-O-(4-methoxytrityl) adenosine (lF):
To a solution of 4.05 9 (26.9 mmole) tert-butyldimethylsilylchloride ("TBDMS-Cl") and 3.66 9 (53.8 mmole) imidazole in 100 ml dry pyridine, were added 14.42 g (22.4 mmole) of compound lC which was previously coevaporated with dry pyridine. After 15 h stirring at r.t., 5 ml dry MeOH was added and the mixture was evaporated to 1/3 volume. The crude product was extracted with CHC13 (3 x 250 ml) and washed with water. Upon 1 3 ~
evaporation, the crude product was first purified by a silicagel column (15 x 3 cm) with CH2C12/EtOAc (9/1), and - subsequently purified using medium pressure chromatography (silicagel colum~, GSF-type C (N= 9000, VD = 28 ml) at 8-10 bar pressure with the following mixtures of CH2C12/petrolether/EtOAc/EtOH: 100:100:10:0.5 (2 liters), first; 100/100/10/1 (3 liters), second; and 100/100/31/2 (0.5 liters), third. The title compounds were isolated.
The retention time of the peak maxima for each compound was as follows: 25 min. for compound lF (yield 1.84 g, 9%); 60 min. for compound lD (yield 6.62 9, 39g); 105 min. for compound lE (yield 8.32 g, 49~).
e. 6-N-Benzoyl-2',3'-bis-O-(tert-butyldimethyl-silyl) adenosine (lG): 1.74 g (2 mmole) of compound lD was lS stirred with 20 ml 80% acetic acid,at 22~C. After 20 h the cleavage of the monomethoxytrityl group was complete. The reaction mixture was extracted with CHC13 (3 x'200 ml) and washed with 200 ml 1 M phosphate buffer (pH 7). The organic phase was dried over Na2SO4 and evaporated to dryness. Purification was accomplished using a silica gel column (2 x 10 cm) and eluted with CH2C12/MeOH (96/4). The light yellow product was dissolved in 5 ml CHC13 and treated with Et2O until turbid. 0.982 g of the pure product crystallized out. The pure product crystallized out again from the mother liquor, 0.11 9, m.p. 189~C. The total yield was 1.092 g (91%).
-21- ~ 3 3 ~
EXAMPLE lA
Chloro-octahydroazonino-p-nitrophenylethoxyphosphate a. P-nitrophenylphosphoric acid dichloride. To phosphorus trichloride (Fluka, N.Y., ~79690) (28 ml, 0.317 moles) 80 ml anhydrous ether are added. The mixture is cooled to -30~C. P-nitrophenylethanol (8.35 g, 50 mmoles) is added, followed by stirring for 1.5 hr. Ether and excess PC13 is- removed under vacuum to yield p-nitrophenylphosphoric acid dichloride (yield 80%).
b. OctahydrQazonin. Caprylolactam (Fluka, N.Y., ~21631) (25 g, 117 mmoles) is combined with lithium aluminum hydride (10.5 g ) in ether and reduced with stirring for S hr. The reaction mixture is filtered and evaporated with ether. The product is octahydroazonin (9096 yield).
c. l-Trimethylsilyl octahydroazonin. The silylamine of octahydroazonin is prepared by combining octahydroazonin (12.7 g, 0.1 moles) and trimethylsilane (0.12 moles) and O.S moles hexamethyldisilazane + lS0 mg of ammonium sulfate. The mixture is refluxed for 90 hr and distilled under vacuum to yield 16.5 g of l-trimethylsilyl octahydroazonin (82%).
d. Chloro-octahydroazonino-p-nitrophenylethoxy-phosphate. P-nitrophenylphosphoric acid dichloride (26.8 g, 100 mmoles) and l-trimethylsilyl octahydroazonin (19.9 g, 100 mmoles) are combined under nitrogen at 0~C. The mixture is warmed to room temperature and stirred 2-3 h.
Trimethylsilyl dichloride is removed under vacuum. The product in the residue is chloro-octahydroazonino-p-nitrophenylethoxyphosphate (33.9 g, 9496 yield).
1 ~ 3 '3 9 i-~ 3 ~XAMPLE 2 6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-(4-ethoxytrityl)-adenosine-2'-0-(p-nitrophenylethyl)-octahydroazonino-phosphoramidite (2). Compound lE (0.758 g, 1.0 mmole) and diisopropylethylamine (0.52 g, 4 mmole) were dissolved in dichloromethane (5 ml) and chlorooctahydroazonino-p-nitrophenylethoxyphosphane (0.80 9, 2.22 mmole) was added dropwise. After stirring for 2 h at r.t., TLC analysis indicated complete reaction. The reaction mixture was transferred to a separatory funnel using saturated aqueous NaHCO3 (50ml) and the product was isolated by extraction with ethylacetate (2 x 50 ml). The organic ~ayer was washed with saturated NaCl, dried (Na2SO4), and evaporated to dryness. The residue was dissolved in ethylacetate-triethylamine (95:5 v/v~, chromatographed on a silica gel column (10 x 2 cm) previously calibrated with ethylacetate-triethylamine (9/1) and eluted with ethyl-acetate-triethylamine (95:5 v/v).
The product fractions were collected, evaporated to dryness, ~inally coevaporated with dichloromethane and dried in vacuo at 40~C to give compound 2 (1.05 g, 97~) [Anal. calcd. for CsgH70N7OgPSi ~ 1 H2O: C, 64.52; H, 6.60;
N, 8.92. Found: C, 63.93; H, 6.85; N, 8.62].
EXA~PLE 3 6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-monoethoxytrityl-P-thioadenylyl-2'-[OP-(p-nitro-phenylethyl)-5']-6-N-benzoyl-2',3'-di-0-tert-butyldimethylsilyladenosine (4A + 4B). The phosphoramidite 2 (1.12 g, 1.0 mmole) and 6-N-benzoyl-2',3'-di-tert-butyldimethylsilyladenosine (3) (0.478 g, 0.7 mmole) were dried overnight in a drying pistol at 40~C in vacuo. The dried residue was then d;ssolved in dry acetonitrile (6 ml), and 3-nitro-1,2,4-triazole (0.285 g, 2.5 mmole) was added and stirred at r.t. for 3 h. Pyridine (6 ml) and ~3 ~3-~
sulfur (0.5 g) were added and after stirring at r.t. for 20 h, the reaction mixture was extracted with chloroform (300 ml). The organic phase was washed with saturated NaCl-solution (2 x 2Q0 ml), dried (Na2SO4), and evaporated to dryness. Final evaporation was performed with toluene to remove pyridine. The residue was dissolved in chloroform and chromatographed on a silica gel column (15 x 2.5 cm) with 1 liter of chloroform to give a product fraction containing both Rp and Sp isomers. The separation of the diastereoisomers was carried out on preparative silica gel plates, using dichloromethane/ethylacetate/n-hexane (1:1:1 v/v). The plates were developed thrice. The higher Rf isomer (0.47 g; 42%, TLC in dichloromethane/ethylacetate/n-hexane, 1:1:1, 0.54) and the lower Rf isomer (0.31 g; 28%, TLC in dichloromethane/ethylacetate/n-hexane, 0.46) were obtained as colorless amorphous powders after drying at 40~C in vacuo. The higher Rf isomer was compound 4A.
[Anal. calcd. for CgoHggN10O14PSi3 ~ 1 H2O: C, 59.89; H, 6.32; N, 9.61. Found: C, 59.89; H, 6.32; N, 9.21]. 31p_ NMR (400 MHz, CDC13, 85~6 H3PO4, 69.841 ppm). The lower Rf i some r wa s c ompound 4 B . [Ana 1 . ca lcd . for C80H98N10~14PSi3~ ~ 1 H2O: C, 59~.89; H, 6.28; N, 9.61.
Found: C, 59.91; H, 4.61; N, 9.28]. 31p_NMR (400 MHz, CDC13, 85% H3PO4, 69.223ppm). EXAHPLE -4 6-N-Benzoyl-3 ' -0-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5']-6-N-benzoyl-2',3'-di-0-tert-butyldimethylsilyladenosine (5A + 5B).
0.258 g, (0.164 mmole) c>f the pure isomers 4A and 4B, were detritylated separately by treatment of each with 296 p-toluenesulfonic acid in dichloromethane/methanol (4/1) (3.2 ml) at r.t. for 40 min. The reaction mixture was diluted with chloroform (50 ml), washed with phosphate buffer, pH 7 (2 x 20 ml), and evaporated to a foam. The residue was purified by silica gel column chromatography (10 x 2.5 cm).
~ 3 3 ~
Compounds 5A and 5B were separated on the column by using chloroform and chloroform/methanol (100:0.5 till 100:1).
The product fractions were collected and, after evaporation, dried in vacuo at 40~C to give in the case of 5A, 0.198 g (92%), and in the case of 5B, 0.192 9 (89%).
5A has an Rf of 0.27 in dichloromethane/ethylacetate/n-hexane (1:1:1). [Anal. calcd. for C60H82N11~13PSi3S ~ 1 H2O: C, 54.15; H, 6.36; N, 11.57. Found: C, 53.78; H, 6.44; N, 11.72]. 5B has an Rf of 0.30 in the same system.
[Anal. calcd. for C60Hg2NllO13PSi3S: C, 54.90; H, 6.29; N, 11.73. Found: C, 54.90; H, 6.20; N, 11.45J.
P-Thioadenylyl-(2'-5')-adenosine (6A + 6B). The fully protected dimers 5A and 5B, respectively, were deprotected separately by the following procedure. Each protected dimer ~39 m~, 0.03 mmole) was treated with 0.5 M
1,8-diazabicyclor5.4.0]undec-7-ene(1,5,5)(Fluka, cat. no.
33842, "DBU") in pyridine (9 ml), and after stirring at r.t. for 2 h was neutralized with 1 M acetic acid (4.5 ml) and finally evaporated. The residue was taken up in 1 M
tetrabutylammonium fluoride ("Bu4NF") in tetrahydrofuran ("THF~) and after 24 h again evaporated to dryness.
Deacetylation was achieved by treatment with conc. ammonia - (20 ml) for 48 h followed by evaporation of the mixture.
The residue was then dissolved in water (50 ml) and washed with chloroform (2 x 20 ml). The water phase was applied to a DEAE Sephadex*A-25 column (60 x 1 cm) for elution with a linear gradient of a buffer of 0.001-0.25 M Et3NH+HCO3-, pH 7.5. The product was eluted at a concentration of 0.08-0.1 M. Evaporation to dryness followed by coevaporation with water (10 x 10 ml) and final purification by paper chromatography with i-PrOH/conc. ammonia/water (7:1:2 v/v) yielded in the case of 6A 630 O.D. units (87.5%) and in the * Trademark "
-25- 1~ 3gi3~3 case of _ 648 O.D. units (90~). The Rf of 6A on cellulose sheets, using the above system, was 0.29. The Rf of 6B was 0.30.
6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-monomethoxytrityl-P-thioadenylyl-2'-~0P-(p-nitro--phenylethyl)-5'~-N-6-benzoyl-3'-0-tert-butyldimethylsilyl-P-thioadenylyl-2l-tQp-~p-nitrophenylethyl)-5~]-6-N-benzoyl-2',3'-bis-0-tert-butyldimethylsilyladenosine (7A, 7B and 8A, 8B). The phosphitamide 2 (0.449 g; 0.41 mmole~ was condensed with the 5'-hydroxy dimer SA and 5B (0.0262 g;
0.2 mmole) separately in the presence of 3-nitro-1,2,4-triazole (0.114 g; 1.0 mmole) in dry acetonitrile (3.2 ml).
After stirring at r.t. for 3 h, sulfur (0.2 g; 6.25 mmole) in pyridine (0.4 ml) was added for oxidation. After stirring at r.t. for another 24 h, the product was extracted with dichloromethane (50 ml), the organic phase was washed with saturated NaCl solution (2 x 20 ml), dried (Na2SO4), and then evaporated to ~dryness. ~inal coevaporation was performed with toluene to remove pyridine. The crude product was chromatographed on a silica gel column (lS x 2 cm) and eluted with chloroform/methanol (100:2) to give,~on condensing with compound 5A, the isomer mixture 7A + 7B. The isomer mixture 8A + 8B, was obtained upon condensing the phosphitamide 2 with compound 5B in the same manner. The diastereomeric separation of each isomer mixture was accomplished by using preparative silica gel plates (20x20x0.2 cm) to which about S0 mg of isomer mixture per plate was applied for optimal separation. The plates were developed in dichloromethane/ethylacetate/n-hexane (l:l:O.S
v/v) three times. The appropriate bands were cut out and eluted with chloroform~ethanol (4:1) The higher Rf isomer synthesized from 5A has a Rf of 0 58 in 1~ 3~ ~3 dichloromethane/ethylac~ tate/n-hexane (1:1:1) and yielded 4 8 % ( 0 . 2 1 8 9 ) o f- 7 A . ~ A n a 1 . c a 1 c d . f o r C111~135N17~22P2Si4S2 ~ 1 H2O: C, 57.S6; H, 5.96; N, 10.28.
- Found: C, 57.38; H, 5.99; N, 10.11] . The lower Rf isomer has a Rf of 0.48 in the above-mentioned system, and yielded 3 4 % ( 0 . 1 5 7 g ) o f 7 B . 1 An a 1 . c a 1 c d . f or ClllH135N17~22P2Si4S2 ~ 1 H2O: C, 57.56; H, 5.96; N, 10.28.
Found: C, 57.40; H, 5.97; N, 10.193.
The isomeric mixture derived from the 5 ' -hydroxy dimer 5B
was separated in the same manner and yielded the higher Rf isomer 8A in 41% (0.186 g ) with an Rf of 0.53 in the above solvent system. lAnal. calcd. for ClllH135N17~22P2Si4S2 C, 58.02; H, 5.92; N, 10.36. Found: C, 58.00; H, 5.84; N, 10.66] . The lower Rf isomer 8B showed a Rf value of 0.45 a n d y i e 1 d e d 3 5 % ( 0 . 1 6 1 9 ) . [ A n a 1. c a 1 c d . f o r ClllE~135N17022P2Si4S2 1 H2O C, 57.56; H, 5.96; N, 10.28. Found: C, 57.30; H, 5.78; N, 10.03~.
EXA~PLE 7 ( Rp ) -P-Th ioadenylyl- (2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- (2 ' -5' ~-adenosine (9A). A solution of 0.116 g (0.05 rrunole of the fully protected trimer 7A was detritylated with 2% p-toluenesulfonic acid in 1.5 ml dichloromethane/methanol (4: 1) for 90 min. The mixture was dissolved in CHC13, washed with phosphate buffer (2x15 ml), dried (Na2SO4), and evaporated to dryness. The residue was chromatographed on silica gel plates ( 20x20xO . 2 cm), developed with dichloromethane/ethylacetate/n-hexane ~5:5:3 v/v). The product band (Rf 0. 35) was cut out, eluted with chloroform/methanol (7: 5) and gave on evaporation to a colorless foam a yield of 70-83~. 38.5 mg (18.9 micromole) of the product was then stirred with 0.5 M DBU in pyridine (7.5 ml) for 20 h, neutralized with lM acetic acid (3.75 ml) and finally evaporated. The evaporated product was desilylated through treatment with lM B~14NF in THF (6 ml) ~ 3 ~ 9 '.~
for 24 h. The mixtur-e was concentrated in vac~o. The residue was dissolved in conc. ammonia (25 ml) and stirred at r.t. for 48 h. After evaporating the solution, the residue was taken up in water (20 ml) and washed with chloroform (2xlO ml). The aqueous phase was put on a DEAE
Sephadex A-25 column (60xl cm) and the product was eluted with a linear gradient of Et3NH+HC03-buffer. The product fraction was collected, evaporated and further purified by paper chromatography using i-PrOH/conc. ammonia/water (6:1:3) to give the title compound in 75-80~ yield.
(Sp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine ~9B). A solution of 0.116 9 (0.05 mmole~ of the fully protected trimer 7B was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
(Rp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5')-adenosine (lOA). A solution of 0.116 g (0.05 mmole) of the fully protected lrimer 8A was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
(Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine ~lOB). A solution of 0.116 9 (0.05 mmole) of the fully protected trimer 8B was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
The UV-absorption spectra in methyl alcohol and lH-~MR spectra of the above-prepared protected monomer, dimer and trimer cores are set ~orth in Tables 1 and 2, respectively.
-28- ~3~ ,3 W-Absorption Spectra of Protected Monomer, Dimer and Trimer Cores in MeOn Compound ~max (nm) 19~
_ 230 277 4.47 4.50 4A 231 277 4.66 4.70 4B 231 277 4.66 4.70 5A 278 4.70 5~ 278 4.70 7A 230 278 4.78 4.90 7B 230 278 4.78 4.89 8A 230 278 4.79 4.90 8B 230 278 4.78 4.90 lH-NMR Spectra of Protected Monomer, Dimer and Trimer Cores Con~
pound 1 '-H 2-~ 8-H Solvent 2 6.11 6.13 8.70 8.23 CDC13 4A 6.30d 5.87d 8.68; 8.60 8.19; 8.17 CDC13 4B 6.29d 5.94d 8.72; 8.62 8.26; 8.18 Cl)C13 5A 6.06d 5.94d 8.82; 8.75 8.25; 8.08 CDC13 5B 6.13d 5.90d 8.74; 8.73 8.26; 8.24 CDC13 7A 6.23d 6.08d 5.84d 8.69; 8.58; 8.55; 8.20; 8.11;8.01 CDC13 7B 6.22d 6.17d 5.85d 8.67; 8.60; 8.57; 8.23; 8.10;8.00 CDC13 8A 6.27d 6.13d 5.93d 8.71; 8.61; 8.60; 8.21; 8.13;8.00 CDC13 8B 6.27d 6.22d 5.90d 8.71; 8.64; 8.61; 8.27; 8.22;8.19 CDC13 1 ~values in ppm; Standard T~lS; characteristic 3 0 s i 9 na 1 s 1 3 3 ~ 3 Assiqnment of Absolute Configuration of 2',5'-Phosphorothioate Adenylate Trimer Cores Determination of the absolute configurations of the trimer cores was accomplished by 31P-NMR fast bombardment mass spectrometry and enzymatic digestion.
It is known that the enzyme SVPD preferentially cleaves Rp-3',5'- or 2',5'-phosphorothioate linkages from the 2'/3'-terminus. Nelson et al, J. Org. Chem. 49:2314-2317 (1984); Eppstein et al, J. Biol. Chem. 261:5999-6003 (1986); Lee et al, Biochemistry 24:551-5S5 (1985). SVPD
hydrolysis of the chemically synthesized dimer core ARpA
yielded adenosine and AMPS in a molar ratio of 1:1, respectively; the half-life was 3 hours (Table 3). The ASpA dimer core was not a substrate for SVPD under these conditions. Trimer core 9A has the Rp ~ internucleotide linkage con iguration as determined by hydrolysis by SVPD
to yield AMPS plus ARpA in a molar ratio of 1:1, respectively. Similarly, SVPD hydrolysis of trimer core 9B
yielded ASpA and AMPS, thus identifying trimer core 9B as having the SpRp internucleotide linkage configuration (Table 3). Trimer cores 10A and 10B were not substrates for SVPD (Table 3), revealing the presence of the Sp configuration in the internucleotide linkage adjacent to the 2'/3'-termini.
1339.iJ.~3 ~ " ~, .. ..
o ' oc ~U ~ Q 0 ~~ O ~ 0 0 V~ ~ ~ Q
L
O C
~ O O ~ 0 0 ~ CJ
O ~ J ~,_ ~ > > > >
~' .~ O Q '_ 0 ~ 0 0 . ~'1-- J O O O ~> C
L. ~ _ C~
~_ O O 1~ C Z
O ~ L L
~_ o o '~ . E
O O O O O O
0 ~- c cn~ c c c o ~ O L Q
0 L ._ ~ J
O
O ~~-- ~O
~ ~r ~-- c c<n C
O ~1 ~ ~ 0 ~~ 0 -n I E
_ ~ 0 0 ~ ~ ~ ~
~,~ ~ ., ~ ~ ~ O
L S -- 0 0 0 0 ~ 0 O ~ o O
", ~' X .------ -- C 0 L E
O ~ ~' ~_ _ V U O O O O
O ~~ C CC~~. C ~ I
_ O J
O ~ ~ O
L ~o ~ ., Z ~' ~ _ c _ C ~ 1 0 -- ~ ~ 0~ 0 0 0 ~_ ~ > ~ ~ r~
C ~ O O ~ O
C~ _ J J Cl O
C Z _ ~
._ ~L C
oV~ O ~ ~ E ~ 0 ~- L ~ 0 .
~1 _ ~ Z
~ O
._ 0 r C
O ~u~
,.~ .. .... 00 O' ~ O~ V~O' -- --~ O O
J l. . . .>~ :~
~: ~ ~ 0 u 0 o o ~J ~ ~' ' '~ E e E
~ Oa ~ ~ --~ Z ~ ~O ~ ~ u~
c ~ ~ I~ ~ I~ o ~ C C C
o o o O
O ~ o. ~
0 ~ "
~1 0 0 ~' ~' C
L o ~ ~ C C ~
~_ ~ o ~ o o ~
v- O ~1 ~ E E O
r ~ e~ ¦ol ~ ol ~ ~ ~ C C
'01 '01 0 O~ O~ ~ ~ O O O -- --- ~~
O E <~
U~ E . 0 ~ ~ ~~ a 0 I
N ~ ~ ~t ~ ~ ~ < > ~
~3~3-~3 The four 2,5-phosphorothioate adenylate trimer cores were further characterized by hydrolysis with the enzyme 2'-phosphodiesterase ("2'-PDE"), an exoribonuclease found in L cell extract. The enzyme cleaves from the 2'/3'-terminus. Whereas authentic A2 and A3 cores where hydrolyzed to adenosine and AMP with a half-life of 10 min, the dimer cores ARpA and ASpA were not substrates for 2'-PDE (Table 3). The fact that the 2,5-phosphorothioate dimer cores were not substrates for 2'-PDE (unlike authentic 2-5A) greatly assisted in the assignment of the stereoconfigurations of the 2',5'-phosphorothioate adenylate trimer cores. Trimer core 9A was a substrate for 2'-PDE; the products of hydrolysis were ARpA and AMPS.
Trimer core 9B was a substrate for SVPD, yielding ASpA and AMPS; trimer core lOA was a substrate, yielding ARpA and AMPS; trimer lOB was not a substrate for 2'-PDE.
31P-NMR spectroscopy has revealed that _p stereoisomers of phosphorothioates resonate to higher field than Rp diastereomers. Further, Sp diastereomers have a longer retention time on reverse phase HPLC than Rp diastereomers . The ASpA dimer core resonates upfield from the ARpA (Table 3). Similarly, two singlets observed for ASpAspA resonate upfield from the two singlets observed for ARpARpA (Table 3). Assignment of the absolute configurations of trimer cores 9A (RpRp) and lOB (Sp_p) was based on the two singlets which resonate at the same frequency as the singlets observed for the ARpA and ASpA
dimer cores. Assignment o~ configurations for trimer cores 9B and lOA was made in combination with the enzyme degradations and HPLC analyses (Table 3). The 3IP-NMR
spectra revealed that the ~ppm between the two singlets for the ASpARpA trimer core is 1.2, whereas the two singlets for the ARpAspA have a ~ppm of 0.8 (assignment is 5' to 2'/3' terminus).
-33- ~3~3i.l ,3 The metabolic stability of the 2,5'-phosphorothioate dimer and trimer cores is markedly greater than authentic 2-5A. The rate of hydrolysis of the trimer cores by the 3'-exonuclease SVPD is, in order of decreasing stability:
AspAp~pA>ARpARpA>>>A3~ The trimer cores ARpASpA and ASpAspA
are not substrates of SVPD (Table 3). The 3'->'5'direction of stepwise cleavage by SVPD is blocked by an _p configuration, preventing cleavage of the upstream adjacent phosphorothioate linkage. With 2'-PDE, the ARpARpA, ASpARpA and ARpASpA trimer cores, but not the ASpAspA
trimer core, were substrates. With both SVPD and 2'-PDE, the dimer cores (either ARpA or ASpA) accumulate following hydrolysis of the ARpARpA, ASpARpA and ARpASpA trimer cores. Hydrolysis of the 2-5A molecule by SVPD and 2'-PDE
proceeds from the 2'/3'-terminus. Therefore, introduction of the phosphorothioate group into tne trimer core results ;n the accumulation of the ARpA or ASpA dimer cores from the 5'-terminus and the accumulation of AMPS from the 2'/3'-terminus (Table 3). With authentic A3, there is no detectable accumulation of A2 following hydrolysis by SVPD
or 2'-PDE.
None of the _p linkage-containing tri~er cores were cleaved by SVPD. While the half-life of ASpARpA upon cleavage by L-cell extract (15 hours) did not differ significantly from that of ARpARpA (18 hours), the half-life for the ARpASpA trimer was orders of magnitude longer (20 days). ASpAspA was not cleaved ~y L-cell extract (Table 3).
Preparation of Phosphorothioate Tetramer Cores The following non-limitin~ examples illustrate the preparation of the fully-resolved tetra~f core co~pounds of the invention.
-34- 13 3~ g-)3 a. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5)-adenosine b. (Rp)-P-thiodenylyl-(2~'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5')-adenosine.
A solution of 0.149 g (0.065 mmole) of fully protected trimer 8B, which has the stereoconfiguration SpSp, was detritylated with 2% p-toluenesulfonic acid in 1.5 ml dichloromethane/methanol (4:1) for 3 h at room temperature. The mixture was diluted with 50 ml CHC13, washed with phosphate buffer (2 x 15 ml), dried (Na2SO4), and evaporated to dryness. The residue was chromatographed on silica gel plates (20 x 20 x 0.2 cm) developed with dichloromethane/ethylacetate/n-hexane (5:5:3 v/v). The product band, Rf 0.55, was cut out, eluted with chloroform/ethanol (1:1) and gave, on evaporation to a colorless foam of 0.108 9 (yield 88~). The 5'-deblocked _pSp trimer 8B (101 mg; 0.05 mM) was dissolved in 0.5 ml acetonitrile overnight with phosphitamide 2 (0.105 g; 0.1 mmole). 3-Nitro-1,2,4-triazole (0.023 g; 0.2 mmole) was added. After stirring at room temperature for 3 h, sulfur (0.042 9; 1.3 mmole) in pyridine (0.084 ml) w~s added for oxidation. After stirring at room temperature for another 24 h, the product was extracted with dichloromethane (50 ml), the organic phase was washed with saturated NaCl solution (2 x 20 ml), dried over Na2SO4, and then evaporated to dryness. Final coevaporation was performed with toluene to remove pyridine. The crude product was purified by using pre~arative silica gel plates (20 x 20 x 0.2 cm) to which about 50 mg per plate was applied for optimal separation by developing in dichloromethane/
ethylacetate/n-hexane (1:1:0.5 v/v) three times. The band containing the~fully protected SpSp_p tetramer (Rf 0.3) and the band containing the fully protected P~pSp_p tetramer (RF
133~3 )3 0.4), were cut out and eluted with chloroform/methanol (4:1). The yield of the fully protected Sp~pSp tetramer was 43 mg; 29%. The yield of the fully protected ~pSpSp compound was 53 mgi 35.5%. The two isomers (7.3 micromoles; 0.22 mg) were deblocked by stirring with 0.5 M
DBU in pyridine (5.0 ml) for 20 h, neutralized with lM
acetic acid/ pyridine (0.5 ml) and finally evaporated. The subsequent desilylation was achieved with lM
tetrabutylammonium fluoride in tetrahydrofuran (3.6 ml) for 48 h at r.t. The mixture was concentrated in vacuo, the residue dissolved in conc. ammonia (15 ml) and stirred at r.t. for 48 h. After evaporating the solution, the residue was taken up in 5 ml of 80~ acetic acid and allowed to stand for 20 h at r.t. The residue was dissolved in about 5 ml water and put on a DEAE Sephadex A-25 column (60 x 1 cm) and the product was eluted with a linear gradient of Et3NH+HCO3- buffer (pH 7.5) (gradient 0.001 - 1 M). The product fractions were collected, evaporated and further purified by paper chromatography using; i-PrOH/conc.
ammonia/water (6:1:3). The tetramer isomers were eluted with water to give ASpAspAspA (72% yield; Rf 0.23) and ARpASpAspA (73% yield; Rf 0.29) as the ammonium salt.
a. (Rp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine b. (Sp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine 13 ~ ~.3 ~
The title compounds are prepared by following the procedure of Example 11, but substituting the fully - protected trimer 7A for 8B as the starting material.
a. (Rp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5i)-adenosine b. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine The title compounds are prepared by following the procedure of Example 11, but substituting the fully protected trimer 7B for 8B as the starting material.
a. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5'j-(Sp)-P-thioadenylyl-(2'-5')-adenosin,e - b. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2~-5~ ? - ( sp ) -P-thioadenylyl-(2'-5')-adenosine The title compounds are prepared by following the procedure of Example 11, but substituting the fully protected trimer 8A for 8B as the starting material.
20 - Preparation of 2'~5'-Phosphorothioate Oligoadenylalte 5'-Monophosphates 5'-Monophosphates of 2',5'-oligoadenylates are readily prepared by reacting the corresponding core compounds with POC13. Such treatment would result in the elimination of sulfur from the phosphorothioate internucleotide linkages of the compounds of the present invention, and the formation of 2-5A. Thus, the 5'-monophosphates of the phosphorothioate oligoadentylates must be prepared from the corresponding fully protected core compounds from which the monomethoxytrityl blocking group on the 5'-terminal nucleotide has been removed. The conditions of the phosphorylation must be such that the p-nitrophenylethyl blocking groups on the internucleotide phosphorous atoms remain intact.
~33~53 The 5'-monophosphate of each resolved trimer core of the present invention was prepared from the 5'-hydroxy - analogue of the corresponding fully protected trimer 7A, 7B, 8A or 8B. The intermediate 5'-phosphotriester (11A, 11B, 12A or 12B) was prepared according to Example 15 and then freed of all blocking groups according to Example 16 to yield the 5'-monophosphate. The procedure of Examples 15 and 16 may be used for forming the 5'-monophosphate of any of the four trimer core stereoisomers.
5'-0-(2,5-Dichlorophenyl-p-nitrophenylethyl)-phosphoryl-6-N-benzoyl-3'-O-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5']-6-N-benzoyl-3'-O-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5'~-6-N-benzoyl-2',3'-di-O-tert-butyldimethylsilyl adenosine (llA, 11B, 12A or 12B): To a solution of 1,2,4-triazole (0.011 g; 0.16 mmole) and 2,5-dichlorophenylphosphorodichloridate (O.022 g; 0.018 mmole) in dry pyridine (0.5 ml) was added the 5'-deblocked analogue of either 7A, 7B, _ or 8B (0.1 9; 0.049 mmole) (~repared as an intermediate in Example 11), and after stirring for 30 min, p-nitrophenylethanol (0.02g; 0.119 - mmole) was added and stirring continued for 20 h. The solution was then extracted with chloroform (50 ml), the organic phase was washed with water ( 2 X 20 ml), evaporated to dryness, and finally co-evaporated with toluene. The residue was purified by silica gel chromatography on preparative plates ( 20 X 20 X 0.2 cm) using the system dichloromethane/n-hexane/ethylacetate (1:1:1 v/v). The product band was eluted with chloroform/methanol (4:1) and evaporated -in vacuo to give 11A, 11B, 12A or 12B in 70-80%
yield, respectively.
t 3~9a3 a. 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine (13A) b. 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine (13B) c. 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine (14A) d. 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine (14B) p-Nitrobenzaldoxime (0.036 g; 0.216 mmole) was stirred for 30 min in dioxane/triethylamine/water (each 0.5 ml), the appropriate 5'-phosphotriester llA, llB, 12A or 12B (0.05 g, 0.02 mmole) was added and the mixture was kept at r.t. for 4 h. The solution was evaporated to dryness, followed by coevaporation with toluene ~2x5 ml), and the residue purified by preparative TLC on plates (20x20x0.2 cm) in chloroform/methanol (95:5). The product band was eluted with chloroform/methanol/triethylamine (5:1:1) and evaporated to dryness. This material (0.022 g;
10 micromole) was stirred with 0.5 M DBU in pyridine (8 ml) at r.t. for 24 h, the solution neutralized with lM acetic acid (4 ml) and evaporated to dryness. The residue was - treated with lM Bu4NF in THF (6 ml) for 48 h and after evaporation the debenzoylation was accomplished by treatment with conc. ammonia (25 ml) at r.t. for 48 h. The solution was evaporated. The deblocked crude trimer 5'-monophosphate was taken up in water (25 ml) and washed with chloroform (2x10 ml). The aqueous phase put on a DEAE
Sephadex A-25 column (60xl cm) for elution with a linear gradient of 0.001-lM Et3NH+HCO3- buffer. The product fractions were collectecl, evaporated to dryness, and after several coevaporations with water were further purified by paper chromatography using the i-PrOH/conc ammonia/water-system (55:10:35) The product band was eluted with water 13:~'33~
and gave on lyophilization the trimeric P-thioadenylate 5'-monophosphate 13A, 13B, 14A or 14B as ammonium salts in 68-74~ yield.
-39a-1~'.39.3.'j3 Z ~Z
z~z o~~ 1l o (~) I
A Rp AS p A Rp A : ( Rp ) - P - t h i o a d e n y l y l - ( 2 ' - 5 ' ) ~ P-th ioadenyl yl - ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenos ine .
A Rp A Rp A S p A : ( P~p ) - P - t h i o a d e ny 1 y 1 - ~ 2 ' - 5 ' ) - ( Rp ) - P -th ioadeny ly 1- ( 2 ' -5 ' ) - ( _p ) -P-th ioadenylyl- ( 2 ' -5 ' ) -adenos i ne .
ARpASpAspA: (Rp)-P-thioadenylyl-(2'-5')-(_p)-P-thioadenylyl-(2' -5' )-(Sp)-P-thioadenylyl-(2'-5' )--ade nos i ne .
ASpARpARpA: ( Sp ) -P-th ioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenosine .
ASpASpARpA: (_p)-P-thioadenylyl-(2'-5~ )-(_p)-p-thioadenylyl-(2'-5' )-(_p)-P-thioadenylyl-(2~-5~ )-adenosine.
ASpARpAspA: ( Sp ) -P-th ioadenylyl- ( 2 ' -5 ' ) - ( Rp ) -P-thioadenylyl-(2'-5' )-(Sp)-P-thioadenylyl-(2'-5' )-adenosine.
ASpASpASpA: (_p)-P-thioadenylyl-(2'-5~ )-(_p) th ioadenylyl- ( 2 ' -5 ' ) - ( Sp ) -P-thioadenylyl- ( 2 ' -5 ' ) -adenosi ne .
pARpARpARpA, ppARpARpARpA, pppARpARpARpA, pARpAspARpA~ ppARpAspARpA~ pPPARpAspARpA~ pARpARpASPA' ppARpARpAspA, pppARpARpAspA ~ pARpAspAspA ~ ppARpASpASp PPPARpASpASpA~ pASpARpARpA~ ppAspARpARpA~ pppAspARpARpA~
PASpASpARpA ~ pPASpASpARpA ~ pppAspAspARpA~ pAspARpAspA~
ppAspARpAspA~ pppAspARpAspA~ pAspAspAspA~ pPASpASpASpA' pppAspAspAspA: 5 ' -mono-, di- and triphosphates of the above tetramers .
(_p) - ATP-alpha-S: Adenosine 5'0-(Sp)-(l-th i ot r iph ospha te ) .
Background of the Invent ion The 2-5A system is widely expected to be involved in the antiviral mechanism of interferon and may also be 1 ~ '3 '~ 9 ~-~ 3 involved in the regulation of cell growth and differentiation. 2-5A synthesized from ATP by 2',5'-oligoadenylate synthetase [ATP: (2'-5')oligo(A)-adenyltransferase (EC 2.7.7.19)1 exerts its biological effects by binding to and activating its only known target enzyme, the unique 2-5A-dependent endoribonuclease RNase L
(EC 3.1.27). RNase L cleaves viral and cellular m~NA or rRNA, thereby inhibiting protein synthesis. Hovanessian et al, ~ur. J. Biochem. 93:515-526 (1979); Kerr et al, Proc.
Natl. Acad. Sci. USA. 75:256-260 (1978). It has been reported that 2-5A protects plant tissue from infection by tobacco mosaic virus. Devash et al, Science 216:415 (1982). 2-5A, however, is metabolically unstable. It is degraded by a cellular 2'-phosphodiesterase and phosphatases. Knight et al, Meth. Enzymol. 79:216-227 (1981); Minks et al, Nucleic Acids Res. 6:767-780 (1979);
Williams et al, Eur. J. Biochem. 92:455-462 (1978).
The literature is replete with structurally-modified 2-5A molecules with modifications in the adenyl or ribosyl moiety designed to explore the biological role of the 2-5A
synthetase/RNase L system. The primary source of conformational flexibility in the 2-5A molecule is in the backbone, similar to 3',5'-linked RNA and DNA. Srinivasan et al, Nucleic Acids Res. 13:5707-5716 (1985). However, theoretical and experimental analyses have revealed that the conformation of 2', 5'-linked dinucleotides and polynucleotide chains are significantly different from 3',5'-linked nucleotides. Id. The ribose-phosphate backbone of 2-5A has also been demonstrated to be the major antigenic determinant in the molecule. Johnston et al, Biochemistry 22:3453-3460 (1983).
Few reports have appeared on the synthesis of 2-5A
analogues with backbone m-odifications. Core analogues containing methylphosphonate and methylphosphotriester 13~9 73~ 3 groups have been synthesized. Eppstein et al, J. Biol.
Chem. 257:13390-13397 (1982); Jager et al, Nucleic Acids Res. Sym. Ser. No. 9:l49-152 (1981). However, complete loss of activity was observed with the "uncharged"
methylphosphotriester analogues. Eppstein et al, supra.
Substitution of the 2',5'-phosphodiester linkages with 3', 5'-linkages has also lead to substantial decrease in biological activity. Lesiak et al, J. Biol. Chem.
258:13082-13088 (1983). Replacement of only one 2',5'-internucleotide linkage has resulted in at least one order of magnitude loss of activity. Nearly complete loss of biological activity was observed when both 2',5'-phosphodiester linkages in the 2-5A trimer were replaced with 3',5'-bonds.
Haugh et al, Eur. J. Biochem. 132:77-84 (1983), reported that the affinity of pA3 to RNase L in mouse L929 cell extracts is approximately 1,000 times greater than that of A3.
Nelson et al, J. Org. Chem. 49:2314-2317 (1984), describe diastereomeric pairs of the phosphorothioate analogue of A3 without resolution of individual enantiomers. Eppstein et al, J. Biol. Chem. 261:5999-6003 (1986) report metabolic stabilities and antiviral activity of purported ARpARpA/ASpARpA and ARpASpA/AspAspA racemic mixtures without resolution of individual enantiomers.
Lee and Suhadolnik, Biochemistry 24:551-555 (1985), and Suhadolnik and Lee in The 2-5A System: Holecular and Clinical Aspects of the Interferon-Regulator Pathway, Williams, B.R.G. and Silverman, R.H., Eds. (1985), Alan R.
Liss, Inc., New York, p. 115-122, disclose the enzymatic synthesis of the alpha-phosphorothioate 5'-triphosphates of ARpARpA and ARpARpARpA from (_p)-ATP-alpha-S Such compounds are metabolically unstable. Preparation of the corresponding stereoisomers with Sp internucleotide -6- 1~3~ 3 phosphorothioate linkages was not possible owing to the stereospecificity of 2-5A synthetase for the substrate (Sp)-ATP-alpha-S, which is inverted to yield trimer and tetramer products containing 2',5'-phosphorothioate internucleotide linkages of the P~p configuration exclusively. Because nucleoside tranferases provide exclusively the inverted configuration when ~p-ATP-alpha-S
is the substrate, 2',5'-phosphorothioate oligoadenylates containing internucleotide phosphorothioate groups of the Sp configuration cannot be synthesized enzymatically.
Summary of the Invention Compounds of the present invention useful in inhibiting viral infections in plants and mammals have increased metabolic stability and/or antiviral activity.
The compounds are optical isomers and water-soluble salts thereof of the formula NHz HO p-O--C~
~,:
~o NHz -O- '=S N~N
C~N NJ
HO OH
substantially free of contamination by other optical isomers of the same formula, wherein m is zero, 1,2 or 3; n is 1 or 2; and at least one of the internucleotide phosphorothioate groups r -7- 13399 '~
I
is of the Sp configuration.
The invention also comprises a method of inhibiting viral infection in mammals or plants by administering an antiviral effective amount of a compound according to the above formula, or a water-soluble salt thereof, and antiviral compositions containing such compounds with a carrier.
Compounds according to the formula wherein n is 2 may be utilized to form oligoadenylate conjugates with the macromolecular carrier poly(L-lysine) for intracellular transport. Such poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates have the formula l H2 l H2 ( ICH2)4 ( ~CH2)4 NH2CHCO~Rq~NHCHCOOH
wherein q is an integer from about 60 to about 70, and R is randomly R' or (ICH2)4 -NHCHCO-.
From about five to about ten of the R ~rou~s comprise R'.
R' has the following formula wherein m is 0,1,2 or 3:
~33~13 i3 HO--p-O--CH2 N~NJ
o L--~~.l ~ml~j HO
~- ,=5 N ~NZ
~ <~N ~NJ
HO ¦
1 0 ~~ N H2 -O-P=S N~N
HO
-~- '=S NH2 CH ~N~J
,~
t CH2 )~
--NH-CH-CO--Preferably, at least one of the phosphorothioate groups o -O- P=S
o of the poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates is of the Sp configuration.
605~-58 1~3~
g Description of the Figures Figure lA represents the results of a radiobinding assay indicating the ability of 2',5'-phosphorothioate adenylate trimer cores and 5'-monophosphates to compete with p3A4[32PlpCp for binding to the RNase L in L929 cell extracts. Approximately 60% of the probe was bound in the absence of added oligonucleotide (total dpm = 23,000). The curves are labelled as follows: A3 (o); p3A3 (x); pA3 (-);
ARpARpA (~); ASpARpA (O); ARpASpA (~); ASpAsp (O); pARpARp (~); pASpARpA (~); pARpAspA (~); pASpAspA (J).
Figure lB represents the results of a core-cellulose assay indicating the ability of the 2',5'-phosphorothioate adenylate trimer cores and 5'-monophosphates to activate partially-purified RNase L from L929 cell extracts to hydrolyze the substrate poly(U)-3'-[32P3pCp. Activation of RNase L was determined by conversion of poly(U)-3'-[32P]pCp to acid-soluble fragments. 100% represents 30,000 cpm of labelled poly(U)-3'-[32P]pCp bound to glass fiber filters. The curves are labelled in the same manner as Figure lA.
Detailed Description of the Invention The activation of the unique 2-5A-dependent endoribonuclease, RNase L, by 2',5'-oligoadenylates, and its hydrolysis of rRNA, tRNA and cellular and viral mRNA, is important in the inhibition of viral replication and regulation of cell growth. RNase L is known to be the substrate target for 2-5A. It is one of the chief functional enzymes of the interferon-induced biological cascade. While modified analogues of 2-5A have been reported, they are not metabolically stable, or fail to activate RNase L. The introduction of the phosphorothioate group in the 2',5'-internucleotide linkages of 2-5A, induces physical, chemical and biochemical modifications in the 2-5A molecule including (i) Rp/Sp chirality, (ii) -lO- 133~ 3 lowered pKa, (iii) altered metal ion chelation, (iv) charge modulation, (v) increased bond length, (vi) altered degree of hydration and (vii) increased metabolic stabilities.
The metabolic stability of the 2',5'-phosphorothioate oligoadenylates is greater than authentic 2-5A. This metabolic ~,tability is greatly enhanced where at least one of the internucleotide phosphorothioate 2',5'-linkages is of the Sp configuration. While racemic mixtures of the trimer cores have been reported, Nelson et al, J. Org. Chem. 49:2314-2317 (1984) and Eppstein et al, J. Biol. Chem 261:5999-6003 (1986), efforts to resolve the compounds have failed. The level of antiviral activity of the trimer core racemates reported by Eppstein et al is such that the dosages required ~or treatment would be prohibitively toxic. At least one of the purported racemates of Eppstein et al, the ARpASpA/AspAspA racemate, is of little value since, as we have found, the ASpAspA
stereoisomer selectively inactivates RNase L, thereby preventing ARpASpA from exerting its antiviral effect through activation of RNase L. This is most undesirable since, as we have found, ARpASpA is the most attractive of the four trimer core stereoisomers, since it both activates RNase L and is metabolicly stable.
We have succeeded in preparing the fully resolved 2',5'-phosphorothioate adenylate trimer cores, thus making possible the practical use of the important ARpASpA
stereoisomer. Our method of stereo-specific chemical synthesis also makes possible the preparation of the eight separate stereoisomers of the 2',5'-phosphorothioate tetramer. Preparation of the tetramer molecules enables conjugation with the carrier (poly)L-lysine, shown to be an effective vector for introducing 2',5'-oligoadenylates and analogues into intact cells. Poly(L-lysine) conjugation to trimer molecules is not feasible, owing to the destruction -11- 1339l~-j3 of the 2'-terminal ribosyl moiety and subsequent i nact ivat ion of the molecu le . Con jugat ion to poly ( L-lysine) permits efficient intracellular transport of the 2' ,5'-phosphorothioate oligoadenylates while preserving intact within the con jugate the trimer moiety believed necessary for good biological activity.
Correlation of biological properties with absolute configuration has only been possible with the preparation of the fully resolved 2 ',5 ' -phosphorothioate adenylate trimer cores described herein. However, the trimer core compounds have been found to bind and/or activate RNase L
only modestly. We have found that the RNase L activation by the 2 ',5 ' -phosphorothioate core molecules is significantly enhanced by 5 ' -phosphorylation.
P~ase L activation by authentic 2-SA requires the triphosphate form of the trimer . The 5 ' -monophosphate form of 2-5A is a potent inhibitor of the RNase L-activating activity of the triphosphate. Miyamoto et al., J. Biol.
Chem 258: 15232-15237 (1983) i Black et al., FEBS Let.
191: 154 - 158 (1985); Torrence et al., Proc. Natl. Acad. Sci.
USA 78: 5993-5997 (1981) . We have surprisingly found that the cores and monophosphates of the present phosphorothioate analogues of 2-5A, unlike authentic 2-5A, activate RNase L.
The phosphorothioate trimer cores ARpARpA, ASpARpA, ARpASpA, and ASpAspA, are chemically synthesized and separated by preparative thin layer chromatography on silica gel . The four t rimer cores are prepared from 6-N-benzoyl- 3 ' -O-tert -butyld imethyls i lyl-5 ' -O-monomethoxytri tyladenos ine-2-O- (p-nitrophenylethyl )-octahydroazonino-phosphoramidite by stereospec i f ic synthesis, which relies on separation of fully resolved protected intermediates followed by removal of all blocking ~ ~ 3 ~3 1~ ~ 3 groups to yield the fully-resolved 2',5'-phosphorothioate trimer adenylate cores.
The trimer cores are prepared according to the following reactiorn scheme wherein "BZ" denotes the benzoyl radical ~Si" denotes the tert-butyldimethylsilyl radical and "MMTr" re~resents the monomethoxytrityl radical. While not part of the invention, the preparation of the dimer core enantiomers ARpA (6A) and ASpA (6B) is included for completeness.
-13- ~339~3 NH - C - C~,Hs N11B2 NHB2 CH30 ~C~O ~N 02N ~ CH2CH2 0 P - N~ s~ N
MMTrO~J HO~
CH3 - C - Si-O OH (~)O 1O ~) o O(~) CH3 C~3 02N 1~ CH2CH20 - P -N ~
N8Z NHeZ
~N NHBZ
MMTrO ~ N> Mt1TrO
02N~CH2CH20-Pj ~~ 02N~o pO ;5 N
~00~ - y, ~A I ~B I (~)~ ~ (~) NHBZ NHBZ
~N NtlE~Z ~N
6 A -- HO ~ N~S~ \> ~ ~N>
02N ~ H2017 ~S ~ 02N~ CH2CH20 _ ~ S ~I
(~30 ~(~) ~0 0 -14- 13 3 ~ ~ ) 3 NHBZ ¦ ~1BZ
~[ N N11BZ ~N N-IBZ
MMTrl) ~ N~N~ ~ MMTrO ~ N
o N , NHBZ @)o S I Nt~Z
02N~ 0~,0 - ~ --~~ ~N
~ O .--~~J 02N ~ Ot2CH20 - P~ yy S (~)0 0~) - 5 @)0 0(~) ~A ~B
NHBZ I NHE~2 ~N NHBZ ~N MlBZ
NMMTrO ~ N~5~N~>
o2N~3 0~0 P~ ~ ~J N NHE~ZN O N ~ 0~ ~ ~ ~ ~ N NllBZN
(~)~ ~ )0 1 ~ ~
02N~ ~~20 ~~~5 N ~O N~ 0120'l2o ~!~5 ~N~'N
(~)0 0(~ ~)0 0(~) -15- 1339~-~3 The blocking groups are removed from the fully-protected intermediates 7A, 7B, 8A, and 8B to yield the corresponding fully resolved trimer cores ARpARpA (9A), ASpA~pA ( 9B), ARpASpA ( lOA) and ASpASpA ( lOB):
1 3 3 9 9 j rf3 ~N~N HO-C~Ng <N~N ~NX~N
O ~x~H~ H ~ Ng ~N~
HO ~' ~~ NH2 HO O~ ,O NH HO o 'OcH ~N~N'J ~ <N~N'; ~N~HO o~p--s HO OH HO OH HO OH, HO ON
RpRp -SpRp RpSp SpSp 1339~ ~3 The compounds of the invention are advantageously prepared as soluble salts of sodium, ammonium or potassium.
- The preparative scheme begins with 6-N-benzoyl-3 ' -0-tert-butyldimethylsilyl-5 '-0-monomethoxy-trityladenosine (compound lE), which is advantageously prepared from adenosine according to the procedure of Flockerzi et al, Liebigs Ann. Chem., 1568-1585 (1981) .
Preparation of the compounds of the present invention is illustrated in more detail by reference to the following non-limiting examples. 3-Nitro-1,2,4-triazole; chloro-octahydroazonino-p-nitrophenylethoxyphosphate; 2,5-dichlorophenylphosphoro-dichloridate; and p-nitrophenylethanol used in the examples may be prepared advantageously from published procedures: Chattopadhyaya et. al. Nucleic Acids Res. 8:2039-2053 (1980); Schwarz et al., Tetrahedron Lett. 5513-5516 (1984); Uhlmann et al., ~elv. Chim. Acta 64:1688-1703 (1981). These compounds are also available commercially in the United States. 2,5-Dichlorophenyl-phosphorodichloridate may be obtained from Fluka Chemical Corp., 980 S. Second St., Ronkonkoma, New York 11779, ( "Catalog 15: Chemika-Biochemika" 1986/1987, no. 36212). 3-Nitro-1,2,4-triazole is available from Aldrich Chemical Co., P.O. Box 355, Milwaukee , WI 53201 (1986-1987 cat. no. 24,179.2). P-Nitrophenylethanol is available from Fluka Chemical Corp. (cat. no. 73,610).
Chloro-octahydroazonino-p-ni trophenylethoxyphosphate may be prepared according to Example lA, below.
Pyridine and triet:hylamine used in the examples were purified by distillation over ~OH, tosyl chloride and calcium hydride. Dichloromethane was distilled over calcium chloride and then passed through bas ic a lumina .
Pure acetonitrile was obtained by distillation over calcium hyd r i de .
Purification of the protected nucleotides was achieved by preparative column chromatography on silica gel 60 (0.063-0.2 mesh, Merck) and by preparative thick layer chromatography on silica gel 60 P~2s4 (Merck). Thin layer chromatography ("TLC") was carried out on precoated thin layer sheets F 1500 LS 254 and cellulose thin layer sheets F 1440 from Schleicher ~ Scheull.
The starting material, 6-N-Benzoyl-3-0-tert-butyldimethylsilyl-5'-0-(4-monomethoxytrityl~adenosine (Compound lE) and the reagent 6-N-benzoyl-2',3'-bis-O-(tert-butyldimethylsilyl)-adenosine (Compound lG), are prepared according to Example 1.
a. N6,N6,2',3',5'-O-Pentabenzoyladenosine: (lA) To a suspension of 5.34 g (20 mmole) adenosine (Sigma, dried at 80~C/10-3 Torr for 24 h) in 100 ml dry pyridine, 33.74 g (240 mmole) benzoyl chloride was added dropwise. After 20 h stirring at room temperature (nr.t.") the mixture was treated with 16 ml dry MeOH and then extracted with CHC13 (3 x 250 ml). The organic phase was washed with water (3 x 250 ml), dried over Na2SO4, and evaporated to dryness.
Final coevaporation was performed with toluene. The residue was dissolved in CHC13/MeOH 2/1 by heating, and after cooling to r.t., petrolether (diethylether) was added until the sol~tion became turbid. After standing for 12 h at 0~C 12.18 g was obtained, and from the mother liquor, 2.66 g of the product were isolated as colorless needles of m.p. 183-184~C., yield 14.84 9 (94%).
b. 6-N-Benzoyl adenosine (lB): A solution of 7.88 g (10 mmole) of the pentabenzoyl adenosine (lA) in 150 ml dry pyridine and 50 ml dry MeOH was treated with 50 ml 1 M
sodium methylate solution. After 15 min the solution was poured onto an ice cold solution of a 110 ml DOWEX ion exchanger 50 x 4 (pyridinium form) in ca 20 ml water.
* Trademarks .. .
, .
-19- ~ 3 ~ 3 After 5 h stirring the pH was 5.5-6Ø After filtering from the ion exchanger, the residue was washed with boiling - MeOH/water (3/1). The filtrate was evaporated to dryness and crystallized,from IMeOH/water 2/1 to give 3.25 g (83%) of the product as colorless needles, m.p. 151-153~C.
c. 6-N-Benzoyl-5'-O-(4-methoxytrityl) adenosine (lC): 17.9 9 (46 mmole) 6-N-benzoyl adenosine H2O (lB) was evaporated with dry pyridine (3 x 100 ml) and finally dissolved in 150 ml dry pyridine and 21.31 9 (69 mmole) p-monomethoxytrityl chloride. The reaction solution was stirred at 50~C for 14 h and dry MeOH (50 ml) was added and allowed to come to r.t. The product was extracted with CHC13 (3 x 400 ml) and washed with water (3 x 400 ml). The organic phase was dried over Na2SO4 and evaporated to dryness. Final coevaporation was performed with toluene.
Purification was performed using a silica gel column (16 x 2.5 cm, Merck) and eluted with 3 liter EtOAc/MeOH 7/3 to give 25.6 9 (87%) of an amorphous powder. Crystallization was accomplished with acetone/water to yield the product, m.p. 120-125~C.
d. 6-N-Benzoyl,-2'-O-(tert-butyldimethylsi,lyl)-5'-O-(4-methoxytrityl) adenosine (lD);
6-N-Benzoyl-3'-O-(tert-butyldimethylsilyl)-5'-0-(4-methoxytrityl) adenosine (lE);
6-N-benzoyl-2',3'-O-bis(tert-butyldimethylsilyl)-5'-O-(4-methoxytrityl) adenosine (lF):
To a solution of 4.05 9 (26.9 mmole) tert-butyldimethylsilylchloride ("TBDMS-Cl") and 3.66 9 (53.8 mmole) imidazole in 100 ml dry pyridine, were added 14.42 g (22.4 mmole) of compound lC which was previously coevaporated with dry pyridine. After 15 h stirring at r.t., 5 ml dry MeOH was added and the mixture was evaporated to 1/3 volume. The crude product was extracted with CHC13 (3 x 250 ml) and washed with water. Upon 1 3 ~
evaporation, the crude product was first purified by a silicagel column (15 x 3 cm) with CH2C12/EtOAc (9/1), and - subsequently purified using medium pressure chromatography (silicagel colum~, GSF-type C (N= 9000, VD = 28 ml) at 8-10 bar pressure with the following mixtures of CH2C12/petrolether/EtOAc/EtOH: 100:100:10:0.5 (2 liters), first; 100/100/10/1 (3 liters), second; and 100/100/31/2 (0.5 liters), third. The title compounds were isolated.
The retention time of the peak maxima for each compound was as follows: 25 min. for compound lF (yield 1.84 g, 9%); 60 min. for compound lD (yield 6.62 9, 39g); 105 min. for compound lE (yield 8.32 g, 49~).
e. 6-N-Benzoyl-2',3'-bis-O-(tert-butyldimethyl-silyl) adenosine (lG): 1.74 g (2 mmole) of compound lD was lS stirred with 20 ml 80% acetic acid,at 22~C. After 20 h the cleavage of the monomethoxytrityl group was complete. The reaction mixture was extracted with CHC13 (3 x'200 ml) and washed with 200 ml 1 M phosphate buffer (pH 7). The organic phase was dried over Na2SO4 and evaporated to dryness. Purification was accomplished using a silica gel column (2 x 10 cm) and eluted with CH2C12/MeOH (96/4). The light yellow product was dissolved in 5 ml CHC13 and treated with Et2O until turbid. 0.982 g of the pure product crystallized out. The pure product crystallized out again from the mother liquor, 0.11 9, m.p. 189~C. The total yield was 1.092 g (91%).
-21- ~ 3 3 ~
EXAMPLE lA
Chloro-octahydroazonino-p-nitrophenylethoxyphosphate a. P-nitrophenylphosphoric acid dichloride. To phosphorus trichloride (Fluka, N.Y., ~79690) (28 ml, 0.317 moles) 80 ml anhydrous ether are added. The mixture is cooled to -30~C. P-nitrophenylethanol (8.35 g, 50 mmoles) is added, followed by stirring for 1.5 hr. Ether and excess PC13 is- removed under vacuum to yield p-nitrophenylphosphoric acid dichloride (yield 80%).
b. OctahydrQazonin. Caprylolactam (Fluka, N.Y., ~21631) (25 g, 117 mmoles) is combined with lithium aluminum hydride (10.5 g ) in ether and reduced with stirring for S hr. The reaction mixture is filtered and evaporated with ether. The product is octahydroazonin (9096 yield).
c. l-Trimethylsilyl octahydroazonin. The silylamine of octahydroazonin is prepared by combining octahydroazonin (12.7 g, 0.1 moles) and trimethylsilane (0.12 moles) and O.S moles hexamethyldisilazane + lS0 mg of ammonium sulfate. The mixture is refluxed for 90 hr and distilled under vacuum to yield 16.5 g of l-trimethylsilyl octahydroazonin (82%).
d. Chloro-octahydroazonino-p-nitrophenylethoxy-phosphate. P-nitrophenylphosphoric acid dichloride (26.8 g, 100 mmoles) and l-trimethylsilyl octahydroazonin (19.9 g, 100 mmoles) are combined under nitrogen at 0~C. The mixture is warmed to room temperature and stirred 2-3 h.
Trimethylsilyl dichloride is removed under vacuum. The product in the residue is chloro-octahydroazonino-p-nitrophenylethoxyphosphate (33.9 g, 9496 yield).
1 ~ 3 '3 9 i-~ 3 ~XAMPLE 2 6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-(4-ethoxytrityl)-adenosine-2'-0-(p-nitrophenylethyl)-octahydroazonino-phosphoramidite (2). Compound lE (0.758 g, 1.0 mmole) and diisopropylethylamine (0.52 g, 4 mmole) were dissolved in dichloromethane (5 ml) and chlorooctahydroazonino-p-nitrophenylethoxyphosphane (0.80 9, 2.22 mmole) was added dropwise. After stirring for 2 h at r.t., TLC analysis indicated complete reaction. The reaction mixture was transferred to a separatory funnel using saturated aqueous NaHCO3 (50ml) and the product was isolated by extraction with ethylacetate (2 x 50 ml). The organic ~ayer was washed with saturated NaCl, dried (Na2SO4), and evaporated to dryness. The residue was dissolved in ethylacetate-triethylamine (95:5 v/v~, chromatographed on a silica gel column (10 x 2 cm) previously calibrated with ethylacetate-triethylamine (9/1) and eluted with ethyl-acetate-triethylamine (95:5 v/v).
The product fractions were collected, evaporated to dryness, ~inally coevaporated with dichloromethane and dried in vacuo at 40~C to give compound 2 (1.05 g, 97~) [Anal. calcd. for CsgH70N7OgPSi ~ 1 H2O: C, 64.52; H, 6.60;
N, 8.92. Found: C, 63.93; H, 6.85; N, 8.62].
EXA~PLE 3 6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-monoethoxytrityl-P-thioadenylyl-2'-[OP-(p-nitro-phenylethyl)-5']-6-N-benzoyl-2',3'-di-0-tert-butyldimethylsilyladenosine (4A + 4B). The phosphoramidite 2 (1.12 g, 1.0 mmole) and 6-N-benzoyl-2',3'-di-tert-butyldimethylsilyladenosine (3) (0.478 g, 0.7 mmole) were dried overnight in a drying pistol at 40~C in vacuo. The dried residue was then d;ssolved in dry acetonitrile (6 ml), and 3-nitro-1,2,4-triazole (0.285 g, 2.5 mmole) was added and stirred at r.t. for 3 h. Pyridine (6 ml) and ~3 ~3-~
sulfur (0.5 g) were added and after stirring at r.t. for 20 h, the reaction mixture was extracted with chloroform (300 ml). The organic phase was washed with saturated NaCl-solution (2 x 2Q0 ml), dried (Na2SO4), and evaporated to dryness. Final evaporation was performed with toluene to remove pyridine. The residue was dissolved in chloroform and chromatographed on a silica gel column (15 x 2.5 cm) with 1 liter of chloroform to give a product fraction containing both Rp and Sp isomers. The separation of the diastereoisomers was carried out on preparative silica gel plates, using dichloromethane/ethylacetate/n-hexane (1:1:1 v/v). The plates were developed thrice. The higher Rf isomer (0.47 g; 42%, TLC in dichloromethane/ethylacetate/n-hexane, 1:1:1, 0.54) and the lower Rf isomer (0.31 g; 28%, TLC in dichloromethane/ethylacetate/n-hexane, 0.46) were obtained as colorless amorphous powders after drying at 40~C in vacuo. The higher Rf isomer was compound 4A.
[Anal. calcd. for CgoHggN10O14PSi3 ~ 1 H2O: C, 59.89; H, 6.32; N, 9.61. Found: C, 59.89; H, 6.32; N, 9.21]. 31p_ NMR (400 MHz, CDC13, 85~6 H3PO4, 69.841 ppm). The lower Rf i some r wa s c ompound 4 B . [Ana 1 . ca lcd . for C80H98N10~14PSi3~ ~ 1 H2O: C, 59~.89; H, 6.28; N, 9.61.
Found: C, 59.91; H, 4.61; N, 9.28]. 31p_NMR (400 MHz, CDC13, 85% H3PO4, 69.223ppm). EXAHPLE -4 6-N-Benzoyl-3 ' -0-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5']-6-N-benzoyl-2',3'-di-0-tert-butyldimethylsilyladenosine (5A + 5B).
0.258 g, (0.164 mmole) c>f the pure isomers 4A and 4B, were detritylated separately by treatment of each with 296 p-toluenesulfonic acid in dichloromethane/methanol (4/1) (3.2 ml) at r.t. for 40 min. The reaction mixture was diluted with chloroform (50 ml), washed with phosphate buffer, pH 7 (2 x 20 ml), and evaporated to a foam. The residue was purified by silica gel column chromatography (10 x 2.5 cm).
~ 3 3 ~
Compounds 5A and 5B were separated on the column by using chloroform and chloroform/methanol (100:0.5 till 100:1).
The product fractions were collected and, after evaporation, dried in vacuo at 40~C to give in the case of 5A, 0.198 g (92%), and in the case of 5B, 0.192 9 (89%).
5A has an Rf of 0.27 in dichloromethane/ethylacetate/n-hexane (1:1:1). [Anal. calcd. for C60H82N11~13PSi3S ~ 1 H2O: C, 54.15; H, 6.36; N, 11.57. Found: C, 53.78; H, 6.44; N, 11.72]. 5B has an Rf of 0.30 in the same system.
[Anal. calcd. for C60Hg2NllO13PSi3S: C, 54.90; H, 6.29; N, 11.73. Found: C, 54.90; H, 6.20; N, 11.45J.
P-Thioadenylyl-(2'-5')-adenosine (6A + 6B). The fully protected dimers 5A and 5B, respectively, were deprotected separately by the following procedure. Each protected dimer ~39 m~, 0.03 mmole) was treated with 0.5 M
1,8-diazabicyclor5.4.0]undec-7-ene(1,5,5)(Fluka, cat. no.
33842, "DBU") in pyridine (9 ml), and after stirring at r.t. for 2 h was neutralized with 1 M acetic acid (4.5 ml) and finally evaporated. The residue was taken up in 1 M
tetrabutylammonium fluoride ("Bu4NF") in tetrahydrofuran ("THF~) and after 24 h again evaporated to dryness.
Deacetylation was achieved by treatment with conc. ammonia - (20 ml) for 48 h followed by evaporation of the mixture.
The residue was then dissolved in water (50 ml) and washed with chloroform (2 x 20 ml). The water phase was applied to a DEAE Sephadex*A-25 column (60 x 1 cm) for elution with a linear gradient of a buffer of 0.001-0.25 M Et3NH+HCO3-, pH 7.5. The product was eluted at a concentration of 0.08-0.1 M. Evaporation to dryness followed by coevaporation with water (10 x 10 ml) and final purification by paper chromatography with i-PrOH/conc. ammonia/water (7:1:2 v/v) yielded in the case of 6A 630 O.D. units (87.5%) and in the * Trademark "
-25- 1~ 3gi3~3 case of _ 648 O.D. units (90~). The Rf of 6A on cellulose sheets, using the above system, was 0.29. The Rf of 6B was 0.30.
6-N-Benzoyl-3'-0-tert-butyldimethylsilyl-5'-0-monomethoxytrityl-P-thioadenylyl-2'-~0P-(p-nitro--phenylethyl)-5'~-N-6-benzoyl-3'-0-tert-butyldimethylsilyl-P-thioadenylyl-2l-tQp-~p-nitrophenylethyl)-5~]-6-N-benzoyl-2',3'-bis-0-tert-butyldimethylsilyladenosine (7A, 7B and 8A, 8B). The phosphitamide 2 (0.449 g; 0.41 mmole~ was condensed with the 5'-hydroxy dimer SA and 5B (0.0262 g;
0.2 mmole) separately in the presence of 3-nitro-1,2,4-triazole (0.114 g; 1.0 mmole) in dry acetonitrile (3.2 ml).
After stirring at r.t. for 3 h, sulfur (0.2 g; 6.25 mmole) in pyridine (0.4 ml) was added for oxidation. After stirring at r.t. for another 24 h, the product was extracted with dichloromethane (50 ml), the organic phase was washed with saturated NaCl solution (2 x 20 ml), dried (Na2SO4), and then evaporated to ~dryness. ~inal coevaporation was performed with toluene to remove pyridine. The crude product was chromatographed on a silica gel column (lS x 2 cm) and eluted with chloroform/methanol (100:2) to give,~on condensing with compound 5A, the isomer mixture 7A + 7B. The isomer mixture 8A + 8B, was obtained upon condensing the phosphitamide 2 with compound 5B in the same manner. The diastereomeric separation of each isomer mixture was accomplished by using preparative silica gel plates (20x20x0.2 cm) to which about S0 mg of isomer mixture per plate was applied for optimal separation. The plates were developed in dichloromethane/ethylacetate/n-hexane (l:l:O.S
v/v) three times. The appropriate bands were cut out and eluted with chloroform~ethanol (4:1) The higher Rf isomer synthesized from 5A has a Rf of 0 58 in 1~ 3~ ~3 dichloromethane/ethylac~ tate/n-hexane (1:1:1) and yielded 4 8 % ( 0 . 2 1 8 9 ) o f- 7 A . ~ A n a 1 . c a 1 c d . f o r C111~135N17~22P2Si4S2 ~ 1 H2O: C, 57.S6; H, 5.96; N, 10.28.
- Found: C, 57.38; H, 5.99; N, 10.11] . The lower Rf isomer has a Rf of 0.48 in the above-mentioned system, and yielded 3 4 % ( 0 . 1 5 7 g ) o f 7 B . 1 An a 1 . c a 1 c d . f or ClllH135N17~22P2Si4S2 ~ 1 H2O: C, 57.56; H, 5.96; N, 10.28.
Found: C, 57.40; H, 5.97; N, 10.193.
The isomeric mixture derived from the 5 ' -hydroxy dimer 5B
was separated in the same manner and yielded the higher Rf isomer 8A in 41% (0.186 g ) with an Rf of 0.53 in the above solvent system. lAnal. calcd. for ClllH135N17~22P2Si4S2 C, 58.02; H, 5.92; N, 10.36. Found: C, 58.00; H, 5.84; N, 10.66] . The lower Rf isomer 8B showed a Rf value of 0.45 a n d y i e 1 d e d 3 5 % ( 0 . 1 6 1 9 ) . [ A n a 1. c a 1 c d . f o r ClllE~135N17022P2Si4S2 1 H2O C, 57.56; H, 5.96; N, 10.28. Found: C, 57.30; H, 5.78; N, 10.03~.
EXA~PLE 7 ( Rp ) -P-Th ioadenylyl- (2 ' -5 ' ) - ( Rp ) -P-thioadenylyl- (2 ' -5' ~-adenosine (9A). A solution of 0.116 g (0.05 rrunole of the fully protected trimer 7A was detritylated with 2% p-toluenesulfonic acid in 1.5 ml dichloromethane/methanol (4: 1) for 90 min. The mixture was dissolved in CHC13, washed with phosphate buffer (2x15 ml), dried (Na2SO4), and evaporated to dryness. The residue was chromatographed on silica gel plates ( 20x20xO . 2 cm), developed with dichloromethane/ethylacetate/n-hexane ~5:5:3 v/v). The product band (Rf 0. 35) was cut out, eluted with chloroform/methanol (7: 5) and gave on evaporation to a colorless foam a yield of 70-83~. 38.5 mg (18.9 micromole) of the product was then stirred with 0.5 M DBU in pyridine (7.5 ml) for 20 h, neutralized with lM acetic acid (3.75 ml) and finally evaporated. The evaporated product was desilylated through treatment with lM B~14NF in THF (6 ml) ~ 3 ~ 9 '.~
for 24 h. The mixtur-e was concentrated in vac~o. The residue was dissolved in conc. ammonia (25 ml) and stirred at r.t. for 48 h. After evaporating the solution, the residue was taken up in water (20 ml) and washed with chloroform (2xlO ml). The aqueous phase was put on a DEAE
Sephadex A-25 column (60xl cm) and the product was eluted with a linear gradient of Et3NH+HC03-buffer. The product fraction was collected, evaporated and further purified by paper chromatography using i-PrOH/conc. ammonia/water (6:1:3) to give the title compound in 75-80~ yield.
(Sp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine ~9B). A solution of 0.116 9 (0.05 mmole~ of the fully protected trimer 7B was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
(Rp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5')-adenosine (lOA). A solution of 0.116 g (0.05 mmole) of the fully protected lrimer 8A was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
(Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine ~lOB). A solution of 0.116 9 (0.05 mmole) of the fully protected trimer 8B was subjected to the procedure of Example 7. The title compound was obtained in 75-80~ yield.
The UV-absorption spectra in methyl alcohol and lH-~MR spectra of the above-prepared protected monomer, dimer and trimer cores are set ~orth in Tables 1 and 2, respectively.
-28- ~3~ ,3 W-Absorption Spectra of Protected Monomer, Dimer and Trimer Cores in MeOn Compound ~max (nm) 19~
_ 230 277 4.47 4.50 4A 231 277 4.66 4.70 4B 231 277 4.66 4.70 5A 278 4.70 5~ 278 4.70 7A 230 278 4.78 4.90 7B 230 278 4.78 4.89 8A 230 278 4.79 4.90 8B 230 278 4.78 4.90 lH-NMR Spectra of Protected Monomer, Dimer and Trimer Cores Con~
pound 1 '-H 2-~ 8-H Solvent 2 6.11 6.13 8.70 8.23 CDC13 4A 6.30d 5.87d 8.68; 8.60 8.19; 8.17 CDC13 4B 6.29d 5.94d 8.72; 8.62 8.26; 8.18 Cl)C13 5A 6.06d 5.94d 8.82; 8.75 8.25; 8.08 CDC13 5B 6.13d 5.90d 8.74; 8.73 8.26; 8.24 CDC13 7A 6.23d 6.08d 5.84d 8.69; 8.58; 8.55; 8.20; 8.11;8.01 CDC13 7B 6.22d 6.17d 5.85d 8.67; 8.60; 8.57; 8.23; 8.10;8.00 CDC13 8A 6.27d 6.13d 5.93d 8.71; 8.61; 8.60; 8.21; 8.13;8.00 CDC13 8B 6.27d 6.22d 5.90d 8.71; 8.64; 8.61; 8.27; 8.22;8.19 CDC13 1 ~values in ppm; Standard T~lS; characteristic 3 0 s i 9 na 1 s 1 3 3 ~ 3 Assiqnment of Absolute Configuration of 2',5'-Phosphorothioate Adenylate Trimer Cores Determination of the absolute configurations of the trimer cores was accomplished by 31P-NMR fast bombardment mass spectrometry and enzymatic digestion.
It is known that the enzyme SVPD preferentially cleaves Rp-3',5'- or 2',5'-phosphorothioate linkages from the 2'/3'-terminus. Nelson et al, J. Org. Chem. 49:2314-2317 (1984); Eppstein et al, J. Biol. Chem. 261:5999-6003 (1986); Lee et al, Biochemistry 24:551-5S5 (1985). SVPD
hydrolysis of the chemically synthesized dimer core ARpA
yielded adenosine and AMPS in a molar ratio of 1:1, respectively; the half-life was 3 hours (Table 3). The ASpA dimer core was not a substrate for SVPD under these conditions. Trimer core 9A has the Rp ~ internucleotide linkage con iguration as determined by hydrolysis by SVPD
to yield AMPS plus ARpA in a molar ratio of 1:1, respectively. Similarly, SVPD hydrolysis of trimer core 9B
yielded ASpA and AMPS, thus identifying trimer core 9B as having the SpRp internucleotide linkage configuration (Table 3). Trimer cores 10A and 10B were not substrates for SVPD (Table 3), revealing the presence of the Sp configuration in the internucleotide linkage adjacent to the 2'/3'-termini.
1339.iJ.~3 ~ " ~, .. ..
o ' oc ~U ~ Q 0 ~~ O ~ 0 0 V~ ~ ~ Q
L
O C
~ O O ~ 0 0 ~ CJ
O ~ J ~,_ ~ > > > >
~' .~ O Q '_ 0 ~ 0 0 . ~'1-- J O O O ~> C
L. ~ _ C~
~_ O O 1~ C Z
O ~ L L
~_ o o '~ . E
O O O O O O
0 ~- c cn~ c c c o ~ O L Q
0 L ._ ~ J
O
O ~~-- ~O
~ ~r ~-- c c<n C
O ~1 ~ ~ 0 ~~ 0 -n I E
_ ~ 0 0 ~ ~ ~ ~
~,~ ~ ., ~ ~ ~ O
L S -- 0 0 0 0 ~ 0 O ~ o O
", ~' X .------ -- C 0 L E
O ~ ~' ~_ _ V U O O O O
O ~~ C CC~~. C ~ I
_ O J
O ~ ~ O
L ~o ~ ., Z ~' ~ _ c _ C ~ 1 0 -- ~ ~ 0~ 0 0 0 ~_ ~ > ~ ~ r~
C ~ O O ~ O
C~ _ J J Cl O
C Z _ ~
._ ~L C
oV~ O ~ ~ E ~ 0 ~- L ~ 0 .
~1 _ ~ Z
~ O
._ 0 r C
O ~u~
,.~ .. .... 00 O' ~ O~ V~O' -- --~ O O
J l. . . .>~ :~
~: ~ ~ 0 u 0 o o ~J ~ ~' ' '~ E e E
~ Oa ~ ~ --~ Z ~ ~O ~ ~ u~
c ~ ~ I~ ~ I~ o ~ C C C
o o o O
O ~ o. ~
0 ~ "
~1 0 0 ~' ~' C
L o ~ ~ C C ~
~_ ~ o ~ o o ~
v- O ~1 ~ E E O
r ~ e~ ¦ol ~ ol ~ ~ ~ C C
'01 '01 0 O~ O~ ~ ~ O O O -- --- ~~
O E <~
U~ E . 0 ~ ~ ~~ a 0 I
N ~ ~ ~t ~ ~ ~ < > ~
~3~3-~3 The four 2,5-phosphorothioate adenylate trimer cores were further characterized by hydrolysis with the enzyme 2'-phosphodiesterase ("2'-PDE"), an exoribonuclease found in L cell extract. The enzyme cleaves from the 2'/3'-terminus. Whereas authentic A2 and A3 cores where hydrolyzed to adenosine and AMP with a half-life of 10 min, the dimer cores ARpA and ASpA were not substrates for 2'-PDE (Table 3). The fact that the 2,5-phosphorothioate dimer cores were not substrates for 2'-PDE (unlike authentic 2-5A) greatly assisted in the assignment of the stereoconfigurations of the 2',5'-phosphorothioate adenylate trimer cores. Trimer core 9A was a substrate for 2'-PDE; the products of hydrolysis were ARpA and AMPS.
Trimer core 9B was a substrate for SVPD, yielding ASpA and AMPS; trimer core lOA was a substrate, yielding ARpA and AMPS; trimer lOB was not a substrate for 2'-PDE.
31P-NMR spectroscopy has revealed that _p stereoisomers of phosphorothioates resonate to higher field than Rp diastereomers. Further, Sp diastereomers have a longer retention time on reverse phase HPLC than Rp diastereomers . The ASpA dimer core resonates upfield from the ARpA (Table 3). Similarly, two singlets observed for ASpAspA resonate upfield from the two singlets observed for ARpARpA (Table 3). Assignment of the absolute configurations of trimer cores 9A (RpRp) and lOB (Sp_p) was based on the two singlets which resonate at the same frequency as the singlets observed for the ARpA and ASpA
dimer cores. Assignment o~ configurations for trimer cores 9B and lOA was made in combination with the enzyme degradations and HPLC analyses (Table 3). The 3IP-NMR
spectra revealed that the ~ppm between the two singlets for the ASpARpA trimer core is 1.2, whereas the two singlets for the ARpAspA have a ~ppm of 0.8 (assignment is 5' to 2'/3' terminus).
-33- ~3~3i.l ,3 The metabolic stability of the 2,5'-phosphorothioate dimer and trimer cores is markedly greater than authentic 2-5A. The rate of hydrolysis of the trimer cores by the 3'-exonuclease SVPD is, in order of decreasing stability:
AspAp~pA>ARpARpA>>>A3~ The trimer cores ARpASpA and ASpAspA
are not substrates of SVPD (Table 3). The 3'->'5'direction of stepwise cleavage by SVPD is blocked by an _p configuration, preventing cleavage of the upstream adjacent phosphorothioate linkage. With 2'-PDE, the ARpARpA, ASpARpA and ARpASpA trimer cores, but not the ASpAspA
trimer core, were substrates. With both SVPD and 2'-PDE, the dimer cores (either ARpA or ASpA) accumulate following hydrolysis of the ARpARpA, ASpARpA and ARpASpA trimer cores. Hydrolysis of the 2-5A molecule by SVPD and 2'-PDE
proceeds from the 2'/3'-terminus. Therefore, introduction of the phosphorothioate group into tne trimer core results ;n the accumulation of the ARpA or ASpA dimer cores from the 5'-terminus and the accumulation of AMPS from the 2'/3'-terminus (Table 3). With authentic A3, there is no detectable accumulation of A2 following hydrolysis by SVPD
or 2'-PDE.
None of the _p linkage-containing tri~er cores were cleaved by SVPD. While the half-life of ASpARpA upon cleavage by L-cell extract (15 hours) did not differ significantly from that of ARpARpA (18 hours), the half-life for the ARpASpA trimer was orders of magnitude longer (20 days). ASpAspA was not cleaved ~y L-cell extract (Table 3).
Preparation of Phosphorothioate Tetramer Cores The following non-limitin~ examples illustrate the preparation of the fully-resolved tetra~f core co~pounds of the invention.
-34- 13 3~ g-)3 a. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5)-adenosine b. (Rp)-P-thiodenylyl-(2~'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thiodenylyl-(2'-5')-adenosine.
A solution of 0.149 g (0.065 mmole) of fully protected trimer 8B, which has the stereoconfiguration SpSp, was detritylated with 2% p-toluenesulfonic acid in 1.5 ml dichloromethane/methanol (4:1) for 3 h at room temperature. The mixture was diluted with 50 ml CHC13, washed with phosphate buffer (2 x 15 ml), dried (Na2SO4), and evaporated to dryness. The residue was chromatographed on silica gel plates (20 x 20 x 0.2 cm) developed with dichloromethane/ethylacetate/n-hexane (5:5:3 v/v). The product band, Rf 0.55, was cut out, eluted with chloroform/ethanol (1:1) and gave, on evaporation to a colorless foam of 0.108 9 (yield 88~). The 5'-deblocked _pSp trimer 8B (101 mg; 0.05 mM) was dissolved in 0.5 ml acetonitrile overnight with phosphitamide 2 (0.105 g; 0.1 mmole). 3-Nitro-1,2,4-triazole (0.023 g; 0.2 mmole) was added. After stirring at room temperature for 3 h, sulfur (0.042 9; 1.3 mmole) in pyridine (0.084 ml) w~s added for oxidation. After stirring at room temperature for another 24 h, the product was extracted with dichloromethane (50 ml), the organic phase was washed with saturated NaCl solution (2 x 20 ml), dried over Na2SO4, and then evaporated to dryness. Final coevaporation was performed with toluene to remove pyridine. The crude product was purified by using pre~arative silica gel plates (20 x 20 x 0.2 cm) to which about 50 mg per plate was applied for optimal separation by developing in dichloromethane/
ethylacetate/n-hexane (1:1:0.5 v/v) three times. The band containing the~fully protected SpSp_p tetramer (Rf 0.3) and the band containing the fully protected P~pSp_p tetramer (RF
133~3 )3 0.4), were cut out and eluted with chloroform/methanol (4:1). The yield of the fully protected Sp~pSp tetramer was 43 mg; 29%. The yield of the fully protected ~pSpSp compound was 53 mgi 35.5%. The two isomers (7.3 micromoles; 0.22 mg) were deblocked by stirring with 0.5 M
DBU in pyridine (5.0 ml) for 20 h, neutralized with lM
acetic acid/ pyridine (0.5 ml) and finally evaporated. The subsequent desilylation was achieved with lM
tetrabutylammonium fluoride in tetrahydrofuran (3.6 ml) for 48 h at r.t. The mixture was concentrated in vacuo, the residue dissolved in conc. ammonia (15 ml) and stirred at r.t. for 48 h. After evaporating the solution, the residue was taken up in 5 ml of 80~ acetic acid and allowed to stand for 20 h at r.t. The residue was dissolved in about 5 ml water and put on a DEAE Sephadex A-25 column (60 x 1 cm) and the product was eluted with a linear gradient of Et3NH+HCO3- buffer (pH 7.5) (gradient 0.001 - 1 M). The product fractions were collected, evaporated and further purified by paper chromatography using; i-PrOH/conc.
ammonia/water (6:1:3). The tetramer isomers were eluted with water to give ASpAspAspA (72% yield; Rf 0.23) and ARpASpAspA (73% yield; Rf 0.29) as the ammonium salt.
a. (Rp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine b. (Sp)-P-Thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine 13 ~ ~.3 ~
The title compounds are prepared by following the procedure of Example 11, but substituting the fully - protected trimer 7A for 8B as the starting material.
a. (Rp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5i)-adenosine b. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine The title compounds are prepared by following the procedure of Example 11, but substituting the fully protected trimer 7B for 8B as the starting material.
a. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5'j-(Sp)-P-thioadenylyl-(2'-5')-adenosin,e - b. (Sp)-P-Thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2~-5~ ? - ( sp ) -P-thioadenylyl-(2'-5')-adenosine The title compounds are prepared by following the procedure of Example 11, but substituting the fully protected trimer 8A for 8B as the starting material.
20 - Preparation of 2'~5'-Phosphorothioate Oligoadenylalte 5'-Monophosphates 5'-Monophosphates of 2',5'-oligoadenylates are readily prepared by reacting the corresponding core compounds with POC13. Such treatment would result in the elimination of sulfur from the phosphorothioate internucleotide linkages of the compounds of the present invention, and the formation of 2-5A. Thus, the 5'-monophosphates of the phosphorothioate oligoadentylates must be prepared from the corresponding fully protected core compounds from which the monomethoxytrityl blocking group on the 5'-terminal nucleotide has been removed. The conditions of the phosphorylation must be such that the p-nitrophenylethyl blocking groups on the internucleotide phosphorous atoms remain intact.
~33~53 The 5'-monophosphate of each resolved trimer core of the present invention was prepared from the 5'-hydroxy - analogue of the corresponding fully protected trimer 7A, 7B, 8A or 8B. The intermediate 5'-phosphotriester (11A, 11B, 12A or 12B) was prepared according to Example 15 and then freed of all blocking groups according to Example 16 to yield the 5'-monophosphate. The procedure of Examples 15 and 16 may be used for forming the 5'-monophosphate of any of the four trimer core stereoisomers.
5'-0-(2,5-Dichlorophenyl-p-nitrophenylethyl)-phosphoryl-6-N-benzoyl-3'-O-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5']-6-N-benzoyl-3'-O-tert-butyldimethylsilyl-P-thioadenylyl-2'-[OP-(p-nitrophenylethyl)-5'~-6-N-benzoyl-2',3'-di-O-tert-butyldimethylsilyl adenosine (llA, 11B, 12A or 12B): To a solution of 1,2,4-triazole (0.011 g; 0.16 mmole) and 2,5-dichlorophenylphosphorodichloridate (O.022 g; 0.018 mmole) in dry pyridine (0.5 ml) was added the 5'-deblocked analogue of either 7A, 7B, _ or 8B (0.1 9; 0.049 mmole) (~repared as an intermediate in Example 11), and after stirring for 30 min, p-nitrophenylethanol (0.02g; 0.119 - mmole) was added and stirring continued for 20 h. The solution was then extracted with chloroform (50 ml), the organic phase was washed with water ( 2 X 20 ml), evaporated to dryness, and finally co-evaporated with toluene. The residue was purified by silica gel chromatography on preparative plates ( 20 X 20 X 0.2 cm) using the system dichloromethane/n-hexane/ethylacetate (1:1:1 v/v). The product band was eluted with chloroform/methanol (4:1) and evaporated -in vacuo to give 11A, 11B, 12A or 12B in 70-80%
yield, respectively.
t 3~9a3 a. 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine (13A) b. 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine (13B) c. 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine (14A) d. 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine (14B) p-Nitrobenzaldoxime (0.036 g; 0.216 mmole) was stirred for 30 min in dioxane/triethylamine/water (each 0.5 ml), the appropriate 5'-phosphotriester llA, llB, 12A or 12B (0.05 g, 0.02 mmole) was added and the mixture was kept at r.t. for 4 h. The solution was evaporated to dryness, followed by coevaporation with toluene ~2x5 ml), and the residue purified by preparative TLC on plates (20x20x0.2 cm) in chloroform/methanol (95:5). The product band was eluted with chloroform/methanol/triethylamine (5:1:1) and evaporated to dryness. This material (0.022 g;
10 micromole) was stirred with 0.5 M DBU in pyridine (8 ml) at r.t. for 24 h, the solution neutralized with lM acetic acid (4 ml) and evaporated to dryness. The residue was - treated with lM Bu4NF in THF (6 ml) for 48 h and after evaporation the debenzoylation was accomplished by treatment with conc. ammonia (25 ml) at r.t. for 48 h. The solution was evaporated. The deblocked crude trimer 5'-monophosphate was taken up in water (25 ml) and washed with chloroform (2x10 ml). The aqueous phase put on a DEAE
Sephadex A-25 column (60xl cm) for elution with a linear gradient of 0.001-lM Et3NH+HCO3- buffer. The product fractions were collectecl, evaporated to dryness, and after several coevaporations with water were further purified by paper chromatography using the i-PrOH/conc ammonia/water-system (55:10:35) The product band was eluted with water 13:~'33~
and gave on lyophilization the trimeric P-thioadenylate 5'-monophosphate 13A, 13B, 14A or 14B as ammonium salts in 68-74~ yield.
-39a-1~'.39.3.'j3 Z ~Z
z~z o~~ 1l o (~) I
7~ o~
~ ~ ~3 Z t~) ¦
0--~--0 ~
.. " {~) I
O ~Z
I~
a:l z ' ~ 7~
o O
O C~. Z
O--~L=O ~ O
O ~
~
Z
-40- ~39~
The lH-NMR of the 5'-monophosphates are as follows:
l~-NMR Spectra of 5'0-Phosphory~
P-thioadenylyl-(2'-5'~-P-thioadenylyl 5 -(2'-5')-adenosine Stereoisomer~
Com~ H 2-H 8-H Solvent pound 13A 6.04 5.92d 5.75d 8.31;8.18; 8.12; 7.98; 7.85; 7.80 D2O
13B 6.12s 5.94d 5.76d 8.26; 8.21; 8.11; 7.99; 7.94; 7.86 D2O
14A 6.03s 5.92d 5.80d 8.27; 8.22; 8.15; 8.04; 7.93; 7.81 D20 14B 6.09s 5.94s 5.81d 8.41; 8.26; 8.14; 8.07; 8.02; 7.89 D2O
2 ~values in ppm; Standard TMS; characteristic signals 13391~-~3 Monophosphorylation of the 5'-deblocked protected trimers to form the 5'-phosphotriesters llA, 11B, 12A or 12B proceeds in high yield, 70-80~, followed by the further high yield (68-74%) step of complete deprotection resulting in the trimer 5'-monophosphates 13A, 13B, 14A or 14B.
~ The 5-monophosphates of each resolved tetramer core compound of the present invention is prepared in the same fashion, using the identical molar quantities as in Examples 15 and 16 except that the starting material for the synthesis is the 5'-hydroxy analogue of the fully protected tetramer rather than the 5'-hydroxy analogue of the fully protected trimer. The following fully resolved tetramer 5'-monophosphates are thus prepared:
5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-- thioadenylyl-(2'-5' ? - ( sp ) -thioade,nylyl-(2'-5')-aden,osine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioaden~ylyl-(2'-5'~)-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphory,l-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl--(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioad,enylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine -42- ~3~3.~3 Preparation of 2',5'-Phosphorothioate Oliqoadenylate 5'-Diphosphates and 5'-Triphosphates The 5'-diphosphate and 5-triphosphate of the 2',5'-phosphorothioate oLigoadenylates may be prepared from the 5'-monophosphate by following the procedure of Example 17.
All reactions are performed in glassware oven-dried at 125~C for 18-24 hr. A 2',5'-phosphorothioate oligoadenylate ster-eoisomer (trimer or tetramer, 400 OD
units at 260 nm) is dissolved in 500 microliters of dry dimethylformamide ("DMF") and dried in vacuo in a 10 ml conical flask at 35~C. This process is repeated three times. To the dry residue, 50 micromoles of triphenylphosphine, 100 micromoles of imidazole and 50 micromoles of dipyridinyl disulfide are added. The mixture is dissolved in 500 microliters dry DMF plus 50 microliters of dry dimethylsulfoxide. The solution is stirred with a stirring bar for 2 hr at room tempe~ature. After 2 hr the solution is homogeneous (after 30 minutes, the solution begins to change to yellow). The solution is transferred dropwise to 10 ml of a 1% NaI/dry acetone (w/v) solution.
The clear white precipitate which forms is the sodium salt of the 5'-phosphoroimidazolidate. The precipitate is centrifuged at room temperature, the supernatant is decanted, and the precipitate is washed three times with 10 ml dry acetone. The centrifuging is repeated. The precitipate is dried over P2Os in vacuo for 2 hr. The precipitate is dissolved in 200 microliters of freshly prepared 0.5 M tributylammonium pyrophosphate in dry DMF.
The solution is maintained at -room temperature for 18 hr after which time the DMF is removed in vacuo. The residue is dissolved in 0.25 M triethylammonium bicarbonate buffer ("TEAB") tpH 7.5). The 5'-di and 5'-triphosphate products are separated using a DEAE-Sephadex A25 column (HCO3 form -43- 13~9~3 1 x 20 cm) with a linear gradient of 0.25 M to 0.75 M TEAB.
Fractions (10 ml) are collected. The product is observed by ultraviolet spectroscopy at 254 nm. The fractions containing the 5'-di- and S'-triphosphates are separately pooled and dried in vacuo. The TEAB is removed by repeated addition of water followed by lyophilization. The yield of the 5'-diphosphate is about 5%; the yield of the 5'-triphosphate is about 6096.
It is genera:lly regarded that activation of RNase L
by 2-5A is key to the antiviral defense mechanisms.
Interferon induces transcription of the enzyme 2-5A
synthetase which produces 2',5' linked oligoadenylates upon activation of double-stranded RNA. The only known biochemical effect of 2-5A is activation of RNase L. This enzyme hydrolyses mRNA and rRNA, thereby resulting in inhibition of protein synthesis. The activation of RNase L
is transient unless 2-5A is continuously synthesized, since 2-5A is rapidly degraded. RNase L activation thus plays a critical role in inhibiting replication, and therefore in defending against infection by viruses.
According t~ the invention,- all four of the 2',5'-phosphorothioate adenylat-e trimer cores, and their 5'-monophosphates bind to RNase L, as determined by radio binding assay according to the method of Knight et al, Heth . Enzymol . 79: 216-227 ( 1981 ). The 2 ', 5 ' -phosphorothioate adenylate trimer cores and authentic A3 were able to displace p3A4~32P]pCp probe from RNase L in L929 cell extracts in a concentration-dependent manner (Fig. lA). IC50s varied from 2 x 10-6 to 5 x 10-6 M.
However, the 5'-monophosphorylated trimers had 1000-fold higher binding aff-inity to RNase L than their respective cores, that is, ICsos ranged from 2 x 10-9 to 5 x 10-9 M
(Fig. lA). ~Jithout wishing to be bound by any theory, this ~ 3 3 ~ 3 increase may be attributed to the ability of the 5'-monophosphates to anchor the molecule to RNase L more - effectively because of increased polarity.
The 2',5'-phosphorothioate cores, with one exception, have the correct stereoconfiguration to activate RNase L.
The activation of partially-purified RNase L by the 2',5'-phosphorothioates was measured according to the core-cellulose assay of Silverman, Analyt. Biochem. 144:450-460 (1985) which relies on hydrolysis of the substrate polytU)-3-[32PlpCp. Surprisingly, three of the four 2',5'-phosphorothioate adenylate cores were able to activate RNase L to cleave poly(U)-3'-[32P]pCp in the core-cellulose assay. (Figure lB) The order of activation of the trimer cores and the corresponding 5'-monophosphates is:
~pRp>SpRp>_pSp (Fig. lB). While pARpARpA was the most efficient activator of RNase L, the compound is metabolically unstable and is readily attacked by phosphodiesterases (See Table 3). The Sp_p trimer core did not activate RNase L, even at a concentration of 10-3 M. As was observed in the binding assay (Fig. lA), there was a 1000-foLd increase in the activation of RNase L
by the 5'-monophosphates of the 2',5'-phosphorothioate trimers compared to their respective cores.
Activation of RNase L by 2',5'-phosphorothioate adenylate trimer cores and their 5'-monophosphates was also measured in an rF'NA cleavage assay using L929 cell extracts. ARpAF~pA and ASpARpA activated RNase L to cleave 28S and 18S rRNA to specific cleavage products at 10-5 M.
However, ARpASpA and ASpAspA did not activate RNase L at concentrations as high as 10-4 M. It appears that the rRNA cleavage assay was not sensitive enough to detect activation of RNase L by ARpASpA Under the experimental conditions used, aulhentic A3 core was also inactive, which ~ 3~9;3 is in agreement with previous reports (Haugh et al, Eur. J
Biochem. 132:77-84 (1983)).
The corresponding 5'-monophosphates pARpARpA~
pASpARpA (at 10-8M) and pARpAspA (at 10 7 M) activated RNase L to cleave 28S and 18S rRNA. Authentic pA3 was active at 10-6 M. Incubation with pASpAspA, even at coneentrations as high at 10-5 M, did not result in detectable rRNA degradation.
The increased bonding strength of the 5'-phosphorylated triMer eore ARpASpA provides a relatively metabolically stable and highly efficient activator for RNase L.
ASpAspA and corresponding 5'-monophosphate were observed to inhibit RNase L activation in both the eore-cellulose and rRNA cleavage assays. Notwithstanding, these compounds are extremely useful as probes in the evaluation of the role of RNase L in the interferon-induced biological eascade. Most importantly, pAspAspA seleetively inhibits aetivation of RNase L at physiologieal coneentrations, and is metabolically stable to speeific and non-specific phosphodiesterases. The molecule provides the means to selectively shut off RNase L activa~ion.
Individuals afflicted with chronic myelogenous leukemia ("CML") display a highly elevated RNase L
activity, as evide~ced by novel rRNA CML-speeifie eleavage products. Thus, pAspAspA~ which is a metabolically stable inhibitor of RNase L, has potential utility in treating myelogenous leukemi 3 .
pAspAspA is the most effective inhibitor of RNase L
reported to date. Moreover, notwithstanding its RNase L
inhibitory effect, pAspAspA is observed to inhibit HIV
reverse transcript:ase activity and tobacco mosaic virus replication.
-46- 133~ 33 ~or phaLmaceutical use, the compounds of the invention m~y be taken up in pharmaceutically acceptable carriers, such ~s, solutions, suspensions, tablets, capsules, ointments, elixirs and injectable composition and the like. They are ad~inistered to subjects sufferin~ from viral infection. The dosage administered depends upon the nature and severity of the infection, the disease stage, and, when administered systematically, the size and weight of the infected subject.
- The compounds are generally administered in the form of water-soluble salts. Pharmaceutically acceptable water soluble salts include, for example, the sodium, potassium or ammonium salts of the active compounds. They are readily dissolved in water or saline solution. Thus, the preferred ~ormulation for pharmacological use comprises a saline solution of the desired compound in salt form. The formulation may further contain an agent, such as a sugar or protein, to maintain osmotic balance. The salt form of the compound is preferred owing to the relatively high acidity (about pH 3) of the acid form of the compounds.
The compounds of the invention may be used to treat or protect humans and animals from viral infectives such as Herpes simplex, rhinovirus, Epstein Barr virus, measles virus, multiple sclerosis (which may be caused by a viral agent) and the various Human Immunodeficiency Viruses ("HIV") such as HIV-I, which causes cutaneou~ T cell lymphoma, HIV-2, which causes Sezary lymphoma, and HIV-3, which is responsible ~or ~cquired immune deficiency syndrome ("AIDS"). The compounds of the invention inhibit the reverse transcriptase activity of HIV.
The compounds may be applied topically to treat skin cancers caused by radiation, carcinogens or viral agents.
Such skin cancers include cutaneous T-cell lymphoma, Sezany lymphoma, Xeroderma pigmentosium, ataxia telangiectasia and -~7- ~ ~ ~g33i~)3 Bloom's syndrome. A sufficient amount of a preparation containing a compound of the invention is applied to cover - the lesion or affected area. An effective concentration of active agent is between about 10-3 M and 10-5 M, with 10-4 M being preferred.
6056-5~
Effect of 2',5'-Phosphorothioate Oligoadenylates on HIV Reverse Transcriptase Activity HIV reverse transcriptase (RNA-dependent DNA
nucleotidyl-transferase) activity was assayed by a modi~ication of the procedure of Poiesz et al. (Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., Bunn, P.S., Minna, J.D., and Gallo, R.C., Proc. Natl. Acad. Sci. U.S.A. 77:, 7415-7419 (1980~).
Cultured H-9 cells are grown at 106 cells/ml il RPMI-1640 ~edium and 20% heat-inactivated fetal calf serum.
Cell suspensions are centrifuged (1000 x 9, 10 min.) and the supernatant is removed. Virus particles are precipitated from this cell-free supernatant to which 0.3 ml of 4 M NaCl and 3.6 ml of 30~ tweight/volume) polyethylene ~lycol are added. The suspension is placed on ice for 2 hr following centrifugation at 15,000 x g for 30 min at 0~C. The precipitate is resuspended in 200 microliters of 50% glycerol (vol./vol.)/25 mM Tris-HCl (pH
7.5)/5 mM dithiothreitol/50 mM KCl/0.025~ Triton*X-100.
Virus particles are lysed by the addition of 100 microliters of 0.9% Triton X-100/1.5 M KCl. Reverse transcriptase assays are performed at 37~C for l hr with 10 microliters of the lysed virus solution in a final reaction volume of 100 microliters containing: 40 mM Tris-HCl (pH
7.8), 4 mM dithiothreitol, 45 mM KCl and 2.5 micrograms of template primer [Poly(A)-dT15. 0.5 micro~rams/microliter]
(with a final Mg++ concentration of 10 mM). At this time, 10 microliters of the 2',5'-phosphorothioate oligoadenylate is added to a final concentration of 200 micromolar.
Reaction mixtures also contain 4 micromoles of ~3H]dTTP.
Reactions are stopped by the addition of cold 5%
trichloroacetic acid and filtered through nitrocellulose discs. The discs are dried and the radioactivity bound to * Trademark 1339~ ~3 the discs is determined. Reverse transcriptase activity is expressed as the percent relative to a control.
The data is ,hown in Table 5. The compounds were assayed in the above manner in two sets, each set having a separate set of controls. The compounds of reactions 1-4 were assayed against control ~1, which was 187 x 103 cpm.
The compounds used in reactions 5-13 were assayed against control ~2, which was 273 x 103 cpm.
-50- 13 ~9 ~3 TABL E S
Inh ibi t ion of HIV (HTLV-IIIBH-g) Reverse Transcriptase Activity by 2',5'-Phosphorothioate Oligoadenylates Reaction Compound Concentra- Reverse Trans- Percent No. - tion criptase Inhibi-Activity tion (uM) (cpm x 10-~) 1 p3A3 200 187 0 2 pA3 200 133 29 4 2ARpARpA 200 144 25 pASPARPA 200 230 16 6 PARpASpA 200 206 25 7 pAspAspA 200 232 15 8 RpARpA 200 224 18 9 ASpARpA 200 258 6 ARpASpA 200 247 10 11 ASpAspA 200 219 20 12 AspAspAspA 200 149 45 13 ARpAspAspA 200 147 46 1~ 3~'3~3 Although p3A3, pA3 and A3 are found in mammalian cells, only the monophosphate inhibits HIV reverse transcriptase. The core compounds of the present invention on the other hand are observed to inhibit HIV reverse transcriptase. While all the compounds of the invention (reaction nos. 5,6,7,9,10,11,12 and 13) inhibit the transcriptase to some degree, the tetramers are particularly effective.
The compoundc; of the invention may be administered in amounts of from about 10 micromoles to about 200 micromoles to inhibit HIV reverse transcriptase and treat HIV.
The compounds also possess antiviral activity against plant-infecting virus, particularly tobacco mosaic virus.
Similar results may be obtained against other viruses which cause necrosis in turnips, cucumber, orchids and in other plants. Such viruses include, but are not limited to, tobacco vein mottling virus, vesicular stomatitis virus, vaccinia virus, turnip necrosis virus, and cymbidium orchid virus.
The compounds may be administered effectively to plants by topical application by abrasion of the leaf surface, aerosol spray, treatment of the soil, spray;ng, or dusting.
An effective antiviral composition may be formed by combining one or more of the compounds of the invention with a suitable carrier material. While the individual stereoisomers are preferred for pharmaceutical use, mixtures of one or more of stereoisomers may be employed in agricultural applications. The active compound may also be administered ~y spraying insect vectors such as aphids, thrips and whiteflies which carry virus to plants. The dosage administer-ed depends upon the severity of the infection.
-52- 1~39~
The compounds of the invention may be applied to plant seeds prior to germination to control viruses contained in the germ plasm. The seeds may be soaked in a solution of polyethylene glycol ("PEG") containing one or more of the compounds. PEG brings the seeds to physiological activity and arrest. The relative concentration of active compound to PEG depends upon the type of seed under treatment.
Plants are effectively treated with an aqueous formulation containing from about 10-1 to about 10-2 M
concentration of active ingredient. The compounds of the invention may be applied at very low concentrations. An effective amount of active ingredient on the plant surface is from about 10-8 to about 10-12 mole per cm2 of plant surface area, with about 10-1~ mole to about 10-12 mole per cm2 being preferred. For the typical tobacco plant of 1,000 cm2, 10-5 M of compound is effective. At this rate, one pound of active ingredient is sufficient to treat 2 x 108 tobacco plants.
For agricultura] application, the compounds are advantageously administered in the form of water-soluble salts, e.g. ammonium or potassium salts. Sodium salts are generally avoided in treating edible plants.
The compounds of the invention are readily dissolved in water, particularly at such low concentrations. Aqueous formulations for agricultural use may optionally contain a sticker and/or a UV-stabilizer. Such agents are well-known to those skilled in the art. ratty acids (1~) are useful as spreader sticker agents. Effective I~V-stabilizers include, for example, p-aminobenzoic acid.
-53- 1~ 3~ 3 Effect of 2',5'Phosphorothioate Oligoadenylates on Tobacco Mosaic Virus (TMV) Replication in Intact Tobacco Plants The effectiveness of the 2',5'-phosphorothioate oligoadenylates against plant virus was demonstrated by infectivity tests on intact Nicotiana glutinosa plants as follows.
Carborundum (400 m~sh) was sprinkled lightly onto leaves. Solutions containing 0.2 micrograms per ml of TMV
and 2 x 10-5 M 2',5'-phosphorothioate oligoadenylate in phosphate buffer were applied onto half-leaves of N.
glutinosa with either a gloved finger or with a pipettor.
The remaining half-leaves were controls (inoculated with the buffer solution containing TMV, but no active compound). The infection was allowed to proceed 48 h under continuous illumination of about 1500 Lx at which time local virus lesions appeared. Inhibition of TMV
replication was calculated as the percent of local lesions produced in 2',5'-phosphorothioate oligoadenylate-treated half-leaves compared to control half-leaves. The data is set forth in Table 6.
6056-5~
13~9~3 Compound3 Percent TMV Inhibition4 s O
ARpARpA 57 ASpAspA 80 ARpASpA 70 ASpARpA 33 pARpA~pA 75 pARpASpA 15 pASpARpA 23 pASpAspA 40 ASpAspAspA
RpAspAspA 80 3 All compounds were added at 2 x 10-5 M in the infecting solution.
4 Inhibition of TMV replication was detected 48 hr after infection and was calculated as the percent of local lesions produced in treated half-leaves of N. glutinosa compared to control half-leaves.
-55- ~ 339'9~
Non-infected plants were treated with 2 x 10-6 M and 2 x 10-5 M of the 2',5'-phosphorothioate core and 5'-monophosphate analogues. No toxicity (chlorosis or necrosis) was observed during the two week period tested.
-5 Of the ten phosphorothioate trimer and tetramer cores and 5'-monophosphates tested, the ~p~p phosphorothioate trimer core inhibited TMV replication to the greatest extent (~0%). Sim;larly, the corresponding tetramer core, SpSpSp, inhibited TMV replication ~y 70%. The RpSpSp tetramer core inhibited TMV replication by 80%. The remarkable inhibition by ASpAspA, ASpAspAspA and ARpASpAspA, as well as the 70% inhibition by ARpASpA, compares with only a 16g inhibition with authentic A3. By introducing the property of chirality, as well as increased metabolic stability, there is a marked increase of the inhibition of TMV replication by the compounds of the invention over 2-5A.
In addition to administration with conventional carriers, the compounds of the present invention may be administered by a variety of specialized oligonucleotide or nucleic acid delivery techniques. 2-5A and its analogues have been successfully encapsulated in unilamellar liposomes and delivered with the aid of monoclonal antibodies to cells (Bayard et al, Eur. J. Biochem.
151:319-325 (1985)). Reconstituted Sendai virus envelopes have been successfully used to deliver RNA and DNA to cells (Arad et al, Biochem. Biophys. Acta 859:88-94 (1986)).
These techniques may be utilized for introduction of the present 2',5'-phosphorothioate oligoadenylates into cells.
It is ~urther contemplated that the compounds of the invention may be administered in the ~orm of prodrugs in which lipophilic groups are attached to, for example, the 5'-terminal hydroxyl group of the core compound.
605~-58 56 iL 3 ~ ~ t Conjugation of 2',5'-Phosphorothioate Tetramer Adenylates Poly(L-lysine) has been described as a versatile membrane carrier for 2-SA and other macro~olecules (Bayard et al, Biochem. 25:3730-3726 (1986)). The tetramer cores and phosphorylated tetramers of the present invention may be conveniently administered in the form of poly(L-lysine) conjugates. The conjugates are formed by introducing two aldehyde functions at the 2' end of the tetramer-by periodate oxidation of the alpha-glycol group of the ribose residue. The resulting aldehyde groups are then randomly coupled to the epsilon-amino groups of lysine residues of poly(L-lysine) by Schiff base formation, and then reduced with sodium cyanoborohydride at pH 8Ø This procedure converts the 2',3'-terminal ribose ring into a morpholine structure. The poly(L-lysine) peptide preferably contains from about 60 to about 70 lysine residues. From about five to about ten of the lysine residues are coupled in this manner to tetramer moieties. The resulting 2',S'-phosphorothioate/poly(L-lysine) conjugates may then be isolated by gel filtration chromatography on a Sephadex G-50 column.
The poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates have the formula:
(fH2)4 (fH2)4 wherein q is an integer ~rom about 60 to about 70 and R is rando~ly R' or -57- ~39'3~3 (~H2)4 -NHCHCO-.
From about five to about ten of the R groups comprise R'.
The R' group has the following formula wherein m is 0,1,2 or 3:
OH<~ ~JN
~m~
~ ~N ~J
~ NH2 ~0- P=S N ~N
1~0 -0_ p=5 ~2 -o~l ~NJ
(CH2)~
~L~ 3~3 .-~3 The conjugates may be advantageously prepared by the procedure of Bayard et al, Biochem.25:3730-3736 (1986):
Example 18 Preparation of Poly(L-lysine)/
2',5'-Phosphorothioate Oligoadenylate Conjugates A 4-microliter aliquot of sodium metaperiodate (0.6 micromole in 0.1 M sodium acetate buffer, pH 4.75) is added to an ice-cold solution of 2',5'-phosphorothioate tetramer adenylate in 400 microliter of distiller water.
The reaction mixture is stirred on ice for 30 min; 400 microliter of poly(L-lysine) (0.14 micromole in 0.2 M
phosphate buffer, pH 8.0) and 200 microliter of sodium cyanoborohydride (20 micromole in 0.2 M phosphate buffer, pH 8.0) are added. The mixture is incubated for 2 h at room temperature and then loaded on a Sephadex G-50 column equilibrated with 0.1 M sodium acetate buffer, pH 4.75.
Each fraction is assayed for its phosphorothioate oligoadenylate/poly(L-lysine) content by the method described by Lowry et al, J. Biol. Chem. 193:265-275 (1951), and by absorbance at 260 nm.
Conjugation of the 2',5'-phosphothioate tetramer to poly(L-lysine) leaves the remaining three 2',5'-linked phosphorothioate adenylic residues intact for optimal ~'~ase L binding and activation.
Liposome Encapsulation of 2',5'-Phosphorothioate Oligoadenylates Encapsulation of the compounds of the present invention comprises another attractive non-disruptive technique for introduction into cells. Liposome encapsulation may be advantageously accomplished according to the technique described by Kondorosi et al., FEBS Lett.
120:37-40 (1980):
133~ 3-~3 Preparation of Large Unilamellar Vesicles (Liposomes) Loaded with 2',5'-Phosphorothioate Oligoadenylates Briefly, a phospholipid mixture from bovine brain (Sigma Chemical Co., Folch fraction III composed of 80-85%
phosphatidylserine with the remaining 15% composed of other brain lipids; 35 mg) is suspended in 5 ml of buffer A [0.1 M NaCl, 2 mM histidine, 2 rnM N-tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid ("TES"), 0.4 mM EDTA (pH 7.4) by vortexing. The suspension is sonicated under nitrogen for 10 minutes at 0~C. The suspension is further incubated for hr at 37~C after adjusting the final concentration of Ca++ to 20 mM by the addition of 125 microliters of 800 mM
CaC12. The resulting precipitate is sedimented by centrifugation (2500 x g, 10 min), ~ortexing and mixing with 100 microliters of 1 x 10-4 M 2',5'-phosphorothioate oligoadenylate, which is dissolved in phosphate-buffered saline. The final concentration of EDTA is then adjusted to 120 mM by the addition of 400 microliters of buffer B
[150 mM EDTA, pH 7.4, 0.1 M NaCl, 2 mM histidine, 2 mM
TES] . Liposomes are formed after incubation of this mixture for 30 minutes at 37~C. The excess of EDTA and non-encapsulated components are removed by passing the 1 iposomes through a Sephadex G-25 column which is equilibrated with phosphate-buffered saline. About 10% of the 2',5'-phosphorothioate oligoadenylate is encapsulated into liposomes by this procedure. The liposome suspension is stable at 4~C for one week following preparation.
Preparation of Reconstituted Sendai Virus E:nvelopes Containing 2',5'-Phosphorothioate Oligoadenylates Reconstituted Sendai virus envelopes may be used as efficient vehicles for the introduction of polynucleotides L3393~3 into cells. Arad et al, Biochimica et Biophysica Acta 859:88-94 (1986) disclose introduction of poly(I) poly(C) into cultured cells by the use of reconstituted Sendai virus envelopes. Fusion of thus-loaded reconstituted Sendai virus envelopes leads to introduction of the enclosed macromolecules into the recipient cell cytoplasm.
Reconstituted Sendai virus envelopes may be obtained by detergent solubilization of intact Sendai virus particles. The reconstituted envelopes are fusogenic vesicles consisting of the viral envelope phospholids and their glycoproteins, devoid of the viral genomic RNA.
Incorporation of the compounds of the present invention into reconstituted Sendai virus envelopes for fusion-mediated micro-injection may be accomplished by following the procedure or Arad et al. Briefly, a pellet of Sendai virus particles (1.5 mg protein) is dissolved in 30 microliters of a solution containing 10% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl (pH 7.4) and 0.1 mM
phenylmethylsulfonyl fluoride (Triton X-lOO:protein ratio, 2:1, w/w). To the clear supernatant obtained after centrifugation, 2',5'-phosphorothioate oligoadenylate dissolved in a solution A (160 mM NaCl, 20 mM Tris-HCl, (pH
7.4)) is added to give a final concentration of active ingredient of 5-20 mg/ml and a final volume of 150 microliters. Triton X-100 is removed from the supernatant by direct addition of 40 mg of SM-2 Bio-Beads. The turbid suspension obtained (containing reconstituted Sendai virus envelopes) is centrifuged at 100,000 x 9 for 1 h. The pellet, containing about 10% of the original viral protein, is then suspended in solution A to give a final protein concentration of 25 micrograms/ml.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference 13~99~3 should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.
~ ~ ~3 Z t~) ¦
0--~--0 ~
.. " {~) I
O ~Z
I~
a:l z ' ~ 7~
o O
O C~. Z
O--~L=O ~ O
O ~
~
Z
-40- ~39~
The lH-NMR of the 5'-monophosphates are as follows:
l~-NMR Spectra of 5'0-Phosphory~
P-thioadenylyl-(2'-5'~-P-thioadenylyl 5 -(2'-5')-adenosine Stereoisomer~
Com~ H 2-H 8-H Solvent pound 13A 6.04 5.92d 5.75d 8.31;8.18; 8.12; 7.98; 7.85; 7.80 D2O
13B 6.12s 5.94d 5.76d 8.26; 8.21; 8.11; 7.99; 7.94; 7.86 D2O
14A 6.03s 5.92d 5.80d 8.27; 8.22; 8.15; 8.04; 7.93; 7.81 D20 14B 6.09s 5.94s 5.81d 8.41; 8.26; 8.14; 8.07; 8.02; 7.89 D2O
2 ~values in ppm; Standard TMS; characteristic signals 13391~-~3 Monophosphorylation of the 5'-deblocked protected trimers to form the 5'-phosphotriesters llA, 11B, 12A or 12B proceeds in high yield, 70-80~, followed by the further high yield (68-74%) step of complete deprotection resulting in the trimer 5'-monophosphates 13A, 13B, 14A or 14B.
~ The 5-monophosphates of each resolved tetramer core compound of the present invention is prepared in the same fashion, using the identical molar quantities as in Examples 15 and 16 except that the starting material for the synthesis is the 5'-hydroxy analogue of the fully protected tetramer rather than the 5'-hydroxy analogue of the fully protected trimer. The following fully resolved tetramer 5'-monophosphates are thus prepared:
5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Rp)-- thioadenylyl-(2'-5' ? - ( sp ) -thioade,nylyl-(2'-5')-aden,osine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioaden~ylyl-(2'-5'~)-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphory,l-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl--(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-(Rp)-thioad,enylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Sp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine 5'-O-Phosphoryl-(Rp)-thioadenylyl-(2'-5')-(Sp)-thioadenylyl-(2'-5')-(Rp)-thioadenylyl-(2'-5')-adenosine -42- ~3~3.~3 Preparation of 2',5'-Phosphorothioate Oliqoadenylate 5'-Diphosphates and 5'-Triphosphates The 5'-diphosphate and 5-triphosphate of the 2',5'-phosphorothioate oLigoadenylates may be prepared from the 5'-monophosphate by following the procedure of Example 17.
All reactions are performed in glassware oven-dried at 125~C for 18-24 hr. A 2',5'-phosphorothioate oligoadenylate ster-eoisomer (trimer or tetramer, 400 OD
units at 260 nm) is dissolved in 500 microliters of dry dimethylformamide ("DMF") and dried in vacuo in a 10 ml conical flask at 35~C. This process is repeated three times. To the dry residue, 50 micromoles of triphenylphosphine, 100 micromoles of imidazole and 50 micromoles of dipyridinyl disulfide are added. The mixture is dissolved in 500 microliters dry DMF plus 50 microliters of dry dimethylsulfoxide. The solution is stirred with a stirring bar for 2 hr at room tempe~ature. After 2 hr the solution is homogeneous (after 30 minutes, the solution begins to change to yellow). The solution is transferred dropwise to 10 ml of a 1% NaI/dry acetone (w/v) solution.
The clear white precipitate which forms is the sodium salt of the 5'-phosphoroimidazolidate. The precipitate is centrifuged at room temperature, the supernatant is decanted, and the precipitate is washed three times with 10 ml dry acetone. The centrifuging is repeated. The precitipate is dried over P2Os in vacuo for 2 hr. The precipitate is dissolved in 200 microliters of freshly prepared 0.5 M tributylammonium pyrophosphate in dry DMF.
The solution is maintained at -room temperature for 18 hr after which time the DMF is removed in vacuo. The residue is dissolved in 0.25 M triethylammonium bicarbonate buffer ("TEAB") tpH 7.5). The 5'-di and 5'-triphosphate products are separated using a DEAE-Sephadex A25 column (HCO3 form -43- 13~9~3 1 x 20 cm) with a linear gradient of 0.25 M to 0.75 M TEAB.
Fractions (10 ml) are collected. The product is observed by ultraviolet spectroscopy at 254 nm. The fractions containing the 5'-di- and S'-triphosphates are separately pooled and dried in vacuo. The TEAB is removed by repeated addition of water followed by lyophilization. The yield of the 5'-diphosphate is about 5%; the yield of the 5'-triphosphate is about 6096.
It is genera:lly regarded that activation of RNase L
by 2-5A is key to the antiviral defense mechanisms.
Interferon induces transcription of the enzyme 2-5A
synthetase which produces 2',5' linked oligoadenylates upon activation of double-stranded RNA. The only known biochemical effect of 2-5A is activation of RNase L. This enzyme hydrolyses mRNA and rRNA, thereby resulting in inhibition of protein synthesis. The activation of RNase L
is transient unless 2-5A is continuously synthesized, since 2-5A is rapidly degraded. RNase L activation thus plays a critical role in inhibiting replication, and therefore in defending against infection by viruses.
According t~ the invention,- all four of the 2',5'-phosphorothioate adenylat-e trimer cores, and their 5'-monophosphates bind to RNase L, as determined by radio binding assay according to the method of Knight et al, Heth . Enzymol . 79: 216-227 ( 1981 ). The 2 ', 5 ' -phosphorothioate adenylate trimer cores and authentic A3 were able to displace p3A4~32P]pCp probe from RNase L in L929 cell extracts in a concentration-dependent manner (Fig. lA). IC50s varied from 2 x 10-6 to 5 x 10-6 M.
However, the 5'-monophosphorylated trimers had 1000-fold higher binding aff-inity to RNase L than their respective cores, that is, ICsos ranged from 2 x 10-9 to 5 x 10-9 M
(Fig. lA). ~Jithout wishing to be bound by any theory, this ~ 3 3 ~ 3 increase may be attributed to the ability of the 5'-monophosphates to anchor the molecule to RNase L more - effectively because of increased polarity.
The 2',5'-phosphorothioate cores, with one exception, have the correct stereoconfiguration to activate RNase L.
The activation of partially-purified RNase L by the 2',5'-phosphorothioates was measured according to the core-cellulose assay of Silverman, Analyt. Biochem. 144:450-460 (1985) which relies on hydrolysis of the substrate polytU)-3-[32PlpCp. Surprisingly, three of the four 2',5'-phosphorothioate adenylate cores were able to activate RNase L to cleave poly(U)-3'-[32P]pCp in the core-cellulose assay. (Figure lB) The order of activation of the trimer cores and the corresponding 5'-monophosphates is:
~pRp>SpRp>_pSp (Fig. lB). While pARpARpA was the most efficient activator of RNase L, the compound is metabolically unstable and is readily attacked by phosphodiesterases (See Table 3). The Sp_p trimer core did not activate RNase L, even at a concentration of 10-3 M. As was observed in the binding assay (Fig. lA), there was a 1000-foLd increase in the activation of RNase L
by the 5'-monophosphates of the 2',5'-phosphorothioate trimers compared to their respective cores.
Activation of RNase L by 2',5'-phosphorothioate adenylate trimer cores and their 5'-monophosphates was also measured in an rF'NA cleavage assay using L929 cell extracts. ARpAF~pA and ASpARpA activated RNase L to cleave 28S and 18S rRNA to specific cleavage products at 10-5 M.
However, ARpASpA and ASpAspA did not activate RNase L at concentrations as high as 10-4 M. It appears that the rRNA cleavage assay was not sensitive enough to detect activation of RNase L by ARpASpA Under the experimental conditions used, aulhentic A3 core was also inactive, which ~ 3~9;3 is in agreement with previous reports (Haugh et al, Eur. J
Biochem. 132:77-84 (1983)).
The corresponding 5'-monophosphates pARpARpA~
pASpARpA (at 10-8M) and pARpAspA (at 10 7 M) activated RNase L to cleave 28S and 18S rRNA. Authentic pA3 was active at 10-6 M. Incubation with pASpAspA, even at coneentrations as high at 10-5 M, did not result in detectable rRNA degradation.
The increased bonding strength of the 5'-phosphorylated triMer eore ARpASpA provides a relatively metabolically stable and highly efficient activator for RNase L.
ASpAspA and corresponding 5'-monophosphate were observed to inhibit RNase L activation in both the eore-cellulose and rRNA cleavage assays. Notwithstanding, these compounds are extremely useful as probes in the evaluation of the role of RNase L in the interferon-induced biological eascade. Most importantly, pAspAspA seleetively inhibits aetivation of RNase L at physiologieal coneentrations, and is metabolically stable to speeific and non-specific phosphodiesterases. The molecule provides the means to selectively shut off RNase L activa~ion.
Individuals afflicted with chronic myelogenous leukemia ("CML") display a highly elevated RNase L
activity, as evide~ced by novel rRNA CML-speeifie eleavage products. Thus, pAspAspA~ which is a metabolically stable inhibitor of RNase L, has potential utility in treating myelogenous leukemi 3 .
pAspAspA is the most effective inhibitor of RNase L
reported to date. Moreover, notwithstanding its RNase L
inhibitory effect, pAspAspA is observed to inhibit HIV
reverse transcript:ase activity and tobacco mosaic virus replication.
-46- 133~ 33 ~or phaLmaceutical use, the compounds of the invention m~y be taken up in pharmaceutically acceptable carriers, such ~s, solutions, suspensions, tablets, capsules, ointments, elixirs and injectable composition and the like. They are ad~inistered to subjects sufferin~ from viral infection. The dosage administered depends upon the nature and severity of the infection, the disease stage, and, when administered systematically, the size and weight of the infected subject.
- The compounds are generally administered in the form of water-soluble salts. Pharmaceutically acceptable water soluble salts include, for example, the sodium, potassium or ammonium salts of the active compounds. They are readily dissolved in water or saline solution. Thus, the preferred ~ormulation for pharmacological use comprises a saline solution of the desired compound in salt form. The formulation may further contain an agent, such as a sugar or protein, to maintain osmotic balance. The salt form of the compound is preferred owing to the relatively high acidity (about pH 3) of the acid form of the compounds.
The compounds of the invention may be used to treat or protect humans and animals from viral infectives such as Herpes simplex, rhinovirus, Epstein Barr virus, measles virus, multiple sclerosis (which may be caused by a viral agent) and the various Human Immunodeficiency Viruses ("HIV") such as HIV-I, which causes cutaneou~ T cell lymphoma, HIV-2, which causes Sezary lymphoma, and HIV-3, which is responsible ~or ~cquired immune deficiency syndrome ("AIDS"). The compounds of the invention inhibit the reverse transcriptase activity of HIV.
The compounds may be applied topically to treat skin cancers caused by radiation, carcinogens or viral agents.
Such skin cancers include cutaneous T-cell lymphoma, Sezany lymphoma, Xeroderma pigmentosium, ataxia telangiectasia and -~7- ~ ~ ~g33i~)3 Bloom's syndrome. A sufficient amount of a preparation containing a compound of the invention is applied to cover - the lesion or affected area. An effective concentration of active agent is between about 10-3 M and 10-5 M, with 10-4 M being preferred.
6056-5~
Effect of 2',5'-Phosphorothioate Oligoadenylates on HIV Reverse Transcriptase Activity HIV reverse transcriptase (RNA-dependent DNA
nucleotidyl-transferase) activity was assayed by a modi~ication of the procedure of Poiesz et al. (Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., Bunn, P.S., Minna, J.D., and Gallo, R.C., Proc. Natl. Acad. Sci. U.S.A. 77:, 7415-7419 (1980~).
Cultured H-9 cells are grown at 106 cells/ml il RPMI-1640 ~edium and 20% heat-inactivated fetal calf serum.
Cell suspensions are centrifuged (1000 x 9, 10 min.) and the supernatant is removed. Virus particles are precipitated from this cell-free supernatant to which 0.3 ml of 4 M NaCl and 3.6 ml of 30~ tweight/volume) polyethylene ~lycol are added. The suspension is placed on ice for 2 hr following centrifugation at 15,000 x g for 30 min at 0~C. The precipitate is resuspended in 200 microliters of 50% glycerol (vol./vol.)/25 mM Tris-HCl (pH
7.5)/5 mM dithiothreitol/50 mM KCl/0.025~ Triton*X-100.
Virus particles are lysed by the addition of 100 microliters of 0.9% Triton X-100/1.5 M KCl. Reverse transcriptase assays are performed at 37~C for l hr with 10 microliters of the lysed virus solution in a final reaction volume of 100 microliters containing: 40 mM Tris-HCl (pH
7.8), 4 mM dithiothreitol, 45 mM KCl and 2.5 micrograms of template primer [Poly(A)-dT15. 0.5 micro~rams/microliter]
(with a final Mg++ concentration of 10 mM). At this time, 10 microliters of the 2',5'-phosphorothioate oligoadenylate is added to a final concentration of 200 micromolar.
Reaction mixtures also contain 4 micromoles of ~3H]dTTP.
Reactions are stopped by the addition of cold 5%
trichloroacetic acid and filtered through nitrocellulose discs. The discs are dried and the radioactivity bound to * Trademark 1339~ ~3 the discs is determined. Reverse transcriptase activity is expressed as the percent relative to a control.
The data is ,hown in Table 5. The compounds were assayed in the above manner in two sets, each set having a separate set of controls. The compounds of reactions 1-4 were assayed against control ~1, which was 187 x 103 cpm.
The compounds used in reactions 5-13 were assayed against control ~2, which was 273 x 103 cpm.
-50- 13 ~9 ~3 TABL E S
Inh ibi t ion of HIV (HTLV-IIIBH-g) Reverse Transcriptase Activity by 2',5'-Phosphorothioate Oligoadenylates Reaction Compound Concentra- Reverse Trans- Percent No. - tion criptase Inhibi-Activity tion (uM) (cpm x 10-~) 1 p3A3 200 187 0 2 pA3 200 133 29 4 2ARpARpA 200 144 25 pASPARPA 200 230 16 6 PARpASpA 200 206 25 7 pAspAspA 200 232 15 8 RpARpA 200 224 18 9 ASpARpA 200 258 6 ARpASpA 200 247 10 11 ASpAspA 200 219 20 12 AspAspAspA 200 149 45 13 ARpAspAspA 200 147 46 1~ 3~'3~3 Although p3A3, pA3 and A3 are found in mammalian cells, only the monophosphate inhibits HIV reverse transcriptase. The core compounds of the present invention on the other hand are observed to inhibit HIV reverse transcriptase. While all the compounds of the invention (reaction nos. 5,6,7,9,10,11,12 and 13) inhibit the transcriptase to some degree, the tetramers are particularly effective.
The compoundc; of the invention may be administered in amounts of from about 10 micromoles to about 200 micromoles to inhibit HIV reverse transcriptase and treat HIV.
The compounds also possess antiviral activity against plant-infecting virus, particularly tobacco mosaic virus.
Similar results may be obtained against other viruses which cause necrosis in turnips, cucumber, orchids and in other plants. Such viruses include, but are not limited to, tobacco vein mottling virus, vesicular stomatitis virus, vaccinia virus, turnip necrosis virus, and cymbidium orchid virus.
The compounds may be administered effectively to plants by topical application by abrasion of the leaf surface, aerosol spray, treatment of the soil, spray;ng, or dusting.
An effective antiviral composition may be formed by combining one or more of the compounds of the invention with a suitable carrier material. While the individual stereoisomers are preferred for pharmaceutical use, mixtures of one or more of stereoisomers may be employed in agricultural applications. The active compound may also be administered ~y spraying insect vectors such as aphids, thrips and whiteflies which carry virus to plants. The dosage administer-ed depends upon the severity of the infection.
-52- 1~39~
The compounds of the invention may be applied to plant seeds prior to germination to control viruses contained in the germ plasm. The seeds may be soaked in a solution of polyethylene glycol ("PEG") containing one or more of the compounds. PEG brings the seeds to physiological activity and arrest. The relative concentration of active compound to PEG depends upon the type of seed under treatment.
Plants are effectively treated with an aqueous formulation containing from about 10-1 to about 10-2 M
concentration of active ingredient. The compounds of the invention may be applied at very low concentrations. An effective amount of active ingredient on the plant surface is from about 10-8 to about 10-12 mole per cm2 of plant surface area, with about 10-1~ mole to about 10-12 mole per cm2 being preferred. For the typical tobacco plant of 1,000 cm2, 10-5 M of compound is effective. At this rate, one pound of active ingredient is sufficient to treat 2 x 108 tobacco plants.
For agricultura] application, the compounds are advantageously administered in the form of water-soluble salts, e.g. ammonium or potassium salts. Sodium salts are generally avoided in treating edible plants.
The compounds of the invention are readily dissolved in water, particularly at such low concentrations. Aqueous formulations for agricultural use may optionally contain a sticker and/or a UV-stabilizer. Such agents are well-known to those skilled in the art. ratty acids (1~) are useful as spreader sticker agents. Effective I~V-stabilizers include, for example, p-aminobenzoic acid.
-53- 1~ 3~ 3 Effect of 2',5'Phosphorothioate Oligoadenylates on Tobacco Mosaic Virus (TMV) Replication in Intact Tobacco Plants The effectiveness of the 2',5'-phosphorothioate oligoadenylates against plant virus was demonstrated by infectivity tests on intact Nicotiana glutinosa plants as follows.
Carborundum (400 m~sh) was sprinkled lightly onto leaves. Solutions containing 0.2 micrograms per ml of TMV
and 2 x 10-5 M 2',5'-phosphorothioate oligoadenylate in phosphate buffer were applied onto half-leaves of N.
glutinosa with either a gloved finger or with a pipettor.
The remaining half-leaves were controls (inoculated with the buffer solution containing TMV, but no active compound). The infection was allowed to proceed 48 h under continuous illumination of about 1500 Lx at which time local virus lesions appeared. Inhibition of TMV
replication was calculated as the percent of local lesions produced in 2',5'-phosphorothioate oligoadenylate-treated half-leaves compared to control half-leaves. The data is set forth in Table 6.
6056-5~
13~9~3 Compound3 Percent TMV Inhibition4 s O
ARpARpA 57 ASpAspA 80 ARpASpA 70 ASpARpA 33 pARpA~pA 75 pARpASpA 15 pASpARpA 23 pASpAspA 40 ASpAspAspA
RpAspAspA 80 3 All compounds were added at 2 x 10-5 M in the infecting solution.
4 Inhibition of TMV replication was detected 48 hr after infection and was calculated as the percent of local lesions produced in treated half-leaves of N. glutinosa compared to control half-leaves.
-55- ~ 339'9~
Non-infected plants were treated with 2 x 10-6 M and 2 x 10-5 M of the 2',5'-phosphorothioate core and 5'-monophosphate analogues. No toxicity (chlorosis or necrosis) was observed during the two week period tested.
-5 Of the ten phosphorothioate trimer and tetramer cores and 5'-monophosphates tested, the ~p~p phosphorothioate trimer core inhibited TMV replication to the greatest extent (~0%). Sim;larly, the corresponding tetramer core, SpSpSp, inhibited TMV replication ~y 70%. The RpSpSp tetramer core inhibited TMV replication by 80%. The remarkable inhibition by ASpAspA, ASpAspAspA and ARpASpAspA, as well as the 70% inhibition by ARpASpA, compares with only a 16g inhibition with authentic A3. By introducing the property of chirality, as well as increased metabolic stability, there is a marked increase of the inhibition of TMV replication by the compounds of the invention over 2-5A.
In addition to administration with conventional carriers, the compounds of the present invention may be administered by a variety of specialized oligonucleotide or nucleic acid delivery techniques. 2-5A and its analogues have been successfully encapsulated in unilamellar liposomes and delivered with the aid of monoclonal antibodies to cells (Bayard et al, Eur. J. Biochem.
151:319-325 (1985)). Reconstituted Sendai virus envelopes have been successfully used to deliver RNA and DNA to cells (Arad et al, Biochem. Biophys. Acta 859:88-94 (1986)).
These techniques may be utilized for introduction of the present 2',5'-phosphorothioate oligoadenylates into cells.
It is ~urther contemplated that the compounds of the invention may be administered in the ~orm of prodrugs in which lipophilic groups are attached to, for example, the 5'-terminal hydroxyl group of the core compound.
605~-58 56 iL 3 ~ ~ t Conjugation of 2',5'-Phosphorothioate Tetramer Adenylates Poly(L-lysine) has been described as a versatile membrane carrier for 2-SA and other macro~olecules (Bayard et al, Biochem. 25:3730-3726 (1986)). The tetramer cores and phosphorylated tetramers of the present invention may be conveniently administered in the form of poly(L-lysine) conjugates. The conjugates are formed by introducing two aldehyde functions at the 2' end of the tetramer-by periodate oxidation of the alpha-glycol group of the ribose residue. The resulting aldehyde groups are then randomly coupled to the epsilon-amino groups of lysine residues of poly(L-lysine) by Schiff base formation, and then reduced with sodium cyanoborohydride at pH 8Ø This procedure converts the 2',3'-terminal ribose ring into a morpholine structure. The poly(L-lysine) peptide preferably contains from about 60 to about 70 lysine residues. From about five to about ten of the lysine residues are coupled in this manner to tetramer moieties. The resulting 2',S'-phosphorothioate/poly(L-lysine) conjugates may then be isolated by gel filtration chromatography on a Sephadex G-50 column.
The poly(L-lysine)/2',5'-phosphorothioate oligoadenylate conjugates have the formula:
(fH2)4 (fH2)4 wherein q is an integer ~rom about 60 to about 70 and R is rando~ly R' or -57- ~39'3~3 (~H2)4 -NHCHCO-.
From about five to about ten of the R groups comprise R'.
The R' group has the following formula wherein m is 0,1,2 or 3:
OH<~ ~JN
~m~
~ ~N ~J
~ NH2 ~0- P=S N ~N
1~0 -0_ p=5 ~2 -o~l ~NJ
(CH2)~
~L~ 3~3 .-~3 The conjugates may be advantageously prepared by the procedure of Bayard et al, Biochem.25:3730-3736 (1986):
Example 18 Preparation of Poly(L-lysine)/
2',5'-Phosphorothioate Oligoadenylate Conjugates A 4-microliter aliquot of sodium metaperiodate (0.6 micromole in 0.1 M sodium acetate buffer, pH 4.75) is added to an ice-cold solution of 2',5'-phosphorothioate tetramer adenylate in 400 microliter of distiller water.
The reaction mixture is stirred on ice for 30 min; 400 microliter of poly(L-lysine) (0.14 micromole in 0.2 M
phosphate buffer, pH 8.0) and 200 microliter of sodium cyanoborohydride (20 micromole in 0.2 M phosphate buffer, pH 8.0) are added. The mixture is incubated for 2 h at room temperature and then loaded on a Sephadex G-50 column equilibrated with 0.1 M sodium acetate buffer, pH 4.75.
Each fraction is assayed for its phosphorothioate oligoadenylate/poly(L-lysine) content by the method described by Lowry et al, J. Biol. Chem. 193:265-275 (1951), and by absorbance at 260 nm.
Conjugation of the 2',5'-phosphothioate tetramer to poly(L-lysine) leaves the remaining three 2',5'-linked phosphorothioate adenylic residues intact for optimal ~'~ase L binding and activation.
Liposome Encapsulation of 2',5'-Phosphorothioate Oligoadenylates Encapsulation of the compounds of the present invention comprises another attractive non-disruptive technique for introduction into cells. Liposome encapsulation may be advantageously accomplished according to the technique described by Kondorosi et al., FEBS Lett.
120:37-40 (1980):
133~ 3-~3 Preparation of Large Unilamellar Vesicles (Liposomes) Loaded with 2',5'-Phosphorothioate Oligoadenylates Briefly, a phospholipid mixture from bovine brain (Sigma Chemical Co., Folch fraction III composed of 80-85%
phosphatidylserine with the remaining 15% composed of other brain lipids; 35 mg) is suspended in 5 ml of buffer A [0.1 M NaCl, 2 mM histidine, 2 rnM N-tris(hydroxymethyl)methyl-2-aminoethane sulfonic acid ("TES"), 0.4 mM EDTA (pH 7.4) by vortexing. The suspension is sonicated under nitrogen for 10 minutes at 0~C. The suspension is further incubated for hr at 37~C after adjusting the final concentration of Ca++ to 20 mM by the addition of 125 microliters of 800 mM
CaC12. The resulting precipitate is sedimented by centrifugation (2500 x g, 10 min), ~ortexing and mixing with 100 microliters of 1 x 10-4 M 2',5'-phosphorothioate oligoadenylate, which is dissolved in phosphate-buffered saline. The final concentration of EDTA is then adjusted to 120 mM by the addition of 400 microliters of buffer B
[150 mM EDTA, pH 7.4, 0.1 M NaCl, 2 mM histidine, 2 mM
TES] . Liposomes are formed after incubation of this mixture for 30 minutes at 37~C. The excess of EDTA and non-encapsulated components are removed by passing the 1 iposomes through a Sephadex G-25 column which is equilibrated with phosphate-buffered saline. About 10% of the 2',5'-phosphorothioate oligoadenylate is encapsulated into liposomes by this procedure. The liposome suspension is stable at 4~C for one week following preparation.
Preparation of Reconstituted Sendai Virus E:nvelopes Containing 2',5'-Phosphorothioate Oligoadenylates Reconstituted Sendai virus envelopes may be used as efficient vehicles for the introduction of polynucleotides L3393~3 into cells. Arad et al, Biochimica et Biophysica Acta 859:88-94 (1986) disclose introduction of poly(I) poly(C) into cultured cells by the use of reconstituted Sendai virus envelopes. Fusion of thus-loaded reconstituted Sendai virus envelopes leads to introduction of the enclosed macromolecules into the recipient cell cytoplasm.
Reconstituted Sendai virus envelopes may be obtained by detergent solubilization of intact Sendai virus particles. The reconstituted envelopes are fusogenic vesicles consisting of the viral envelope phospholids and their glycoproteins, devoid of the viral genomic RNA.
Incorporation of the compounds of the present invention into reconstituted Sendai virus envelopes for fusion-mediated micro-injection may be accomplished by following the procedure or Arad et al. Briefly, a pellet of Sendai virus particles (1.5 mg protein) is dissolved in 30 microliters of a solution containing 10% Triton X-100, 100 mM NaCl, 50 mM Tris-HCl (pH 7.4) and 0.1 mM
phenylmethylsulfonyl fluoride (Triton X-lOO:protein ratio, 2:1, w/w). To the clear supernatant obtained after centrifugation, 2',5'-phosphorothioate oligoadenylate dissolved in a solution A (160 mM NaCl, 20 mM Tris-HCl, (pH
7.4)) is added to give a final concentration of active ingredient of 5-20 mg/ml and a final volume of 150 microliters. Triton X-100 is removed from the supernatant by direct addition of 40 mg of SM-2 Bio-Beads. The turbid suspension obtained (containing reconstituted Sendai virus envelopes) is centrifuged at 100,000 x 9 for 1 h. The pellet, containing about 10% of the original viral protein, is then suspended in solution A to give a final protein concentration of 25 micrograms/ml.
The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference 13~99~3 should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.
Claims (46)
1. A compound which is an optical isomer of the formula:
substantially free of contamination by other optical isomers of the same formula, wherein m is zero, 1,2 or 3; n is 1 or 2; and at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
substantially free of contamination by other optical isomers of the same formula, wherein m is zero, 1,2 or 3; n is 1 or 2; and at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
2. A compound according to claim 1 where m is 1.
3. A compound according to claim 1 wherein the internucleotide phosphorothioate group adjacent the 2' terminal adenylate moiety is of the Sp configuration.
4. (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
5. (Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
6. (Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound according to claim 1.
7. 5'-O-phosphoryl-(Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
8. 5'-O-phosphoryl-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound of claim 1.
9. 5'-O-phosphoryl-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, being a compound according to claim 1.
10. (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
11. The 5'-monophosphate according to claim 10.
12. (Rp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 10.
13. The 5'-monophosphate according to claim 12.
14. (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
15. The 5'-monophosphate according to claim 14.
16. (Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Rp)-P-thioadenylyl-(2'-5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
17. The 5'-monophosphate according to claim 16.
18. (Sp)-P-thioadenylyl-(2'- 5')-(Rp)-P-thioadenylyl-(2'- 5')-(Sp)-P-thioadenylyl-(2'- 5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
19. The 5'-monophosphate according to claim 18.
20. (Sp)-P-thioadenylyl-(2' - 5')-(Sp)-P-thioadenylyl-(2' - 5')-(Sp)-P-thioadenylyl-(2' - 5')-adenosine, and 5'-mono-, di-, and triphosphates thereof, being compounds according to claim 1.
21. The 5'-monophosphate according to claim 20.
22. An antiviral composition comprising a compound according to claim 1 contained in a reconstituted Sendai virus envelope.
23. An antiviral composition comprising a compound according to claim 1 encapsulated in a liposome.
24. Use of a compound according to any one of claims 1 to 21 for inhibiting viral infection in mammals.
25. A compound according to claim 2 for use in inhibiting viral infection in mammals.
26. A method of inhibiting viral infection in plants comprising administering thereto an antiviral effective amount of a compound according to claim 1.
27. A method of inhibiting viral infection in plants comprising administering thereto an antiviral effective amount of compound according to claim 2.
28. A method of inhibiting viral infection in plants comprising administering thereto an antiviral effective amount of a compound of the following formula, or water-soluble salt thereof, wherein m is zero, 1, 2 or 3 and n is 1 or 2:
,
,
29. A method according to claim 28, wherein the compound is (Sp) -P-thioadenylyl- ( 2'-5' )-( Sp) -P-thioadenylyl-(2'-5')-adenosine or the 5'-monophosphate thereof.
30. A method according to claim 28, wherein the compound is (Rp)-P-thioadenylyl-(2'-5 ')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
31. A method according to claim 28, wherein the compound is (Rp)-P-thioadenylyl-(2'-5' )-(Rp)-P-thioadenylyl-(2'-5')-adenosine or the 5'-monophosphate thereof.
32. A method according to claim 29 wherein the compound is (Rp) -P-thioadenylyl-(2'-5')- (Sp) -P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine
33. A method according to claim 28 wherein the compound is (Sp) -P-thioadenylyl- (2'-5') -(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine.
34. A conjugate of poly(L-lysine) and a 2'-5'-phosphorothioate oligoadenylate, said conjugate having the formula wherein q is an integer from about 60 to about 70 and each R
is independently R' or , provided from about five to about ten of the R groups are R', which R' has the following formula wherein m is 0,1,2 or 3:
is independently R' or , provided from about five to about ten of the R groups are R', which R' has the following formula wherein m is 0,1,2 or 3:
35. A compound of the formula wherein m is zero, 1, 2 or 3 and n is 2, and water-soluble salts thereof.
36. A compound according to claim 1 wherein m is 3.
37. A method according to claim 26 or 28 for inhibiting tobacco mosaic infection.
38. Use according to claim 24 for inhibiting human immunodeficiency virus.
39. Use according to claim 38 wherein the internucleotide phosphorothioate group adjacent the 2'-terminal adenylate moiety in the compound is of the Sp configuration.
40. Use according to claim 38 wherein the compound is (Rp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-(Sp)-P-thioadenylyl-(2'-5')-adenosine, or the 5'-monophosphate thereof.
41. A pharmaceutical composition comprising a pharmaceutical carrier and a compound according to claim 1.
42. A pharmaceutical composition comprising a pharmaceutical carrier and a compound according to claim 35.
43. A conjugate according to claim 34, wherein the 2', 5'- phosphorothioate oligoadenylate from which said conjugate is formed is an optical isomer of the formula substantially free of contamination of other optical isomers of the same formula, where m is zero, 1, 2,, or 3, and at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
44. An antiviral composition comprising a compound according to claim 35 contained in a reconstituted Sendai virus envelope.
45. An antiviral composition comprising a compound according to claim 35 encapsulated in a liposome.
46. A compound according to claim 35 wherein at least one of the internucleotide phosphorothioate groups is of the Sp configuration; or water-soluble salt thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/112,591 US4924624A (en) | 1987-10-22 | 1987-10-22 | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US112,591 | 1987-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1339953C true CA1339953C (en) | 1998-07-14 |
Family
ID=22344763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000580426A Expired - Fee Related CA1339953C (en) | 1987-10-22 | 1988-10-18 | 2',5'-phosphorothioate oligoadenylates and antiviral uses thereof |
Country Status (8)
Country | Link |
---|---|
US (3) | US4924624A (en) |
EP (2) | EP0694559B1 (en) |
JP (1) | JP2733777B2 (en) |
AT (2) | ATE135579T1 (en) |
AU (1) | AU2628088A (en) |
CA (1) | CA1339953C (en) |
DE (2) | DE3856326T2 (en) |
WO (1) | WO1989003683A1 (en) |
Families Citing this family (836)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5550111A (en) * | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US5643889A (en) * | 1984-07-11 | 1997-07-01 | Temple University-Of The Commonwealth System Of Pennsylvania | Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof |
US4924624A (en) * | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
JP2976436B2 (en) * | 1988-04-27 | 1999-11-10 | 味の素株式会社 | Novel oligoribonucleotide derivatives and use as antiviral agents |
DK0497875T3 (en) | 1989-10-24 | 2000-07-03 | Gilead Sciences Inc | 2'-modified oligonucleotides |
US5635488A (en) * | 1991-10-15 | 1997-06-03 | Isis Pharmaceuticals, Inc. | Compounds having phosphorodithioate linkages of high chiral purity |
US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
US5587361A (en) * | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5620963A (en) * | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
US5470967A (en) * | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
US6446032B1 (en) * | 1990-09-21 | 2002-09-03 | Massachusetts Institute Of Technology | Designing compounds specifically inhibiting ribonucleic acid by binding to the minor groove |
US6041910A (en) * | 1997-09-22 | 2000-03-28 | Jervis B. Webb Company | Baggage pusher device and system |
GB9111967D0 (en) * | 1991-06-04 | 1991-07-24 | Erba Carlo Spa | 2,5'-nucleotide analogs as antiviral agents |
US5571799A (en) * | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
WO1993003733A1 (en) * | 1991-08-12 | 1993-03-04 | Basco, Ltd. | Syntheses, pharmaceutical composition and method of application of (2'-5') oligoadenylate analogues |
US5576302A (en) * | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
US5599797A (en) * | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5607923A (en) * | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
US5661134A (en) * | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
US5654284A (en) * | 1991-10-15 | 1997-08-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
CA2130926C (en) * | 1992-03-12 | 2003-10-21 | Robert J. Suhadolnik | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
US20040127446A1 (en) * | 1992-05-14 | 2004-07-01 | Lawrence Blatt | Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication |
US5532130A (en) * | 1993-07-20 | 1996-07-02 | Dyad Pharmaceutical Corporation | Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides |
DE69433036T2 (en) | 1993-09-03 | 2004-05-27 | Isis Pharmaceuticals, Inc., Carlsbad | AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES |
US6653458B1 (en) | 1993-09-03 | 2003-11-25 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides |
US7276335B1 (en) * | 1993-09-29 | 2007-10-02 | Massachusetts Institute Of Technology | Designing compounds specifically inhibiting ribonucleic acid function |
WO1996008256A1 (en) * | 1994-09-14 | 1996-03-21 | Temple University - Of The Commonwealth System Of Higher Education | 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US20050042647A1 (en) * | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
WO2005121371A2 (en) * | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US20040171031A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
US20040171028A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US6111085A (en) * | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US5955446A (en) * | 1997-01-16 | 1999-09-21 | Pentose Pharmaceuticals, Inc. | Method of treating herpes infections with 2',5'-oligoadenylate-2',3'-cyclophosphate compounds |
US6468991B1 (en) | 1997-01-16 | 2002-10-22 | Cyclis Pharmaceuticals, Inc. | Method of treating rhinoviral infections |
US6281201B1 (en) | 1997-06-12 | 2001-08-28 | Temple University- Of The Commonwealth System Of Higher Education | Base-modified derivatives of 2′,5′-oligoadenylate and antiviral uses thereof |
US6362171B1 (en) | 1997-06-12 | 2002-03-26 | Temple University-Of The Commonwealth System Of Higher Education | Aminoaklanoyl-linked conjugates of 2′,5′-oligoadenylate and antiviral uses thereof |
CA2294988C (en) | 1997-07-01 | 2015-11-24 | Isis Pharmaceuticals Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
WO1999005160A2 (en) * | 1997-07-25 | 1999-02-04 | Hybridon, Inc. | Oligonuclotides having 3' terminal stereospecific phosphorothioates |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US6958148B1 (en) | 1998-01-20 | 2005-10-25 | Pericor Science, Inc. | Linkage of agents to body tissue using microparticles and transglutaminase |
US6919076B1 (en) | 1998-01-20 | 2005-07-19 | Pericor Science, Inc. | Conjugates of agents and transglutaminase substrate linking molecules |
US7321828B2 (en) * | 1998-04-13 | 2008-01-22 | Isis Pharmaceuticals, Inc. | System of components for preparing oligonucleotides |
US20040186071A1 (en) * | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
AU745880B2 (en) * | 1998-05-21 | 2002-04-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
JP2002515514A (en) | 1998-05-21 | 2002-05-28 | アイシス・ファーマシューティカルス・インコーポレーテッド | Compositions and methods for local delivery of oligonucleotides |
US6461815B1 (en) | 1998-05-22 | 2002-10-08 | North Carolina State University | Antibacterial agents and methods of screening for the same |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6867294B1 (en) | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
US6225293B1 (en) | 1998-09-02 | 2001-05-01 | Isis Pharmaceuticals, Inc. | Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations |
BR9914465A (en) * | 1998-09-29 | 2001-10-09 | Gamida Cell Ltd | Methods to control the proliferation and differentiation of stem cells and progenitor cells and a pharmaceutical composition to induce differentiation in a cell population |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6300320B1 (en) | 1999-01-05 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Modulation of c-jun using inhibitors of protein kinase C |
US6127124A (en) * | 1999-01-20 | 2000-10-03 | Isis Pharmaceuticals, Inc. | Fluorescence based nuclease assay |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6593466B1 (en) | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
DE19940748A1 (en) * | 1999-08-27 | 2001-03-01 | Hugo Seinfeld | Medicaments containing xenogenic oligo- and / or polyribonucleotides |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US20030176385A1 (en) * | 2000-02-15 | 2003-09-18 | Jingfang Ju | Antisense modulation of protein expression |
ATE452906T1 (en) * | 2000-04-13 | 2010-01-15 | Thomas N Wight | THERAPEUTIC SUMMARY AND METHODS FOR MODULATING V3, AN ISOFORM OF VERSICAN |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
US6686188B2 (en) * | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US20060166227A1 (en) * | 2000-06-20 | 2006-07-27 | Stephen Kingsmore | Protein expression profiling |
US6323009B1 (en) * | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
CA2425779C (en) | 2000-10-12 | 2013-08-06 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
KR20020069627A (en) * | 2001-02-27 | 2002-09-05 | 동부한농화학 주식회사 | Phosphorothioate oligonucleotides containing modified nucleotides with six-membered azasugars and use for aids therapy thereof |
JP2004533815A (en) | 2001-03-14 | 2004-11-11 | ミリアド・ジェネティックス・インコーポレイテッド | TSG101-GAG interaction and use thereof |
ATE522623T1 (en) | 2001-06-20 | 2011-09-15 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS |
EP1404698A4 (en) | 2001-06-21 | 2004-12-22 | Isis Pharmaceuticals Inc | Antisense modulation of superoxide dismutase 1, soluble expression |
DE10133858A1 (en) | 2001-07-12 | 2003-02-06 | Aventis Pharma Gmbh | Synthetic double-stranded oligonucleotides for targeted inhibition of gene expression |
US6822088B2 (en) | 2001-07-17 | 2004-11-23 | Isis Pharmaceuticals, Inc. | Synthesis of oligonucleotides on solid support |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
CA2455424A1 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
EP2153843B1 (en) | 2001-09-18 | 2012-08-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
NZ585001A (en) | 2001-10-09 | 2011-08-26 | Isis Pharmaceuticals Inc | Antisense modulation of insulin-like growth factor binding protein 5 expression |
WO2005049075A2 (en) | 2003-11-17 | 2005-06-02 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
JP2005525095A (en) | 2002-01-02 | 2005-08-25 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
EP1465982A4 (en) * | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US7553619B2 (en) * | 2002-02-08 | 2009-06-30 | Qiagen Gmbh | Detection method using dissociated rolling circle amplification |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
EP2011886A3 (en) | 2002-04-16 | 2009-02-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20030199464A1 (en) | 2002-04-23 | 2003-10-23 | Silviu Itescu | Regeneration of endogenous myocardial tissue by induction of neovascularization |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
AU2003231912A1 (en) * | 2002-06-12 | 2003-12-31 | Tel Aviv Medical Center Research Development Fund | Methods of detecting and treating prostate cancer |
US20040092470A1 (en) * | 2002-06-18 | 2004-05-13 | Leonard Sherry A. | Dry powder oligonucleotide formualtion, preparation and its uses |
EP2116604A1 (en) | 2002-08-05 | 2009-11-11 | University of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
EP1537208A1 (en) | 2002-09-13 | 2005-06-08 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
EP1546170A4 (en) | 2002-09-20 | 2007-08-29 | Univ Yale | Riboswitches, methods for their use, and compositions for use with riboswitches |
US7229976B2 (en) | 2002-09-26 | 2007-06-12 | Isis Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
JP2006515318A (en) * | 2002-10-29 | 2006-05-25 | ファルマシア・コーポレーション | Specifically associated cancer-related gene, polypeptide encoded thereby and method of use thereof |
US9827263B2 (en) | 2002-11-05 | 2017-11-28 | Ionis Pharmaceuticals, Inc. | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
US9150605B2 (en) | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US9150606B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
WO2004044139A2 (en) | 2002-11-05 | 2004-05-27 | Isis Parmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
SI1569695T1 (en) | 2002-11-13 | 2013-08-30 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
AU2003294281B2 (en) | 2002-11-13 | 2010-05-20 | Kastle Therapeutics, Llc | Antisense modulation of apolipoprotein B expression |
US20060009378A1 (en) * | 2002-11-14 | 2006-01-12 | Itshak Golan | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
ES2392511T3 (en) | 2002-11-15 | 2012-12-11 | Musc Foundation For Research Development | Complement modulators targets on complement receptor 2 |
CA2506127C (en) | 2002-11-15 | 2013-07-09 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
EP2410332A1 (en) | 2002-11-21 | 2012-01-25 | The University Of Utah | Method for identifying purinergic modulators of the olfactory system |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
EP1583843B1 (en) | 2002-12-20 | 2018-07-18 | QIAGEN GmbH | Single primer whole genome amplification |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
US6977153B2 (en) * | 2002-12-31 | 2005-12-20 | Qiagen Gmbh | Rolling circle amplification of RNA |
WO2004072284A1 (en) | 2003-02-11 | 2004-08-26 | Antisense Therapeutics Ltd | Modulation of insulin like growth factor i receptor expression |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
US20040198640A1 (en) * | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
CA2522184A1 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Of New York | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
BRPI0410886A (en) | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide |
DK2336317T3 (en) | 2003-06-13 | 2019-12-16 | Alnylam Europe Ag | Double-stranded ribonucleic acid with increased efficiency in an organism |
EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
EP1677822B1 (en) * | 2003-09-18 | 2014-04-23 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
KR100750788B1 (en) | 2003-09-18 | 2007-08-20 | 아이시스 파마수티컬즈 인코포레이티드 | 4 MODULATION OF eIF4E EXPRESSION |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
WO2005056571A1 (en) * | 2003-12-05 | 2005-06-23 | Biovitrum Ab | Improved synthesis of 2-substituted adenosines |
EP2363480A3 (en) | 2004-01-20 | 2015-10-07 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
US20060147946A1 (en) * | 2004-01-27 | 2006-07-06 | Pinchas Akiva | Novel calcium channel variants and methods of use thereof |
US7842459B2 (en) | 2004-01-27 | 2010-11-30 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
WO2005089268A2 (en) | 2004-03-15 | 2005-09-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of rna by rnase h |
KR101147147B1 (en) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Modified polynucleotides for reducing off-target effects in rna interference |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US20050267300A1 (en) | 2004-04-05 | 2005-12-01 | Muthiah Manoharan | Processes and reagents for oligonucleotide synthesis and purification |
US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
EP3034510A1 (en) | 2004-04-30 | 2016-06-22 | Alnylam Pharmaceuticals Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
JP2008500064A (en) | 2004-05-21 | 2008-01-10 | ザ ユーエービー リサーチ ファウンデーション | Variable lymphocyte receptor, related polypeptides and nucleic acids, and uses thereof |
EP1766052A4 (en) * | 2004-06-03 | 2009-12-16 | Isis Pharmaceuticals Inc | Chimeric gapped oligomeric compositions |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US20090048192A1 (en) * | 2004-06-03 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
EP1799812A4 (en) * | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
TR201907874T4 (en) * | 2004-09-23 | 2019-06-21 | Arc Medical Devices Inc | Pharmaceutical compositions and methods for inhibiting fibrous adhesions or inflammatory diseases using low sulphate fucans. |
CA2588087A1 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
US20060166234A1 (en) | 2004-11-22 | 2006-07-27 | Barbara Robertson | Apparatus and system having dry control gene silencing compositions |
US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
CN101175769A (en) | 2005-03-10 | 2008-05-07 | 健泰科生物技术公司 | Methods and compositions for modulating vascular integrity |
US7476733B2 (en) * | 2005-03-25 | 2009-01-13 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease |
EP1863908B1 (en) * | 2005-04-01 | 2010-11-17 | Qiagen GmbH | Reverse transcription and amplification of rna with simultaneous degradation of dna |
JP5329949B2 (en) | 2005-05-31 | 2013-10-30 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
WO2006133022A2 (en) | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
JP5383186B2 (en) | 2005-07-07 | 2014-01-08 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム リミテッド | Nucleic acid agents that down-regulate H19 and methods of using the same |
MY144014A (en) | 2005-08-11 | 2011-07-29 | Synthetic Genomics Inc | Method for in vitro recombination |
KR20080036646A (en) | 2005-08-17 | 2008-04-28 | 메덱시스 에스.에이. | Composition and method for determination of ck19 expression |
CA2620856C (en) | 2005-08-29 | 2017-11-28 | Isis Pharmaceuticals, Inc. | Methods for use in modulating mir-122a |
EP1762627A1 (en) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Method for the activation of a nucleic acid for performing a polymerase reaction |
IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for diagnosis of preeclamsia |
AU2006304321B2 (en) | 2005-10-14 | 2012-10-04 | Musc Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8080534B2 (en) * | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
AU2006305886C1 (en) | 2005-10-28 | 2011-03-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
AU2006311730B2 (en) | 2005-11-09 | 2010-12-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Factor V Leiden mutant gene |
EP1966377A2 (en) | 2005-11-21 | 2008-09-10 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
JP2009524411A (en) * | 2005-12-21 | 2009-07-02 | イェール ユニバーシティー | Methods and compositions related to the regulation of riboswitches |
JP5713377B2 (en) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | Natural antisense and non-coding RNA transcripts as drug targets |
WO2007080597A2 (en) | 2006-01-16 | 2007-07-19 | Compugen Ltd. | Polynucleotide and polypeptide sequences and methods for diagnosis |
KR101304071B1 (en) * | 2006-01-27 | 2013-09-06 | 아이시스 파마수티컬즈 인코포레이티드 | 6-modified bicyclic nucleic acid analogs |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
JP5213723B2 (en) | 2006-01-27 | 2013-06-19 | アイシス ファーマシューティカルズ, インコーポレーテッド | Oligomer compounds and compositions for use in modulating microRNA |
SG170780A1 (en) | 2006-03-31 | 2011-05-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of eg5 gene |
DE102006020885A1 (en) * | 2006-05-05 | 2007-11-08 | Qiagen Gmbh | Inserting a tag sequence into a nucleic acid comprises using an anchor oligonucleotide comprising a hybridizing anchor sequence and a nonhybridizing tag-template sequence |
EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
US7666854B2 (en) * | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
AU2007249349B2 (en) | 2006-05-11 | 2012-03-08 | Isis Pharmaceuticals, Inc. | 5'-Modified bicyclic nucleic acid analogs |
AU2007249329C1 (en) | 2006-05-11 | 2011-03-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the PCSK9 gene |
WO2007137156A2 (en) | 2006-05-19 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of aha and therapeutic uses thereof |
WO2007137220A2 (en) | 2006-05-22 | 2007-11-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of ikk-b gene |
US8198253B2 (en) | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
JP2010502752A (en) * | 2006-09-11 | 2010-01-28 | イェール ユニバーシティー | Lysine riboswitch, structure-based compound design using lysine riboswitch, and methods and compositions for use with lysine riboswitch |
WO2008036933A2 (en) | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
CA2663601C (en) | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
CA2665225C (en) | 2006-10-03 | 2015-06-30 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
EP2081596A4 (en) | 2006-10-06 | 2010-07-21 | Univ Utah Res Found | Method of detecting ocular diseases and pathologic conditions and treatment of same |
US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
JP2010512327A (en) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Compositions and methods for the treatment of pathological angiogenesis and vascular permeability |
EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP2111450A2 (en) * | 2007-01-16 | 2009-10-28 | Yissum Research Development Company of the Hebrew University of Jerusalem | Nucleic acid constructs and methods for specific silencing of h19 |
WO2008093331A1 (en) * | 2007-01-29 | 2008-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antibody conjugates for circumventing multi-drug resistance |
EP2121987B1 (en) | 2007-02-09 | 2012-06-13 | Northwestern University | Particles for detecting intracellular targets |
KR20100015757A (en) | 2007-03-22 | 2010-02-12 | 예일 유니버시티 | Methods and compositions related to riboswitches that control alternative splicing |
PE20090064A1 (en) | 2007-03-26 | 2009-03-02 | Novartis Ag | DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
AP2014007971A0 (en) | 2007-03-29 | 2014-09-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expressionof a gene from the ebola |
EP2639316A1 (en) | 2007-05-11 | 2013-09-18 | The Johns Hopkins University | Biomarkers for melanoma |
WO2008150884A1 (en) * | 2007-05-29 | 2008-12-11 | Yale University | Methods and compositions related to riboswitches that control alternative splicing and rna processing |
CN101849020A (en) | 2007-05-29 | 2010-09-29 | 耶鲁大学 | The method and composition of riboswitch and use riboswitch |
CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2160464B1 (en) * | 2007-05-30 | 2014-05-21 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
AU2008272918B2 (en) * | 2007-07-05 | 2012-09-13 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
CN103215269B (en) | 2007-07-05 | 2015-01-21 | 诺瓦提斯公司 | Dsrna for treating viral infection |
ES2439591T3 (en) | 2007-08-15 | 2014-01-23 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
CA2704729C (en) | 2007-08-28 | 2020-06-23 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
WO2009032702A2 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
ES2719728T3 (en) | 2007-09-04 | 2019-07-12 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof as a pharmacological target to produce drugs and biological agents |
WO2009039466A1 (en) | 2007-09-20 | 2009-03-26 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
WO2009039442A1 (en) * | 2007-09-21 | 2009-03-26 | California Institute Of Technology | Nfia in glial fate determination, glioma therapy and astrocytoma treatment |
CA2700953A1 (en) | 2007-10-02 | 2009-04-09 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
US20110152346A1 (en) * | 2007-11-05 | 2011-06-23 | Baltic Technology Development Ltd. | Use of Oligonucleotides with Modified Bases in Hybridization of Nucleic Acids |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
EP2222851B1 (en) * | 2007-11-20 | 2017-06-28 | Ionis Pharmaceuticals, Inc. | Modulation of cd40 expression |
US8546556B2 (en) * | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
WO2009076400A2 (en) | 2007-12-10 | 2009-06-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor vii gene |
EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
WO2009100320A2 (en) * | 2008-02-07 | 2009-08-13 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
CN104975020B (en) * | 2008-02-11 | 2020-01-17 | 菲奥医药公司 | Modified RNAi polynucleotides and uses thereof |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
WO2009111658A2 (en) | 2008-03-05 | 2009-09-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 and vegf genes |
EP2282744B1 (en) * | 2008-03-21 | 2018-01-17 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucleosides and methods for their use |
WO2009124238A1 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
CA2720675C (en) | 2008-04-18 | 2019-08-27 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
WO2009134917A2 (en) * | 2008-04-29 | 2009-11-05 | Wyeth | Methods for treating inflammation |
US8082730B2 (en) * | 2008-05-20 | 2011-12-27 | Caterpillar Inc. | Engine system having particulate reduction device and method |
AU2009272841A1 (en) * | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of TGF-beta receptor genes |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
EP2323667A4 (en) * | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | Modulation of transthyretin expression for the treatment of cns related disorders |
AU2009275387B2 (en) | 2008-08-25 | 2010-07-08 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP2331690B1 (en) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of mutant egfr gene |
CN102405286A (en) | 2008-09-22 | 2012-04-04 | 阿克赛医药公司 | Reduced size self-delivering rnai compounds |
DK2361256T3 (en) | 2008-09-24 | 2013-07-01 | Isis Pharmaceuticals Inc | Cyclohexenyl-nucleic acid analogues |
DK2356129T3 (en) * | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituted alpha-L bicyclic nucleosides |
JP5529142B2 (en) | 2008-09-25 | 2014-06-25 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Lipid formulation composition and method for inhibiting expression of serum amyloid A gene |
EP2350043B9 (en) | 2008-10-09 | 2014-08-20 | TEKMIRA Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
CN102245186B (en) | 2008-10-15 | 2014-08-27 | Isis制药公司 | Modulation of factor 11 expression |
US8168775B2 (en) | 2008-10-20 | 2012-05-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
US8987435B2 (en) | 2008-10-24 | 2015-03-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
JP5763539B2 (en) | 2008-10-24 | 2015-08-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5 'and 2' bis-substituted nucleosides and oligomeric compounds produced therefrom |
WO2010055041A1 (en) * | 2008-11-17 | 2010-05-20 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of factor vii genes |
US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
KR101692880B1 (en) * | 2008-11-24 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | Polyvalent rna-nanoparticle compositions |
WO2010061393A1 (en) | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
US20110237649A1 (en) | 2008-12-04 | 2011-09-29 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
CN102317458B (en) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases |
MX358603B (en) | 2008-12-04 | 2018-08-28 | Curna Inc | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene. |
ES2442168T3 (en) | 2008-12-05 | 2014-02-10 | Yeda Research And Development Co. Ltd. | Diagnostic methods of motor neuron diseases |
JP5855462B2 (en) | 2008-12-10 | 2016-02-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | DsRNA compositions targeting GNAQ and methods for inhibiting expression |
WO2010080554A1 (en) | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
CN102307470B (en) * | 2009-01-08 | 2015-05-20 | 西北大学 | Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
KR101546673B1 (en) * | 2009-01-15 | 2015-08-25 | 삼성전자주식회사 | Toner for electrophotographic and process for preparing the same |
CA3036963A1 (en) | 2009-01-29 | 2010-08-05 | Arbutus Biopharma Corporation | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
AU2010211133A1 (en) * | 2009-02-03 | 2011-07-21 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of PTP1B genes |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
WO2010090969A1 (en) | 2009-02-06 | 2010-08-12 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
CN102439149B (en) | 2009-02-12 | 2018-01-02 | 库尔纳公司 | By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF) |
PL2396038T3 (en) | 2009-02-12 | 2016-05-31 | Curna Inc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
EP2403946A4 (en) | 2009-03-04 | 2012-11-14 | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1 | |
NZ594995A (en) | 2009-03-12 | 2013-06-28 | Alnylam Pharmaceuticals Inc | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES |
EP2408919B1 (en) | 2009-03-16 | 2017-10-18 | CuRNA, Inc. | Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
US9708604B2 (en) | 2009-03-17 | 2017-07-18 | Curna, Inc. | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 |
EP2419535B1 (en) | 2009-04-15 | 2022-08-17 | Northwestern University | Delivery of oligonucleotide-functionalized nanoparticles |
EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
WO2010127195A2 (en) | 2009-05-01 | 2010-11-04 | Curna, Inc. | Antisense oligonucleotides of hemoglobins |
WO2010129687A1 (en) | 2009-05-05 | 2010-11-11 | Alnylam Pharmaceuticals, Inc | Methods of delivering oligonucleotides to immune cells |
CA3151387A1 (en) | 2009-05-05 | 2010-11-11 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
CN106237345A (en) | 2009-05-06 | 2016-12-21 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
US20120046236A1 (en) | 2009-05-06 | 2012-02-23 | Opko Curna Llc | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
EP2429657A2 (en) * | 2009-05-15 | 2012-03-21 | F. Hoffmann-La Roche AG | Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
EP2430161A1 (en) | 2009-05-15 | 2012-03-21 | Yale University | Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches |
JP5922017B2 (en) | 2009-05-18 | 2016-05-24 | クルナ・インコーポレーテッド | Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor |
JP2012527248A (en) | 2009-05-22 | 2012-11-08 | クルナ・インコーポレーテッド | Treatment of TFE3 and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcripts against transcription factor E3 (TFE3) |
US20100303795A1 (en) * | 2009-05-27 | 2010-12-02 | Soerensen Karina Dalsgaard | Marker of prostate cancer |
JP5960049B2 (en) | 2009-05-28 | 2016-08-02 | クルナ・インコーポレーテッド | Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes |
NZ622843A (en) | 2009-06-10 | 2015-10-30 | Tekmira Pharmaceuticals Corp | Improved lipid formulation |
CN102612560B (en) | 2009-06-16 | 2017-10-17 | 库尔纳公司 | By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1) |
US20120171170A1 (en) | 2009-06-16 | 2012-07-05 | Opko Curna, Llc | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
US20100331397A1 (en) * | 2009-06-24 | 2010-12-30 | Alios Biopharma, Inc. | 2-5a analogs and their methods of use |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
CA2765815A1 (en) | 2009-06-26 | 2010-12-29 | Opko Curna, Llc | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
US9512164B2 (en) | 2009-07-07 | 2016-12-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
CN102762731B (en) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS) |
US9012421B2 (en) | 2009-08-06 | 2015-04-21 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
AP2015008874A0 (en) | 2009-08-14 | 2015-11-30 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US20120157324A1 (en) | 2009-08-17 | 2012-06-21 | Yale University | Methylation biomarkers and methods of use |
EP2470657B1 (en) | 2009-08-25 | 2019-10-23 | CuRNA, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
ES2599076T3 (en) | 2009-09-02 | 2017-01-31 | Genentech, Inc. | Smoothened mutant and methods of use thereof |
WO2011044902A1 (en) | 2009-10-13 | 2011-04-21 | Aarhus Universitet | Tff3 hypomethylation as a novel biomarker for prostate cancer |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011045796A1 (en) | 2009-10-14 | 2011-04-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions for controlling varroa mites in bees |
CA2778442A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
WO2011056687A2 (en) | 2009-10-27 | 2011-05-12 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
AU2010313154B2 (en) | 2009-10-30 | 2016-05-12 | Northwestern University | Templated nanoconjugates |
US20130084565A1 (en) | 2009-11-03 | 2013-04-04 | University Of Virginia Patent Foundation | Versatile, visible method for detecting polymeric analytes |
US20110112176A1 (en) * | 2009-11-09 | 2011-05-12 | John Frederick Boylan | Compositions and methods for inhibiting expression of kif10 genes |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
CN107312777B (en) | 2009-11-13 | 2020-11-13 | 萨雷普塔治疗公司 | Antisense antiviral compounds and methods of treating influenza virus infection |
WO2011063403A1 (en) | 2009-11-23 | 2011-05-26 | Swift Biosciences, Inc. | Devices to extend single stranded target molecules |
MX2012006072A (en) | 2009-11-30 | 2012-07-23 | Genentech Inc | Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ). |
KR101823702B1 (en) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
DK2516648T3 (en) | 2009-12-23 | 2018-02-12 | Curna Inc | TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF |
JP6031356B2 (en) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー,インコーポレイテッド | Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2. |
CN102770540B (en) | 2009-12-29 | 2017-06-23 | 库尔纳公司 | P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63) |
EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
US8912157B2 (en) | 2010-01-06 | 2014-12-16 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
US8779118B2 (en) | 2010-01-11 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
DK2524039T3 (en) | 2010-01-11 | 2018-03-12 | Curna Inc | TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG |
WO2011088076A2 (en) | 2010-01-12 | 2011-07-21 | Yale University | Structured rna motifs and compounds and methods for their use |
KR101853510B1 (en) | 2010-01-25 | 2018-06-20 | 큐알엔에이, 인크. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
CA2824843A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
WO2011095174A1 (en) | 2010-02-08 | 2011-08-11 | Aarhus Universitet | Human herpes virus 6 and 7 u20 polypeptide and polynucleotides for use as a medicament or diagnosticum |
EP2539452B1 (en) | 2010-02-22 | 2016-07-27 | CuRNA, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
BR112012020373A8 (en) | 2010-02-23 | 2018-01-02 | Genentech Inc | isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
WO2011107100A1 (en) | 2010-03-03 | 2011-09-09 | Aarhus Universitet | Methods and compositions for regulation of herv4 |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
NZ601784A (en) | 2010-03-08 | 2014-08-29 | Monsanto Technology Llc | Polynucleotide molecules for gene regulation in plants |
US8906875B2 (en) | 2010-03-12 | 2014-12-09 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
WO2011113054A2 (en) | 2010-03-12 | 2011-09-15 | Aurasense Llc | Crosslinked polynucleotide structure |
EP2545173A2 (en) | 2010-03-12 | 2013-01-16 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
CN106074591B (en) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | RNA interference in ocular symptoms |
KR101852210B1 (en) | 2010-03-24 | 2018-04-25 | 알엑스아이 파마슈티칼스 코포레이션 | Rna interference in dermal and fibrotic indications |
RU2615143C2 (en) | 2010-03-24 | 2017-04-04 | Адвирна | Self-delivered rnai compounds of reduced size |
US8889350B2 (en) | 2010-03-26 | 2014-11-18 | Swift Biosciences, Inc. | Methods and compositions for isolating polynucleotides |
CA2792291A1 (en) | 2010-03-29 | 2011-10-06 | Kumamoto University | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
EP3517613A1 (en) | 2010-04-09 | 2019-07-31 | CuRNA, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
US20110269194A1 (en) | 2010-04-20 | 2011-11-03 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
US9127033B2 (en) | 2010-04-28 | 2015-09-08 | Isis Pharmaceuticals, Inc. | 5′ modified nucleosides and oligomeric compounds prepared therefrom |
EP3173419A1 (en) | 2010-04-28 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom |
JP5896175B2 (en) | 2010-04-29 | 2016-03-30 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Regulation of transthyretin expression |
CN102958941A (en) | 2010-05-03 | 2013-03-06 | 霍夫曼-拉罗奇有限公司 | Compositions and methods for the diagnosis and treatment of tumor |
KR20130101442A (en) | 2010-05-03 | 2013-09-13 | 큐알엔에이, 인크. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
CA2805086C (en) | 2010-05-13 | 2020-10-20 | Sarepta Therapeutics, Inc. | Antisense modulation of interleukins 17 and 23 signaling |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
WO2011150226A1 (en) | 2010-05-26 | 2011-12-01 | Landers James P | Method for detecting nucleic acids based on aggregate formation |
DK2576783T3 (en) | 2010-05-26 | 2018-03-12 | Curna Inc | TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1 |
CA2801066C (en) | 2010-06-02 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
US8957200B2 (en) | 2010-06-07 | 2015-02-17 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9638632B2 (en) | 2010-06-11 | 2017-05-02 | Vanderbilt University | Multiplexed interferometric detection system and method |
WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
US20130209463A1 (en) | 2010-06-30 | 2013-08-15 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
CN103068982B (en) | 2010-07-14 | 2017-06-09 | 库尔纳公司 | DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG) |
US20130143955A1 (en) | 2010-08-09 | 2013-06-06 | Yale University | Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use |
US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CA2813901C (en) | 2010-10-06 | 2019-11-12 | Curna, Inc. | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
WO2012052872A2 (en) | 2010-10-17 | 2012-04-26 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
EP2851426B1 (en) | 2010-10-18 | 2018-08-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of RRM2 genes |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
EP2633052B1 (en) | 2010-10-27 | 2018-04-11 | CuRNA, Inc. | Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1 |
CN110123830A (en) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare |
GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
JP6336755B2 (en) | 2010-11-12 | 2018-06-06 | ザ ジェネラル ホスピタル コーポレイション | Non-coding RNA related to polycomb |
JP6126009B2 (en) | 2010-11-17 | 2017-05-10 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Regulation of α-synuclein expression |
US8987225B2 (en) | 2010-11-23 | 2015-03-24 | Curna, Inc. | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
US9193973B2 (en) | 2010-12-10 | 2015-11-24 | Alynylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (EPO) production |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
US9045749B2 (en) | 2011-01-14 | 2015-06-02 | The General Hospital Corporation | Methods targeting miR-128 for regulating cholesterol/lipid metabolism |
CN103391777A (en) | 2011-02-02 | 2013-11-13 | 普林斯顿大学理事会 | Sirtuin modulators as virus production modulators |
TWI593416B (en) | 2011-02-02 | 2017-08-01 | 艾克厘德製藥公司 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
CA2831284C (en) | 2011-03-29 | 2023-12-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
JP2014511694A (en) | 2011-04-03 | 2014-05-19 | ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル | Efficient in vivo protein expression using modified RNA (MOD-RNA) |
AU2012241373B2 (en) | 2011-04-15 | 2016-06-09 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9593330B2 (en) | 2011-06-09 | 2017-03-14 | Curna, Inc. | Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN |
CN112961855A (en) | 2011-06-21 | 2021-06-15 | 阿尔尼拉姆医药品有限公司 | Angiopoietin-like 3(ANGPTL3) iRNA compositions and methods of use thereof |
US9068184B2 (en) | 2011-06-21 | 2015-06-30 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
MX344807B (en) | 2011-06-21 | 2017-01-09 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes. |
EP3366312A1 (en) | 2011-06-23 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Serpina 1 sirnas: compositions of matter and methods of treatment |
BR112013031021A2 (en) | 2011-06-30 | 2018-10-09 | Arrowhead Res Corp | compositions and methods for inhibiting hepatitis b virus gene expression |
CA2836855C (en) | 2011-06-30 | 2020-07-14 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
US20140328811A1 (en) | 2011-08-01 | 2014-11-06 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
CA3107434C (en) | 2011-08-04 | 2023-06-06 | Yeda Research And Development Co. Ltd. | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone-associated medical conditions |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
MX362812B (en) | 2011-09-13 | 2019-02-13 | Monsanto Technology Llc | Methods and compositions for weed control. |
BR112014005958A2 (en) | 2011-09-13 | 2020-10-13 | Monsanto Technology Llc | agricultural chemical methods and compositions for plant control, method of reducing expression of an accase gene in a plant, microbial expression cassette, method for making a polynucleotide, method of identifying polynucleotides useful in modulating expression of the accase gene and herbicidal composition |
BR112014005978A8 (en) | 2011-09-13 | 2017-09-12 | Monsanto Technology Llc | AGRICULTURAL CHEMICAL METHODS AND COMPOSITIONS FOR PLANT CONTROL, METHOD FOR REDUCING EXPRESSION OF A GS GENE IN A PLANT, MICROBIAL EXPRESSION CASSETTE, METHOD FOR MAKING A POLYNUCLEOTIDE AND METHOD FOR IDENTIFYING POLYNUCLEOTIDES USEFUL IN MODULATING GS GENE EXPRESSION |
MX350771B (en) | 2011-09-13 | 2017-09-15 | Monsanto Technology Llc | Methods and compositions for weed control. |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
EP3533873A1 (en) | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
AU2012308302A1 (en) | 2011-09-14 | 2014-03-20 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
US9580713B2 (en) | 2011-09-17 | 2017-02-28 | Yale University | Fluoride-responsive riboswitches, fluoride transporters, and methods of use |
CA2851280C (en) | 2011-10-11 | 2021-05-18 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
MX2014004022A (en) | 2011-10-14 | 2014-04-30 | Genentech Inc | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE. |
FR2981650B1 (en) * | 2011-10-24 | 2013-12-27 | Univ Paris Curie | NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF VIRAL INFECTION AND METHOD OF EVALUATING SENSITIVITY TO TREATMENT |
EP2771464B1 (en) | 2011-10-27 | 2018-03-21 | Yeda Research and Development Co. Ltd. | Methods of treating cancer |
US10557136B2 (en) | 2011-12-12 | 2020-02-11 | Oncolmmunin Inc. | In vivo delivery of oligonucleotides |
CN104185681A (en) | 2012-02-01 | 2014-12-03 | 卡姆普根有限公司 | C10RF32 antibodies, and uses thereof for treatment of cancer |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
WO2013124816A2 (en) | 2012-02-22 | 2013-08-29 | Brainstem Biotec Ltd. | Generation of neural stem cells and motor neurons |
US10034902B2 (en) | 2012-02-22 | 2018-07-31 | Exostem Biotec Ltd. | MicroRNAs for the generation of astrocytes |
EP2825672B1 (en) | 2012-03-13 | 2019-02-13 | Swift Biosciences, Inc. | Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase |
US20150031750A1 (en) | 2012-03-15 | 2015-01-29 | The Scripps Research Institute | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
WO2013138662A1 (en) | 2012-03-16 | 2013-09-19 | 4S3 Bioscience, Inc. | Antisense conjugates for decreasing expression of dmpk |
WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
EP2850092B1 (en) | 2012-04-09 | 2017-03-01 | Ionis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
JP2015518485A (en) | 2012-04-20 | 2015-07-02 | アプタミアール セラピューティクス インコーポレイテッド | Thermogenic miRNA regulator |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
EP3597741A1 (en) | 2012-04-27 | 2020-01-22 | Duke University | Genetic correction of mutated genes |
US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
EP3511416A1 (en) | 2012-05-16 | 2019-07-17 | Translate Bio MA, Inc. | Compositions and methods for modulating gene expression |
JP2015523854A (en) | 2012-05-16 | 2015-08-20 | ラナ セラピューティクス インコーポレイテッド | Compositions and methods for modulating SMN gene family expression |
WO2013175480A1 (en) | 2012-05-24 | 2013-11-28 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
US20140038182A1 (en) | 2012-07-17 | 2014-02-06 | Dna Logix, Inc. | Cooperative primers, probes, and applications thereof |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
CA2880833A1 (en) | 2012-08-03 | 2014-02-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
EP2885312A4 (en) | 2012-08-15 | 2016-01-20 | Isis Pharmaceuticals Inc | Method of preparing oligomeric compounds using modified capping protocols |
CA2880869A1 (en) | 2012-08-20 | 2014-02-27 | The Regents Of The University Of California | Polynucleotides having bioreversible groups |
US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2014062989A2 (en) | 2012-10-18 | 2014-04-24 | Monsanto Technology Llc | Methods and compositions for plant pest control |
WO2014071358A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
EP2941487A2 (en) | 2013-01-01 | 2015-11-11 | A.B. Seeds Ltd. | ISOLATED dsRNA MOLECULES AND METHODS OF USING SAME FOR SILENCING TARGET MOLECULES OF INTEREST |
WO2014113729A2 (en) | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
DK2951191T3 (en) | 2013-01-31 | 2019-01-14 | Ionis Pharmaceuticals Inc | PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS |
EP3366772A1 (en) * | 2013-02-22 | 2018-08-29 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage |
WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
UA121846C2 (en) | 2013-03-13 | 2020-08-10 | Монсанто Текнолоджи Ллс | METHOD AND HERBICIDAL COMPOSITION FOR CONTROL OF PLANT SPECIES OF THE GENUS LOLIUM |
CN105074008A (en) | 2013-03-13 | 2015-11-18 | 孟山都技术有限公司 | Methods and compositions for weed control |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
NZ712336A (en) | 2013-03-14 | 2020-03-27 | Alnylam Pharmaceuticals Inc | Complement component c5 irna compositions and methods of use thereof |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
JP2016522679A (en) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Therapeutic use of genome editing with the CRISPR / Cas system |
BR112015027321A8 (en) | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES |
IL293657A (en) | 2013-05-22 | 2022-08-01 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
PT2999785T (en) | 2013-05-22 | 2018-07-09 | Alnylam Pharmaceuticals Inc | Serpina1 irna compositions and methods of use thereof |
US20160113911A1 (en) | 2013-06-06 | 2016-04-28 | The General Hospital Corporation | Methods and compositions for the treatment of cancer |
DK3007704T3 (en) | 2013-06-13 | 2021-03-29 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
UA122662C2 (en) | 2013-07-19 | 2020-12-28 | Монсанто Текнолоджі Ллс | Compositions and methods for controlling leptinotarsa |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
AU2014306271A1 (en) | 2013-08-08 | 2016-03-24 | The Scripps Research Institute | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
WO2015048558A1 (en) | 2013-09-30 | 2015-04-02 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
CN105793423A (en) | 2013-10-02 | 2016-07-20 | 阿尔尼拉姆医药品有限公司 | Compositions and methods for inhibiting expression of the LECT2 gene |
KR102298475B1 (en) | 2013-10-04 | 2021-09-06 | 노파르티스 아게 | 3' END CAPS FOR RNAi AGENTS FOR USE IN RNA INTERFERENCE |
EP3052627B1 (en) | 2013-10-04 | 2018-08-22 | Novartis AG | Novel formats for organic compounds for use in rna interference |
SG10201910929QA (en) | 2013-10-04 | 2020-01-30 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the alas1 gene |
JP6546161B2 (en) | 2013-10-04 | 2019-07-17 | ノバルティス アーゲー | Organic compounds for treating hepatitis B virus |
EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
WO2015061246A1 (en) | 2013-10-21 | 2015-04-30 | Isis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
CA2928779A1 (en) | 2013-10-21 | 2015-04-30 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
US9540642B2 (en) | 2013-11-04 | 2017-01-10 | The United States Of America, As Represented By The Secretary Of Agriculture | Compositions and methods for controlling arthropod parasite and pest infestations |
US10301622B2 (en) | 2013-11-04 | 2019-05-28 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA) |
JP6772062B2 (en) | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | Cancer immunotherapy |
CN112107693B (en) | 2013-12-03 | 2023-05-26 | 西北大学 | Liposome particles, method for preparing said liposome particles and use thereof |
US10385388B2 (en) | 2013-12-06 | 2019-08-20 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
JP6710638B2 (en) | 2013-12-12 | 2020-06-17 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Complement component iRNA composition and method of using the same |
EP3865144A1 (en) | 2013-12-20 | 2021-08-18 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
WO2015108982A2 (en) | 2014-01-15 | 2015-07-23 | Monsanto Technology Llc | Methods and compositions for weed control using epsps polynucleotides |
US20170044232A1 (en) | 2014-02-04 | 2017-02-16 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US10125365B2 (en) | 2014-02-05 | 2018-11-13 | Yeda Research And Development Co. Ltd. | Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions |
KR20230152154A (en) | 2014-02-11 | 2023-11-02 | 알닐람 파마슈티칼스 인코포레이티드 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
PL3119888T3 (en) | 2014-03-19 | 2021-12-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating ataxin 2 expression |
PL3757214T3 (en) | 2014-04-01 | 2022-09-12 | Biogen Ma Inc. | Compositions for modulating sod-1 expression |
CN110506752B (en) | 2014-04-01 | 2022-02-18 | 孟山都技术公司 | Compositions and methods for controlling insect pests |
HUE056155T2 (en) | 2014-04-09 | 2022-01-28 | Scripps Research Inst | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US10221416B2 (en) | 2014-04-24 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
US10098959B2 (en) | 2014-05-01 | 2018-10-16 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
ES2745825T3 (en) | 2014-05-01 | 2020-03-03 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating expression of complement factor B |
WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
SG10202104570TA (en) | 2014-05-22 | 2021-06-29 | Alnylam Pharmaceuticals Inc | Angiotensinogen (agt) irna compositions and methods of use thereof |
EP3148564B1 (en) | 2014-06-02 | 2020-01-08 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
ES2908962T3 (en) | 2014-06-10 | 2022-05-04 | Univ Erasmus Med Ct Rotterdam | Antisense oligonucleotides useful in the treatment of Pompe disease |
CA2953347A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
EP3161159B1 (en) | 2014-06-25 | 2020-08-05 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
JP6671363B2 (en) | 2014-07-15 | 2020-03-25 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド | Isolated polypeptide of CD44 and uses thereof |
US9951327B1 (en) | 2014-07-17 | 2018-04-24 | Integrated Dna Technologies, Inc. | Efficient and rapid method for assembling and cloning double-stranded DNA fragments |
RU2754955C2 (en) | 2014-07-29 | 2021-09-08 | Монсанто Текнолоджи Ллс | Compositions and methods for combating insect pests |
BR112017001860A2 (en) | 2014-07-31 | 2018-02-27 | Uab Research Foundation | synthetic peptide, pharmaceutical composition, methods, dosage regimen, and monoclonal antibody |
EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
US10060921B2 (en) | 2014-08-29 | 2018-08-28 | Alnylam Pharmaceuticals, Inc. | Methods of treating transthyretin (TTR) mediated amyloidosis |
CA2959386A1 (en) | 2014-08-29 | 2016-03-03 | Lee Adam Wheeler | Methods and compositions for the treatment of cancer |
KR102506169B1 (en) | 2014-09-05 | 2023-03-08 | 피오 파마슈티칼스 코프. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
WO2016049512A1 (en) | 2014-09-26 | 2016-03-31 | University Of Massachusetts | Rna-modulating agents |
JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
EP3207138B1 (en) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
WO2016094845A2 (en) | 2014-12-12 | 2016-06-16 | Woolf Tod M | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
RU2723049C2 (en) | 2015-01-22 | 2020-06-08 | Монсанто Текнолоджи Ллс | Compositions and methods for controlling leptinotarsa |
JP2018506715A (en) | 2015-01-23 | 2018-03-08 | ヴァンダービルト ユニバーシティー | Robust interferometer and method of use |
JP6929791B2 (en) | 2015-02-09 | 2021-09-01 | デューク ユニバーシティ | Compositions and methods for epigenome editing |
EP3256587A2 (en) | 2015-02-13 | 2017-12-20 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP3262181A4 (en) | 2015-02-23 | 2018-11-21 | Ionis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
EP3262173A2 (en) | 2015-02-23 | 2018-01-03 | Crispr Therapeutics AG | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
US10781445B2 (en) | 2015-03-11 | 2020-09-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
KR20180020125A (en) | 2015-03-27 | 2018-02-27 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Modified T cells and methods for their manufacture and use |
WO2016164463A1 (en) | 2015-04-07 | 2016-10-13 | The General Hospital Corporation | Methods for reactivating genes on the inactive x chromosome |
WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
US10907152B2 (en) | 2015-05-04 | 2021-02-02 | Monsanto Technology Llc | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2016181393A1 (en) | 2015-05-11 | 2016-11-17 | Yeda Research And Development Co. Ltd. | Citrin inhibitors for the treatment of cancer |
CN107750125A (en) | 2015-06-02 | 2018-03-02 | 孟山都技术有限公司 | For by the composition and method in delivery of polynucleotides to plant |
US10655136B2 (en) | 2015-06-03 | 2020-05-19 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
EP3310918B1 (en) | 2015-06-18 | 2020-08-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
WO2016210241A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
AU2016287499B2 (en) | 2015-06-29 | 2022-08-04 | Caris Science, Inc. | Therapeutic oligonucleotides |
CN108135923B (en) | 2015-07-06 | 2021-03-02 | 菲奥医药公司 | Nucleic acid molecules targeting superoxide dismutase 1(SOD1) |
WO2017007825A1 (en) | 2015-07-06 | 2017-01-12 | Rxi Pharmaceuticals Corporation | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
US10494632B2 (en) | 2015-07-10 | 2019-12-03 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof |
WO2017019918A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
EP3331546B1 (en) | 2015-08-03 | 2023-10-04 | Biokine Therapeutics Ltd. | Cxcr4 inhibitor for the treatment of cancer |
US20180237774A1 (en) | 2015-08-04 | 2018-08-23 | Yeda Research And Development Co. Ltd. | Methods of screening for riboswitches and attenuators |
WO2017027350A2 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
CN108368507B (en) | 2015-09-02 | 2022-03-22 | 阿尔尼拉姆医药品有限公司 | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof |
WO2017064546A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
WO2017053781A1 (en) | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
WO2017066497A2 (en) | 2015-10-13 | 2017-04-20 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
WO2017075038A1 (en) | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
WO2017072590A1 (en) | 2015-10-28 | 2017-05-04 | Crispr Therapeutics Ag | Materials and methods for treatment of duchenne muscular dystrophy |
AU2016344399B2 (en) | 2015-10-30 | 2019-03-28 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use thereof |
WO2017075670A1 (en) | 2015-11-05 | 2017-05-11 | Children's Hospital Los Angeles | "mobilizing leukemia cells" |
CN109328231A (en) | 2015-11-06 | 2019-02-12 | 克里斯普治疗股份公司 | For treating the material and method of 1A type glycogen storage disease |
EP3373939A4 (en) | 2015-11-10 | 2019-06-26 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
US11001622B2 (en) | 2015-11-19 | 2021-05-11 | The Brigham And Women's Hospital, Inc. | Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein |
US11851653B2 (en) | 2015-12-01 | 2023-12-26 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
WO2017096395A1 (en) | 2015-12-04 | 2017-06-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
US10993995B2 (en) | 2015-12-07 | 2021-05-04 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
WO2017106767A1 (en) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production of unnatural nucleotides using a crispr/cas9 system |
CA3009308A1 (en) | 2015-12-23 | 2017-06-29 | Chad Albert COWAN | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
CA3006599A1 (en) | 2016-01-05 | 2017-07-13 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
EP3408649B1 (en) | 2016-01-29 | 2023-06-14 | Vanderbilt University | Free-solution response function interferometry |
US20190038771A1 (en) | 2016-02-02 | 2019-02-07 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
JP2019509721A (en) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | Mutant smoothened and method of using the same |
EP3416689B1 (en) | 2016-02-18 | 2023-01-18 | CRISPR Therapeutics AG | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
EP3419665A4 (en) | 2016-02-25 | 2019-10-16 | The Brigham and Women's Hospital, Inc. | Treatment methods for fibrosis targeting smoc2 |
US10961271B2 (en) | 2016-03-16 | 2021-03-30 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
WO2017158422A1 (en) | 2016-03-16 | 2017-09-21 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
US10577607B2 (en) | 2016-03-16 | 2020-03-03 | Ionis Pharmaceuticals, Inc. | Modulation of DYRK1B expression |
EP3430137A4 (en) | 2016-03-18 | 2019-11-06 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
IL262416B2 (en) | 2016-04-18 | 2024-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
MA45295A (en) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM |
WO2017191503A1 (en) | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
AU2017271579B2 (en) | 2016-05-25 | 2023-10-19 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
WO2017219017A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
US20190218257A1 (en) | 2016-06-24 | 2019-07-18 | The Scripps Research Institute | Novel nucleoside triphosphate transporter and uses thereof |
AU2017290614C1 (en) | 2016-06-29 | 2024-01-18 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
US11174469B2 (en) | 2016-06-29 | 2021-11-16 | Crispr Therapeutics Ag | Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders |
US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
EP3481857A1 (en) | 2016-07-06 | 2019-05-15 | Crispr Therapeutics AG | Materials and methods for treatment of pain related disorders |
AU2017292169B2 (en) | 2016-07-06 | 2021-12-23 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
CA3030701A1 (en) | 2016-07-11 | 2018-01-18 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
EP3487992A4 (en) | 2016-07-21 | 2020-03-18 | Maxcyte, Inc. | Methods and compositions for modifying genomic dna |
WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
JOP20170161A1 (en) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | RNAi Agents for Hepatitis B Virus Infection |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
PT3506909T (en) | 2016-09-02 | 2022-08-16 | Dicerna Pharmaceuticals Inc | 4'-phosphate analogs and oligonucleotides comprising the same |
WO2018055577A1 (en) | 2016-09-23 | 2018-03-29 | Synthena Ag | Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof |
EP3522898A4 (en) | 2016-10-06 | 2020-05-27 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
CA3037046A1 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
JOP20190104A1 (en) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
EP3548620A4 (en) | 2016-12-02 | 2020-07-22 | Cold Spring Harbor Laboratory | Modulation of lnc05 expression |
JP7206214B2 (en) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | Methods for exogenous drug activation of chemo-inducible signaling complexes expressed in engineered cells in vitro and in vivo |
TWI790217B (en) | 2016-12-16 | 2023-01-21 | 美商阿尼拉製藥公司 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS |
AU2018210364B2 (en) | 2017-01-23 | 2022-03-17 | Regeneron Pharmaceuticals, Inc. | HSD17B13 variants and uses thereof |
US11407997B2 (en) | 2017-02-22 | 2022-08-09 | Crispr Therapeutics Ag | Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders |
WO2018154387A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
EP3585898A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
US20200040061A1 (en) | 2017-02-22 | 2020-02-06 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
WO2018165564A1 (en) | 2017-03-09 | 2018-09-13 | Ionis Pharmaceuticals, Inc. | Morpholino modified oligomeric compounds |
US20180284123A1 (en) | 2017-03-30 | 2018-10-04 | California Institute Of Technology | Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform |
CN110913898A (en) | 2017-04-18 | 2020-03-24 | 阿尔尼拉姆医药品有限公司 | Methods of treating subjects having Hepatitis B Virus (HBV) infection |
EP3612546B1 (en) | 2017-04-20 | 2022-07-13 | Synthena AG | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
WO2018193428A1 (en) | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
US11767520B2 (en) | 2017-04-20 | 2023-09-26 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
EP3612232A1 (en) | 2017-04-21 | 2020-02-26 | The Broad Institute, Inc. | Targeted delivery to beta cells |
AU2018367896B2 (en) | 2017-05-12 | 2023-06-01 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
TWI821192B (en) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | Incorporation of unnatural nucleotides and methods thereof |
JP2020526558A (en) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | Common and direct methods for preparing oligonucleotide functionalized metal-organic framework nanoparticles |
WO2019014530A1 (en) | 2017-07-13 | 2019-01-17 | Alnylam Pharmaceuticals Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
KR20200035092A (en) | 2017-08-03 | 2020-04-01 | 신톡스, 인크. | Cytokine conjugates for the treatment of autoimmune diseases |
US11197884B2 (en) | 2017-08-18 | 2021-12-14 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | Modulators of smad7 expression |
WO2019060442A1 (en) | 2017-09-19 | 2019-03-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis |
MX2020004043A (en) | 2017-10-17 | 2021-05-27 | Crispr Therapeutics Ag | Compositions and methods for gene editing for hemophilia a. |
US20210180091A1 (en) | 2017-10-26 | 2021-06-17 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
SG11202002940QA (en) | 2017-11-01 | 2020-04-29 | Alnylam Pharmaceuticals Inc | Complement component c3 irna compositions and methods of use thereof |
MA50578A (en) | 2017-11-09 | 2021-09-15 | Vertex Pharma | CRISPR / CAS SYSTEMS FOR THE TREATMENT OF DMD |
TWI809004B (en) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
EP3710587A1 (en) | 2017-11-16 | 2020-09-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
CA3082450A1 (en) | 2017-11-21 | 2019-05-31 | Crispr Therapeutics Ag | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
US20200384033A1 (en) | 2017-12-05 | 2020-12-10 | Vertex Pharmaceuticals Incorporated | Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof |
CA3084825A1 (en) | 2017-12-14 | 2019-06-20 | Crispr Therapeutics Ag | Novel rna-programmable endonuclease systems and their use in genome editing and other applications |
MX2020006012A (en) | 2017-12-18 | 2020-09-14 | Alnylam Pharmaceuticals Inc | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof. |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
WO2019123429A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a |
WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
MA51637A (en) | 2018-01-12 | 2020-11-18 | Bayer Healthcare Llc | COMPOSITIONS AND METHODS FOR TARGETING GENE EDITING OF TRANSFERRIN |
JP2021511072A (en) | 2018-01-15 | 2021-05-06 | アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. | DNM2 expression modulator |
WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
US11566236B2 (en) | 2018-02-05 | 2023-01-31 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
MA51788A (en) | 2018-02-05 | 2020-12-16 | Vertex Pharma | SUBSTANCES AND METHODS FOR TREATING HEMOGLOBINOPATHIES |
WO2019155465A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
WO2019161310A1 (en) | 2018-02-16 | 2019-08-22 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing by targeting fibrinogen-alpha |
CN112004547A (en) | 2018-02-26 | 2020-11-27 | 新索思股份有限公司 | IL-15 conjugates and uses thereof |
US11732260B2 (en) | 2018-03-02 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-β precursor protein |
TW202000199A (en) | 2018-03-02 | 2020-01-01 | 美商Ionis製藥公司 | Modulators of IRF4 expression |
WO2019170731A1 (en) | 2018-03-07 | 2019-09-12 | Sanofi | Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same |
EP3768834A1 (en) | 2018-03-19 | 2021-01-27 | CRISPR Therapeutics AG | Novel rna-programmable endonuclease systems and uses thereof |
WO2019183440A1 (en) | 2018-03-22 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
CA3095545A1 (en) | 2018-03-30 | 2019-10-03 | Rheinische Friedrich-Wilhelms-Universitat Bonn | Aptamers for targeted activaton of t cell-mediated immunity |
KR20200141470A (en) | 2018-04-06 | 2020-12-18 | 칠드런'즈 메디컬 센터 코포레이션 | Composition and method for adjusting somatic cell reprogramming and imprinting |
SG11202008660TA (en) | 2018-04-11 | 2020-10-29 | Ionis Pharmaceuticals Inc | Modulators of ezh2 expression |
WO2019204668A1 (en) | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
CN112189053A (en) | 2018-05-09 | 2021-01-05 | Ionis制药公司 | Compounds and methods for reducing expression of ATXN3 |
JOP20200280A1 (en) | 2018-05-09 | 2020-11-05 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing fxi expression |
TW202016304A (en) | 2018-05-14 | 2020-05-01 | 美商阿尼拉製藥公司 | Angiotensinogen (agt) irna compositions and methods of use thereof |
WO2019241648A1 (en) | 2018-06-14 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing stmn2 expression |
JP7315594B2 (en) | 2018-06-27 | 2023-07-26 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for reducing LRRK2 expression |
KR20210027389A (en) | 2018-06-28 | 2021-03-10 | 크리스퍼 테라퓨틱스 아게 | Compositions and methods for genome editing by insertion of donor polynucleotides |
AR115847A1 (en) | 2018-07-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2 |
AU2019321375A1 (en) | 2018-08-13 | 2021-03-11 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
AR115960A1 (en) | 2018-08-16 | 2021-03-17 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE LECT2 GENE |
EP3843845A4 (en) | 2018-08-29 | 2022-05-11 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
JP2022500442A (en) | 2018-09-14 | 2022-01-04 | ノースウェスタン ユニバーシティ | Programming of protein polymerization with DNA |
CN112424355A (en) | 2018-09-18 | 2021-02-26 | 阿尔尼拉姆医药品有限公司 | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
US20210348159A1 (en) | 2018-10-17 | 2021-11-11 | Crispr Therapeutics Ag | Compositions and methods for delivering transgenes |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
TW202028222A (en) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
CA3119456A1 (en) | 2018-11-15 | 2020-05-22 | Ionis Pharmaceuticals, Inc. | Modulators of irf5 expression |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
US20210332495A1 (en) | 2018-12-06 | 2021-10-28 | Northwestern University | Protein Crystal Engineering Through DNA Hybridization Interactions |
SG11202106489RA (en) | 2018-12-20 | 2021-07-29 | Vir Biotechnology Inc | Combination hbv therapy |
CA3123617A1 (en) | 2018-12-20 | 2020-06-25 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of kcnt1 related disorders |
JP2022517270A (en) | 2019-01-16 | 2022-03-07 | ジェンザイム・コーポレーション | Serpinc1 iRNA composition and its usage |
WO2020160453A1 (en) | 2019-01-31 | 2020-08-06 | Ionis Pharmaceuticals, Inc. | Modulators of yap1 expression |
KR20210123299A (en) | 2019-02-06 | 2021-10-13 | 신톡스, 인크. | IL-2 conjugates and methods of use thereof |
US11529427B2 (en) | 2019-02-15 | 2022-12-20 | Crispr Therapeutics Ag | Gene editing for hemophilia A with improved factor VIII expression |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
US11279932B2 (en) | 2019-02-27 | 2022-03-22 | Ionis Pharmaceuticals, Inc. | Modulators of MALAT1 expression |
AU2020239225A1 (en) | 2019-03-12 | 2021-09-30 | Bayer Healthcare Llc | Novel high fidelity RNA-programmable endonuclease systems and uses thereof |
CA3134486A1 (en) | 2019-03-29 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of kras associated diseases or disorders |
WO2020205463A1 (en) | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
CN113795581A (en) | 2019-05-03 | 2021-12-14 | 迪克纳制药公司 | Double stranded nucleic acid inhibitor molecules with shortened sense strand |
US20210047649A1 (en) | 2019-05-08 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crispr/cas all-in-two vector systems for treatment of dmd |
US20220339256A1 (en) | 2019-05-13 | 2022-10-27 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus (hbv) infection |
BR112021025130A2 (en) | 2019-06-14 | 2022-03-15 | Scripps Research Inst | Reagents and methods for replication, transcription and translation in semisynthetic organisms |
US20210008161A1 (en) | 2019-06-17 | 2021-01-14 | Crispr Therapeutics Ag | Methods and compositions for improved homology directed repair |
EP3956450A4 (en) | 2019-07-26 | 2022-11-16 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
EP4007811A2 (en) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof |
WO2021022109A1 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP4013870A1 (en) | 2019-08-13 | 2022-06-22 | Alnylam Pharmaceuticals, Inc. | Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof |
EP4013767A4 (en) | 2019-08-15 | 2023-10-25 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds and uses thereof |
CN114555128A (en) | 2019-08-15 | 2022-05-27 | 新索思股份有限公司 | Combination immunooncology therapy with IL-2 conjugates |
BR112022003046A8 (en) | 2019-08-23 | 2024-02-06 | Synthorx Inc | Il-15 conjugate, its method of preparation and its uses, as well as pharmaceutical composition and in vitro method of expanding one or more of the t cell populations |
BR112022003860A2 (en) | 2019-09-03 | 2022-08-16 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE LECT2 GENE |
US20210070827A1 (en) | 2019-09-10 | 2021-03-11 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
EP4045652A1 (en) | 2019-10-18 | 2022-08-24 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
BR112022007540A2 (en) | 2019-10-22 | 2022-07-12 | Alnylam Pharmaceuticals Inc | COMPONENTS COMPLEMENTARY C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
JP2023500661A (en) | 2019-11-01 | 2023-01-10 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
MX2022005251A (en) | 2019-11-04 | 2022-06-08 | Synthorx Inc | Interleukin 10 conjugates and uses thereof. |
CN114981431A (en) | 2019-11-13 | 2022-08-30 | 阿尔尼拉姆医药品有限公司 | Methods and compositions for treating Angiotensinogen (AGT) -related disorders |
WO2021102373A1 (en) | 2019-11-22 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
JP2023503635A (en) | 2019-11-27 | 2023-01-31 | クリスパー・セラピューティクス・アクチェンゲゼルシャフト | Methods of synthesizing RNA molecules |
CA3162717A1 (en) * | 2019-11-27 | 2021-06-03 | Alnylam Pharmaceuticals, Inc. | Synthesis of 3'-rna oligonucleotides |
TW202140509A (en) | 2019-12-13 | 2021-11-01 | 美商阿尼拉製藥公司 | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP4077674A1 (en) | 2019-12-18 | 2022-10-26 | Alia Therapeutics S.R.L. | Compositions and methods for treating retinitis pigmentosa |
IL294599A (en) | 2020-01-15 | 2022-09-01 | Dicerna Pharmaceuticals Inc | 4’-o-methylene phosphonate nucleic acids and analogues thereof |
WO2021154705A1 (en) | 2020-01-27 | 2021-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Rab13 and net1 antisense oligonucleotides to treat metastatic cancer |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
TW202140786A (en) | 2020-02-10 | 2021-11-01 | 美商艾爾妮蘭製藥公司 | Compositions and methods for silencing vegf-a expression |
MX2022010052A (en) | 2020-02-18 | 2022-09-05 | Alnylam Pharmaceuticals Inc | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof. |
MX2022010602A (en) | 2020-02-28 | 2022-09-09 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating smn2. |
WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021178736A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
WO2021195307A1 (en) | 2020-03-26 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
US20230190785A1 (en) | 2020-03-30 | 2023-06-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
JP2023520582A (en) | 2020-04-06 | 2023-05-17 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for silencing MYOC expression |
EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
BR112022021813A2 (en) | 2020-04-27 | 2023-01-17 | Alnylam Pharmaceuticals Inc | APOLIPOPROTEIN AND (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
JP2023523790A (en) | 2020-04-30 | 2023-06-07 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
CA3181546A1 (en) | 2020-05-01 | 2021-11-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating atxn1 |
EP4150090A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231698A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231691A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi) |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
EP4150088A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150076A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
CN115885042A (en) | 2020-05-22 | 2023-03-31 | 波涛生命科学有限公司 | Double-stranded oligonucleotide compositions and methods related thereto |
AR122534A1 (en) | 2020-06-03 | 2022-09-21 | Triplet Therapeutics Inc | METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY |
JP2023530234A (en) | 2020-06-05 | 2023-07-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | Compositions and methods for treating neoplasms |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
CA3184289A1 (en) | 2020-06-18 | 2021-12-23 | Alnylam Pharmaceuticals, Inc. | Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof |
BR112022026316A2 (en) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES |
KR20230027235A (en) | 2020-06-25 | 2023-02-27 | 신톡스, 인크. | Immuno-oncology combination therapy using IL-2 conjugates and anti-EGFR antibodies |
MX2022016338A (en) | 2020-06-29 | 2023-01-24 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating plp1. |
KR20230061389A (en) | 2020-08-04 | 2023-05-08 | 다이서나 파마수이티컬, 인크. | Systemic Delivery of Oligonucleotides |
WO2022066847A1 (en) | 2020-09-24 | 2022-03-31 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
WO2022070107A1 (en) | 2020-09-30 | 2022-04-07 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis |
EP4225917A1 (en) | 2020-10-05 | 2023-08-16 | Alnylam Pharmaceuticals, Inc. | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
EP3978608A1 (en) | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51 |
AU2021356610A1 (en) | 2020-10-09 | 2023-06-15 | Synthorx, Inc. | Immuno oncology therapies with il-2 conjugates |
JP2023546009A (en) | 2020-10-09 | 2023-11-01 | シンソークス, インコーポレイテッド | Immuno-oncology combination therapy with IL-2 conjugate and pembrolizumab |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
WO2022087041A1 (en) | 2020-10-21 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
TW202237841A (en) | 2020-11-13 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | Coagulation factor v (f5) irna compositions and methods of use thereof |
EP4136092A4 (en) | 2020-11-18 | 2023-10-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
CA3202708A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
TW202237150A (en) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
WO2022140702A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
JP2024508714A (en) | 2021-02-12 | 2024-02-28 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Superoxide dismutase 1 (SOD1) iRNA composition and method for using the same for treating or preventing superoxide dismutase 1- (SOD1-) related neurodegenerative diseases |
EP4291243A1 (en) | 2021-02-12 | 2023-12-20 | Synthorx, Inc. | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
TW202245843A (en) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
CN117222739A (en) | 2021-02-25 | 2023-12-12 | 阿尔尼拉姆医药品有限公司 | Prion protein (PRNP) IRNA compositions and methods of use thereof |
TW202302847A (en) | 2021-02-26 | 2023-01-16 | 美商艾拉倫製藥股份有限公司 | Ketohexokinase (khk) irna compositions and methods of use thereof |
IL305414A (en) | 2021-03-04 | 2023-10-01 | Alnylam Pharmaceuticals Inc | Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof |
EP4304640A1 (en) | 2021-03-12 | 2024-01-17 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
WO2022192519A1 (en) | 2021-03-12 | 2022-09-15 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
WO2022212231A2 (en) | 2021-03-29 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Huntingtin (htt) irna agent compositions and methods of use thereof |
WO2022212153A1 (en) | 2021-04-01 | 2022-10-06 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
WO2022231999A1 (en) | 2021-04-26 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof |
EP4330396A1 (en) | 2021-04-29 | 2024-03-06 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
EP4334448A1 (en) | 2021-05-03 | 2024-03-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis |
WO2022245583A1 (en) | 2021-05-18 | 2022-11-24 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
TW202317762A (en) | 2021-06-02 | 2023-05-01 | 美商艾拉倫製藥股份有限公司 | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
WO2022256534A1 (en) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
WO2022256290A2 (en) | 2021-06-04 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
WO2022260939A2 (en) | 2021-06-08 | 2022-12-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
CA3222950A1 (en) | 2021-06-11 | 2022-12-15 | Bayer Aktiengesellschaft | Type v rna programmable endonuclease systems |
AU2022293556A1 (en) | 2021-06-18 | 2024-01-18 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
CA3225469A1 (en) | 2021-06-30 | 2023-01-05 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
WO2023285431A1 (en) | 2021-07-12 | 2023-01-19 | Alia Therapeutics Srl | Compositions and methods for allele specific treatment of retinitis pigmentosa |
TW202333748A (en) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
TW202325312A (en) | 2021-07-23 | 2023-07-01 | 美商艾拉倫製藥股份有限公司 | Beta-catenin (ctnnb1) irna compositions and methods of use thereof |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
IL310244A (en) | 2021-08-03 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Transthyretin (ttr) irna compositions and methods of use thereof |
IL310295A (en) | 2021-08-04 | 2024-03-01 | Alnylam Pharmaceuticals Inc | iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT) |
IL310407A (en) | 2021-08-13 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Factor xii (f12) irna compositions and methods of use thereof |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
WO2023044094A1 (en) | 2021-09-20 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
TW202333749A (en) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Complement factor b (cfb) irna compositions and methods of use thereof |
WO2023118349A1 (en) | 2021-12-21 | 2023-06-29 | Alia Therapeutics Srl | Type ii cas proteins and applications thereof |
WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023177866A1 (en) | 2022-03-18 | 2023-09-21 | Dicerna Pharmaceuticals, Inc. | Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide |
WO2023194359A1 (en) | 2022-04-04 | 2023-10-12 | Alia Therapeutics Srl | Compositions and methods for treatment of usher syndrome type 2a |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2002773B (en) * | 1977-08-10 | 1982-03-03 | Brown R | Nucleotide inhibitor of protein synthesis |
US4210746A (en) * | 1978-08-10 | 1980-07-01 | National Research Development Corporation | Nucleotide inhibitor of protein synthesis |
US4464359A (en) * | 1981-04-10 | 1984-08-07 | Research Corporation | (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof |
US4515781A (en) * | 1983-02-23 | 1985-05-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 2',5'-Riboadenylate-morpholinoadenylate nucleotides |
US4565696A (en) * | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
FR2567892B1 (en) * | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | NOVEL OLIGONUCLEOTIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS AS MEDIATORS IN DEVELOPING THE EFFECTS OF INTERFERONS |
US4663161A (en) * | 1985-04-22 | 1987-05-05 | Mannino Raphael J | Liposome methods and compositions |
US4781871A (en) * | 1986-09-18 | 1988-11-01 | Liposome Technology, Inc. | High-concentration liposome processing method |
US4924624A (en) * | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5866787A (en) * | 1993-03-08 | 1999-02-02 | Cleveland Clinic Foundation | Transgenic plants co-expressing a functional human 2-5A system |
-
1987
- 1987-10-22 US US07/112,591 patent/US4924624A/en not_active Expired - Lifetime
-
1988
- 1988-10-18 AT AT88909900T patent/ATE135579T1/en not_active IP Right Cessation
- 1988-10-18 EP EP95202077A patent/EP0694559B1/en not_active Expired - Lifetime
- 1988-10-18 DE DE3856326T patent/DE3856326T2/en not_active Expired - Fee Related
- 1988-10-18 AU AU26280/88A patent/AU2628088A/en not_active Abandoned
- 1988-10-18 JP JP63509144A patent/JP2733777B2/en not_active Expired - Fee Related
- 1988-10-18 DE DE3855135T patent/DE3855135T2/en not_active Expired - Fee Related
- 1988-10-18 EP EP88909900A patent/EP0389521B1/en not_active Expired - Lifetime
- 1988-10-18 WO PCT/US1988/003634 patent/WO1989003683A1/en active IP Right Grant
- 1988-10-18 CA CA000580426A patent/CA1339953C/en not_active Expired - Fee Related
- 1988-10-18 AT AT95202077T patent/ATE178902T1/en not_active IP Right Cessation
-
1992
- 1992-07-16 US US07/915,771 patent/US5405939A/en not_active Expired - Lifetime
-
1994
- 1994-12-02 US US08/348,419 patent/US5556840A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH04500795A (en) | 1992-02-13 |
ATE135579T1 (en) | 1996-04-15 |
DE3856326D1 (en) | 1999-05-20 |
US4924624A (en) | 1990-05-15 |
WO1989003683A1 (en) | 1989-05-05 |
EP0389521B1 (en) | 1996-03-20 |
EP0389521A1 (en) | 1990-10-03 |
DE3855135D1 (en) | 1996-04-25 |
EP0694559A3 (en) | 1996-07-31 |
US5556840A (en) | 1996-09-17 |
EP0694559B1 (en) | 1999-04-14 |
AU2628088A (en) | 1989-05-23 |
US5405939A (en) | 1995-04-11 |
DE3855135T2 (en) | 1996-09-05 |
DE3856326T2 (en) | 1999-12-02 |
EP0694559A2 (en) | 1996-01-31 |
ATE178902T1 (en) | 1999-04-15 |
EP0389521A4 (en) | 1992-02-05 |
JP2733777B2 (en) | 1998-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1339953C (en) | 2',5'-phosphorothioate oligoadenylates and antiviral uses thereof | |
US5188897A (en) | Encapsulated 2',5'-phosphorothioate oligoadenylates | |
US5550111A (en) | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof | |
US5643889A (en) | Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof | |
US4990498A (en) | 2- and 8-azido(2'-5')oligoadenylates and antiviral uses thereof | |
US4859768A (en) | Derivatives of 2', 5'-oligoadenylate and antiviral uses thereof | |
US6033909A (en) | Oligonucleotide analogs, their preparation and use | |
US5700785A (en) | 3'-deoxy or 3'-O-substituted-2',5'-oligoadenylates as antiviral agents | |
US5863905A (en) | 2',5'-phosphorothioate/phosphodiester oligoadenylates and anti-viral uses thereof | |
WO1998056385A1 (en) | Base-modified derivatives of 2',5'-oligoadenylate and antiviral uses thereof | |
AU637975B2 (en) | Therapeutic uses of 2',5'-oligoadenylate derivatives | |
CA2130926C (en) | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof | |
IL106709A (en) | Antiviral pharmaceutical compositions containing 2',5'-oligoadenylates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKLA | Lapsed |
Effective date: 20130715 |